WO1991005545A1 - Liposome microreservoir composition and method - Google Patents
Liposome microreservoir composition and method Download PDFInfo
- Publication number
- WO1991005545A1 WO1991005545A1 PCT/US1990/006034 US9006034W WO9105545A1 WO 1991005545 A1 WO1991005545 A1 WO 1991005545A1 US 9006034 W US9006034 W US 9006034W WO 9105545 A1 WO9105545 A1 WO 9105545A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liposome
- liposomes
- composition
- compound
- vesicle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a liposome composition and method for administering a therapeutic compound into the bloodstream over an extended period.
- Liposomes have been proposed as a carrier for intraven ⁇ ously (IV) administered compounds.
- IV intraven ⁇ ously
- the use of lipo ⁇ somes for slow release of liposome-entrapped material into the bloodstream has been severely restricted by the rapid clear ⁇ ance of liposomes from the bloodstream by cells of the reti- culoendothelial system (RES) .
- the RES will remove 80-95% of IV injected liposomes within one hour, and effec ⁇ tively remove circulating liposomes from the bloodstream within of 4-6 hours.
- the invention includes, in one aspect, a liposome compo ⁇ sition effective to extend to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount, and which has a blood halflife, in free form, of less than about 4 hours.
- the composition includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole per ⁇ cent of a vesicle-forming lipid derivatized with a biocompa- tible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.1 to 0.4 microns, and the compound in liposome-entrapped form.
- the composition is intended for intravenous administration at a dose which contains an amount of the liposome-entrapped compound which is at least three times the therapeutically effective dose for the compound in free form.
- the hydrophilic polymer is polyethyleneglycol having a molecular weight between about 1,000-5,000 daltons, and the polymer is derivatized with the polar head roup of a phospholipid, such a phosphatidylethanol- amine (PE) .
- a phospholipid such as a phosphatidylethanol- amine (PE)
- the polymer may be other suitable biocompatible hydrophilic polymers, such as polylactic acid and polyglycolic acid.
- the composition is effective to extend to at least 48 hours, the period of thera ⁇ Chamberic activity of an intravenously injected polypeptide which can be administered intravenously in a therapeutically effec ⁇ tive amount.
- the polypeptide may be a peptide or protein, such as superoxide dismutase, glucocerebrosidase, asparagi- nase, adenosine deaminase, interferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor
- TNF - alpha, beta colony stimulating factors
- M-CSF macro- phage
- G-CSF granulocyte
- GM-CSF granulocyte, macrophage
- TPA prourokinase
- urokinase HIV-1 vaccine
- hepatitis B vaccine hepatitis B vaccine
- malaria vaccine hepatitis B vaccine
- melanoma vaccine erythropoietin
- EPO ribosome inhibitor pro- tein
- factor VIII factor VIII
- bone growth factor fibroblast growth factor
- insulin-like growth factor nerve growth factor
- platelet-derived growth factor tumor growth factors (alpha, beta), somatomedin C (IGF-1)
- IGF-1 tumor growth factors
- ribosome inhibitor pro- tein ribosome inhibitor pro- tein
- the composition is effective to deliver a therapeutically effective amount of the peptide into the bloodstream for a period of between 5-10 days.
- Also forming part of the invention is a method for exten ⁇ ding to at least 24 hours, the period of effective activity of an therapeutic compound which can be administered intravenous ⁇ ly in a therapeutically effective amount, and which has a halflife in the blood, in free form, of less than about 4 hours.
- a liposome composition of the type described above is administered intravenously to a subject at a dose which contains an amount of the compound which is at least three times such therapeutically effective amount.
- a liposome composition effective to extend to at least one week, the period of effective activity of an therapeutic compound which can be administered intra ⁇ venously in a therapeutically effective amount.
- the composi- tion includes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid deri ⁇ vatized with a biocompatible hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range between about 0.07-.15 microns, and the compound in liposome- entrapped form.
- the composition is intended for subcutaneous administration at a dose which contains an amount of the lipo ⁇ some-entrapped compound which is at least ten times such therapeutically effective intravenously administered amount.
- the liposome composition is used in a method for extending the period of release of a therapeutic compound, preferably a polypeptide, in a therapeutically active amount, for a period of at least 2 weeks.
- the invention includes a liposome composition composed of vesicle-forming lipids and a vesicle- forming lipid derivatized with polylactic acid or polyglycolic acid, and a lipid composition composed of a vesicle-forming lipid having a polar head group, and a polylactic acid or polyglycolic acid moiety derivatized to the lipid's head group.
- Figure 1 illustrates a general reaction scheme for derivatizing a vesicle-forming lipid amine with a polyalkyl- 5 ether
- Figure 2 is a reaction scheme for preparing phosphati- dylethanolamine (PE) derivatized with polyethyleneglycol via a cyanuric chloride linking agent;
- PE phosphati- dylethanolamine
- Figure 3 illustrates a reaction scheme for preparing 10 phosphatidylethanolamine (PE) derivatized with polyethylene ⁇ glycol by means of a diimidazole activating reagent
- Figure 4 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polyethylene ⁇ glycol by means of a trifluoromethane sulfonate reagent
- Figure 5 illustrates a vesicle-forming lipid derivatized with polyethyleneglycol through a peptide (A) , ester (B) , and disulfide (C) linkage;
- Figure 6 illustrates a reaction scheme for preparing phosphatidylethanolamine (PE) derivatized with polylactic 20 acid
- Figure 7 is a plot of liposome retention time in the blood, expressed in terms of percent injected dose as a function of hours after IV injection, for PEG-PE liposomes containing different amounts of phosphatidylglycerol; 25 Figure 8 is a plot similar to that of Figure 7, showing retention times in the blood of liposomes composed of predomi ⁇ nantly unsaturated phospholipid components;
- Figure 9 is a plot similar to that of Figure 1 , showing retention times in the blood of PEG liposomes (solid tri ⁇
- Figure 10 is a plot of blood lifetimes of PEG-liposomes sized by extrusion through 0.1 micron (solid squares), 0.2 micron (solid circles), and 0.4 micron (solid triangles) polycarbonate membranes;
- Figure 11 is a plot of blood retention times in liposomes containing a vesicle-forming lipid derivatized with polylactic acid (solid squares) and polyglycolic acid (open triangles) ;
- Figure 12 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of aqueous solutions of vasopressin at total doses of 0.2 ⁇ g (closed squares), 0.8 ⁇ g (closed triangles) , and 2 ⁇ g (closed circles) ;
- Figure 13 shows urine flow rates in rats, as a percentage of predosage rate, after surgery and IV administration of saline (control, open circles) and of PEG-liposomes containing entrapped vasopressin at total doses of 2 ⁇ g (closed squares) , 8 ⁇ g (closed triangles) , and 24 ⁇ g (closed circles) ;
- Figure 14 shows urine
- Figure 15 shows the blood clearance kinetics of free macrophage-colony stimulating factor (M-CSF) (solid triangles) , PEG-liposomes containing 30 mole percent cholesterol (solid triangles) , and M-CSF associated with the PEG-liposomes (solid circles) ;
- M-CSF free macrophage-colony stimulating factor
- Figure 16 shows the blood clearance kinetics of free M-CSF (solid triangles) , cholesterol-free PEG-liposomes (solid triangles) , and M-CSF associated with the PEG-liposomes (solid circles) ;
- Figure 17 is a plot of percent release of M-CSF into the blood from PEG liposomes containing 30 (solid, circles) and 0 (solid triangles) mole percent cholesterol;
- Figure 18A shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous administra ⁇ tion of saline (control, open circles) and free vasopressin, in an amount 2 ⁇ g (solid triangles) , 25 ⁇ g " (solid circles) , and 50 ⁇ g (solid diamonds) ; and
- Figure 18B shows urine flow rates in rats, as a percentage of predosage rate, after surgery and subcutaneous administra ⁇ tion of saline (control, open circles) and vasopressin en ⁇ trapped in PEG-liposomes, in an amount 25 ⁇ g (solid triang- les) , 100 ⁇ g (solid circles) , and 400 ⁇ g (solid diamonds) .
- FIG. 1 shows a general reaction scheme for preparing vesicle-forming lipid derivatized a biocompatible, hydrophili polymer, as exemplified by polyethylene glycol (PEG) , poly lactic acid, and polyglycolic acid, all of which are readil water soluble, can be coupled to vesicle-forming lipids, an are tolerated in vivo without toxic effects.
- the hydrophili polymer which is employed, e.g., PEG is preferably capped b a methoxy, ethoxy or other unreactive group at one end, or i one in which one end is more reactive than the other, such a polylactic acid.
- the polymer is activated at one end by reaction with suitable activating agent, such as cyanuric acid, diimadozle, anhydride reagent, or the like, as described below. Th activated compound is then reacted with a vesicle-formin lipid, such as phosphatidylethanol (PE) , to produce th derivatized lipid.
- suitable activating agent such as cyanuric acid, diimadozle, anhydride reagent, or the like
- Th activated compound is then reacted with a vesicle-formin lipid, such as phosphatidylethanol (PE) , to produce th derivatized lipid.
- PE phosphatidylethanol
- the polar group in the vesicle-formin lipid may be activated for reaction with the polymer, or th two groups may be joined in a concerted coupling reaction, according to known coupling methods.
- PEG capped at one end with a methoxy or ethoxy group can be obtained commercially in a variety of polymer sizes, e.g., 500-20,000 ' dalton molecular weights.
- the vesicle-forming lipid is preferably one having two hydrocarbon chains, typically acyl chains, and a polar head group. Included in this class are the phospholipids, such as phosphatidylcholine (PC) , PE, phosphatidic acid (PA) , phospha- tidylinositol (PI) , and sphingomyelin (SM) , where the two hydrocarbon chains are typically between about 14-22 carbon atoms in length, and have varying degrees of unsaturation. Also included in this class are the glycolipids, such as cere- broside and gangliosides. Another vesicle-forming lipid which may be employed is cholesterol and related sterols.
- PC phosphatidylcholine
- PA phosphatidic acid
- PI phospha- tidylinositol
- SM sphingomyelin
- glycolipids such as cere- broside and gangliosides.
- cholesterol may be less tightly anchored to a lipid bilayer membrane, particu ⁇ larly when derivatized with a high molecular weight polyalkyl- ether, and therefore be less effective in promoting liposome evasion of the RES in the bloodstream.
- vesicle-forming lipid is intended to include any amphipathic lipid having hydrophobic and polar head group moieties, and which (a) by itself can form spontaneously into bilayer vesicles in water, as exemplified by phospholipids, or (b) is stably incorporated into lipid bilayers in combination with phospholipids, with its hydrophobic moiety in contact with the interior, hydro- phobic region of the bilayer membrane, and its polar head group moiety oreinted toward the exterior, polar surface of the membrane.
- An example of a latter type of vesicle-forming lipid is cholesterol and cholesterol derivatives, such as cholesterol sulfate and cholesterol hemisuccinate.
- the vesicle-forming lipid may be a relatively fluid lipid, meaning that the lipid phase has a relatively low liquid-to-liquid crystal phase-transition temperature, e.g., at or below room temperature, or relatively rigid lipid, meaning that the lipid has a relatively high melting temperature, e.g., up to 50°C.
- relatively rigid lipid meaning that the lipid has a relatively high melting temperature, e.g., up to 50°C.
- the more rigid, i.e., saturated lipids contribute to greater membrane rigidity in a lipid bilayer structure and also contribute to greater bilayer stability in serum.
- Other lipid components, such as cholesterol are also known to contribute to membrane rigidity and stability in lipid bilayer structures.
- Phospholipids whose acyl chains have a variety of degrees of saturation can be obtained commercially, or prepared according to published methods.
- FIG. 2 shows a reaction scheme for producing a PE-PEG lipid in which the PEG is derivatized to PE through a cyanuric chloride group. Details of the reaction are provided in Example 1. Briefly, ethoxy-capped PEG is activated with cyanuric chloride in the presence in sodium carbonate under conditions which produced the activated PEG compound IV in the figure. This material is purified to remove unreacted cyanuric acid. The activated PEG compound is reacted with PE in the presence of triethyl a ine to produce the desired PE- PEG compound shown at VII in the figure. The yield is about 8-10% with respect to initial quantities of PEG. The method just described may be applied to a variety of lipid amines, including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
- lipid amines including PE, cholesteryl amine, and glycolipids with sugar-amine groups.
- a second method of coupling a polyalkylether, such as capped PEG to a lipid amine is illustrated in Figure 3.
- the capped PEG is activated with a carbonyl diimidazole coupling reagent, to form the activated imidazole compoun shown at X in Figure 3.
- Reaction with a lipid amine, such as PE leads to PEG coupling to the lipid through an amide linkage, as illustrated in the PEG-PE compound shown at XI in the figure. Details of the reaction are given in Example 2.
- a third reaction method for coupling a capped poly ⁇ alkylether to a lipid amine is shown in Figure " 4.
- PEG is first protected at its OH end by a trimethylsilane group.
- the end-protection reaction is shown at A in the figure, and involves the reaction of trimethylsilylchloride with PEG in the presence of triethylamine.
- the protected PEG is then reacted with the anhydride of trifluoromethyl sulfonate (compound XVI in Figure 4) to form the PEG compound activated with trifluoromethyl sulfonate.
- the trimethylsilyl protective group can be released by acid treatment, as indicated at H+ in the figure, or by reaction with a quaternary amine fluoride salt, such as the fluoride salt of tetrabutylamine. It will be appreciated that a variety of known coupling reactions, in addition to those just described, are suitable for preparing vesicle-forming lipids derivatized with hydro ⁇ philic polymers such as PEG.
- the sulfonate anhydride coupling reagent illustrated in Figure 4 can be used to join an activated polyalkylether to the hydroxyl group of an amphipathic lipid, such as the 5'-OH of cholesterol.
- Other reactive lipid groups such as an acid or ester lipid group may also be used for coupling, according to known coupling methods.
- the acid group of phosphatidic acid can be activated to form an active lipid anhydride, by reaction with a suitable anhydride, such as acetic anhydride, and the reactive lipid can then be joined to a protected polyalk 1- amine by reaction in the presence of an isothiocyanate reagent.
- the derivatized lipid component are prepared to include a labile lipid-polymer linkage, suc as a peptide, ester, or disulfide linkage; which can b cleaved under selective physiological conditions, such as i the presence of peptidase or esterase enzymes present in th bloodstream.
- Figure 5 shows exemplary lipids which are linke through (A) peptide, (B) , ester, and (C) , disulfide containin linkages.
- the peptide-linked compound can be prepared, fo example, by first coupling a polyalkylether with the N terminal amine of the tripeptide shown, e.g., via the reactio shown in Figure 3.
- the peptide carboxyl group can then b coupled to a lipid amine group through a carbodiimide couplin reagent conventionally.
- the ester linked compound can b prepared, for example, by coupling a lipid acid, such a phosphatidic acid, to the terminal alcohol group of a poly alkylether, using alcohol via an anhydride coupling agent.
- a lipid acid such as a phosphatidic acid
- an anhydride coupling agent Alternatively, an short linkage fragment containing an inter nal ester bond an suitable end groups, such as primary amin groups can be used to couple the polyalkylether to the amphi pathic lipid through amide or carbamate linkages.
- the linkage fragment may contain an internal disulfide link age, for use in forming the compound shown at C in Figure 5.
- Figure 6 illustrates a method for derivatizing polylacti acid with PE.
- the polylactic acid is reacted, in the presenc of PE, with dicyclohexylcarboimide (DCCI) , as detailed i Example 4.
- DCCI dicyclohexylcarboimide
- a vesicle-forming lipid derivatize with polyglycolic acid may be formed by reaction of polygly colic acid or glycolic acid with PE in the presence of suitable coupling agent, such as DCCI, also as detailed i Example 4.
- the vesicle-forming lipids derivatized with eithe polylactic acid or polyglycolic acid form part of the inven tion herein.
- liposome containing these derivatized lipids in a 1-20 mole percent.
- lipid components used in forming the liposomes of the invention may be selected from a variety of vesicle-forming lipids, typically including phospholipids and sterols. As will be seen, one requirement of the liposomes of the present invention is long blood circulation lifetime. It is therefore useful to establish a standardized measure of blood lifetime which can be used for evaluating the effect of lipid component on blood halflife.
- One method used for evaluating liposome circulation time in vivo measures the distribution of IV injected liposomes in the bloodstream and the primary organs of the RES at selected times after injection.
- RES uptake is measured by the ratio of total liposomes in the bloodstream to total liposomes in the liver and spleen, the principal organs of the RES.
- age and sex matched mice are injected intravenously (IV) through the tail vein with a radiolabeled liposome composition, and each time point is determined by measuring total blood and combined liver and spleen radiolabel counts, as detailed in Example 6.
- the liposomes of the present invention include 1-20 mole percent of the vesicle-forming lipid derivatized with a hydro ⁇ philic polymer, described in Section I.
- the phospholipid components may be composed of predominantly of fluidic, relatively unsaturated, acyl chains, or of more saturated, rigidifying acyl chain components.
- Example 7 which examines blood/RES ratios in liposomes formed with PEG-PE, cholesterol, and PC having varying degrees of saturation (Table 4) .
- the vesicle-forming lipids may be selected to achieve a selected degree of fluidity or rigidity, to control the stability of the liposomes in serum and the rate of release of entrapped drug from the liposomes in the blood ⁇ stream and/or tumor.
- the vesicle-forming lipids may also be selected, in lipid saturation characteristics, to achieve desired liposome preparation properties. It is generally the case, for example, that more fluidic lipids are easier to formulate and down size by extrusion or homogenization than more rigid lipid components. In general, more fluidic lipids
- Cholesterol, or related cholesterol derivatives may be important, however, in regulating the rate of release of lipo ⁇ some entrapped therapeutic compounds into the bloodstream.
- PEG-liposome formulations containing high cholesterol (e.g., 30 mole percent or greater) released very little peptide or protein into serum in vitro, whereas decreasing amounts of cholesterol producing increasing loss of encapsulated poly- peptide.
- the rate of release of compound from long-circulating liposomes can be controlled by the percent cholesterol included in the liposomes.
- the vesicle-forming lipid derivatized with a hydrophilic polymer is present in an amount preferably between about 1-20 mole percent, on the basis of moles of derivatized lipid as a percentage of total moles of vesicle-forming lipids. It will be appreciated that a lower mole ratio, such as 0.1 mole percent, may be appropriate for a lipid derivatized with a large molecular weight polymer, such as one having a molecular weight greater than 100 kilodaltons.
- the hydrophilic polymer in the derivatized lipid preferably has a molecular weight between about 200-20,000 daltons, and more preferably between about 1,000-5,000 daltons.
- Example 8B which examines the effect of very short ethoxy ether moieties on blood/RES ratios indicates that polyether moieties of greater than about 5 carbon ether are required to achieve significant enhancement of blood/RES ratios.
- the liposomes may be prepared by a variety of techniques, such as those detailed in Szoka et al, 1980.
- One method for preparing drug-containing liposomes is the reverse phase evaporation method described by Szoka et al and in U.S. Patent No. 4,235,871.
- the reverse phase evaporation vesicles (REVs) have typical average sizes between about 2-4 microns and are predominantly oligolamellar, that is, contain one or a few lipid bilayer shells.
- the method is detailed in Example 5A. This method is generally preferred for preparing liposomes with encapsulated proteins high encapsulation efficiencies (up to 50%) are possible, and thus protein loss or problems of recovery and purification of non-encapsulated protein are reduced.
- Multilamellar vesicles can be formed by simple lipid-film hydration techniques. In this procedure, a mixtur of liposome-forming lipids of the type detailed above dis solved in a suitable solvent is evaporated in a vessel to for a thin film, which is then covered by an aqueous medium, a detailed in Example 5B. The lipid film hydrates to form MLVs, typically with sizes between about 0.1 to 10 microns.
- the liposomes for intravenous injection are prepared to have substantially homogeneous sizes in a selected size range between about 0.1 and 0.4, and preferably 0.1 to 0.2 micron size ranges. Liposomes in this size range have sufficiently high encapsulation volumes for carrying therapeutically effec ⁇ tive amounts of the compound to be administered. At lower liposome sizes, the ratio of liposome-encapsulated compound to free compound may too low to achieve a requisite initial dose level of liposome-encapsulated compound in the bloodstream or may not remain in circulation due to extravasation. At the same time, 0.1-0.4 micron liposomes are small enough to give long blood circulation times, as discussed below, and also to allow sterilization by sterile filtration.
- One effective sizing method for REVs and MLVs involves extruding an aqueous suspension of the liposomes through a polycarbonate membrane having a selected uniform pore size, typically 0.4, 0.2, and/or 0.1 micron pore sizes.
- the pore size of the membrane is proportional to the largest sizes of the liposomes which are produced, particularly where the pre ⁇ paration is extruded two or more times through the same size membrane.
- This method of liposome sizing is used in preparing homogeneous-size REV and MLV compositions described in the examples below.
- a more recent method involves extrusion through an asymmetric ceramic filter. The method is detailed in U.S. patent application for Liposome Extrusion Method, Serial No. 829,710, filed February 13, 1986. Homogenization methods are also useful for down-sizing liposomes.
- the composition of the invention is used for slow-release delivery into the bloodstream or a poly ⁇ peptide (peptide or protein) which is therapeutically active in the bloodstream when administered IV, but which in free form has a short blood halflife, typically 4 ' hours or less.
- polypeptides examples include hormones, such as vaso ⁇ pressin, calcitonin, oxytocin, somatotropin, human growth hormone, atrial naturectic factor (ANF) , and insulin; enzymes, such as superoxide dismutase, glucocerebrosidase, asparagin- ase, and adenosine deaminase; immunomodulators, such as inter- ferons (alpha, beta, and gamma), interleukin (1,2,3,4,5,6,7), tissue necrosis factor (TNF - alpha, beta) , and colony stimu ⁇ lating factors (M-CSF (macrophage) , G-CSF (granulocyte) , GM- CSF (granulocyte, macrophage) ; anticoagulants, such as TPA, prourokinase, and urokinase; vaccines, such as HIV-1 vaccine, hepatitis B vaccine, malaria vaccine
- polypeptides useful in the invention typically hav relatively short blood halflives, on the order of 2-4 hours o less, and are active in the picogram/ml to nanogram/ml concen tration range in the blood.
- polypeptide is preferably loaded passivel by the reverse-phase emulsion method for preparing liposomes, although many other methods, such as solvent injection o lipid hydration may be employed.
- liposome formation an sizing, free (unbound) drug can be removed by a variety o methods, for example, by gel filtration or ion exchang chromatography or diafiltration.
- the amount of fre peptide in the final sterilized composition is less than abou 20%, and preferably less than 10% of the total polypeptide contained in the composition.
- the encapsulated compound is preferably present in an amount which, in a selected liposome dose, is between 3-20 times the amount of compound which would be given as a therapeutic dose in free form by IV administration.
- a selected liposome dose will pre ⁇ ferably contain between about 3-20 ⁇ g of the peptide. Since 10-20% of this compound, e.g., 2-4 ⁇ g, may be in non-encapsu ⁇ lated form, it will be appreciated that the total amount of liposome which can be administered may be limited by the maxi- mum tolerated dose of the free compound.
- liposomes can be administered by achieving higher ratios of encapsulated to non-encapsulated compound. In general, this ratio is increased with larger liposomes, more complete free drug removal from the liposome composition, and greater liposome stability on storage.
- composition is also useful for slow-release delivery of a variety of non-peptide, water-soluble compounds which are effective in treating circulating cancers such as leukemias, for example, cytarabine, cyclophosphamide, carmustine, thio- guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
- leukemias for example, cytarabine, cyclophosphamide, carmustine, thio- guanine, bleomycin, daunorubicin, vinblastine, vincristine, and asparaginase.
- antibiotics such as gentamicin, tobramycin, amikacin, netilmicin, kanamycin, and streptomycin, cefotaxime, ceftizoxi e, and ceftriaxone
- anti-viral agents such as AZT (zidovidine) , DDI (dideoxyinosine) , DDC (didioxycytidine) , ganciclovir, D4T (didehydrodeoxythymidine) , phosphonoformate, ribavirin, and acyclovir.
- anti-viral agents such as AZT (zidovidine) , DDI (dideoxyinosine) , DDC (didioxycytidine) , ganciclovir, D4T (didehydrodeoxythymidine) , phosphonoformate, ribavirin, and acyclovir.
- Such compounds may be encapsulated by passive loading, as above, during liposome
- drugs which form weak bases at physiological pH may be actively loaded into the liposomes at high drug concentration in the liposomes.
- One method for active loading drugs into liposomes is described in co-owned U.S. patent application Serial No. 413,037, filed September 28, 1988.
- liposomes are prepared in the presence of a relatively high ammonium ion, such as 0.125 M ammonium sulfate. After sizing the liposomes to a desired size, the liposome suspension is treated to create an inside- to-outside ammonium ion gradient across the liposomal membranes.
- the gradient may be created by dialysis against a non-ammonium containing medium, such as an isotonic glucose medium, or by gel filtration, such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KC1, effectively replacing ammonium ions in the exterior phase with sodium or potassium ions.
- a non-ammonium containing medium such as an isotonic glucose medium
- gel filtration such as on a Sephadex G-50 column equilibrated with 0.15 M NaCl or KC1
- ammonium concentration inside the liposomes is preferably at least 10 times, and more preferably at least 100 to 1000 times that in the external liposome phase.
- a rela ⁇ tively dilute suspension of the liposomes e.g., less than about 50 mM lipid
- an aqueous solution of the drug e.g., less than about 50 mM lipid
- the mixture is allowed to equilibrate over an extended period, e.g., 24 hours at room temperature.
- a suspension of liposomes having a lipid con ⁇ centration of 25 mg/ml is mixed with an equal volume of anthracycline drug at a concentration of about 10 mg/ml. At the end of the incubation period, the suspension is treated to remove free (unbound) drug,
- A. Extended Lifetime in the Bloodstream One of the requirements for extended compound release into the bloodstream, in accordance with the invention, is an extended liposome lifetime in the bloodstream with IV liposome administration.
- One measure of liposome lifetime in the bloodstream in the blood/RES ratio determined at a selected time after liposome administration, as discussed above.
- Blood/RES ratios for a variety of liposome compositions are given in Table 3 of Example 6. In the absence of PEG- derivatized lipids, blood/RES ratios were 0.03 or less.
- the blood/RES ratio ranged from 0.2, for low-molecular weight PEG, to between 1.7- 4 for several of the formulations, one of which lacks cholesterol, and three of which lack a charged phospholipid (e.g., PG) .
- the blood/RES values reported above can be compared with blood/RES values reported in co-owned U.S. Patent No. 4,920,016, which used blood/RES measurement methods identical to those used in for the data presented in Tables 3 and 5.
- the best 24-hour blood/RES ratios which were reported in the above-noted patent was 0.9, for a formulation composed of GM lf saturated PC, and cholesterol.
- the next best formulations gave 24-hour blood/RES values of about 0.5.
- typical 24- hour blood/RES ratios obtained in a number of the current formulations were more than twice as high as the best formula ⁇ tions reported which have been reported to date.
- ability to achieve high blood/RES with GM X or HPI lipids was dependent on the presence of predominantly saturated lipids in the liposomes.
- Plasma kinetics of a liposomal marker in the bloodstream can provide another measure of the enhanced liposome lifetime which is achieved by the liposome formulations of the present invention.
- Figure 7 and 8 discussed above show the slow loss of liposomal marker over a 24 hour period in typical PEG-lipo- some formulations, substantially independent of whether the marker is a lipid or an encapsulated water-soluble compound
- Figure 9 shows the kinetics of liposome loss from the bloodstream for a typical PEG-lipsome formulation and the same liposomes in the absence of a PEG-derivatized lipid. After 24 hours, the percent marker remaining in the PEG-liposomes was greater than about 20%, whereas the conventional liposomes showed less than 5% retention in the blood after 3 hours, and virtually no detectable marker at 24 hours.
- liposome size was been investigated by comparing loss of liposomal marker in intra- venously injected liposomes having selected sizes between about 0.1 and 0.25 microns. Experimental details are given in Example 10. The results, given in Figure 10, show about 10% or greater liposome marker present in the blood after 24 hours for each of the liposome formulations. Highest blood life- times were achieved with the smallest liposomes. Thus, although all of the liposome preparations give high blood lifetimes, it is also clear that liposome size can be selected to produce desired increase or decrease in total drug release time.
- the liposome size between 0.1 and 0.4 microns allows relatively high compound loading in the lipo ⁇ somes, for effective compound release as the percentage of liposomes in the bloodstream even at relatively low liposome concentrations in the bloodstream. This is typically an important consideration since the total amount quantity of liposomes which can be administered will be limited, due to the unavoidable presence of some free compound in injected composition.
- Example 16 The study reported in Example 16 demonstrates a simila ability to control release rates of large proteins from long- circulating liposomes.
- PEG-liposomes containing encapsu ⁇ lated M-CSF (a 55 kilodalton protein) were examined for per- cent retention in the bloodstream, of both lipid and protein components.
- the data plotted in Figure 15 show liposome lipi (solid triangles) and protein (solid circles) kinetics 24 hours after IV injection for a PEG-lipsome formulation con ⁇ taining 30 mole percent cholesterol. The data indicate about 20% loss of encapsulated material over 24 hours, as discusse in Example 16.
- Figure 17 shows a similar plot for PEG-liposomes without cholesterol.
- the data here show a 40-50% loss of M-CSF after 24 hours.
- the plots o protein release from cholesterol (solid circles) and no cholesterol (solid triangles) PEG-liposomes are obtained.
- the plots illustrate the markedly different protein release kinetics which can be obtained with long circulating lipo- somes, by varying cholesterol content of the liposomes.
- Another feature of the data shown in Figure 17 is th relatively high percent (at least 3%) of initially injecte protein which is released at 24 hours in both formulations. IV. Intravenous Liposome Treatment
- the invention includes, in one aspect, a method for extending to at least 24 hours, the period of effective activity of an therapeutic compound.
- the compound is one which can be administered intravenously in a therapeutically effective amount, and which has a halflife in the bloodstream, in free form, of less than about 4 hours.
- a liposome composition such as described above, containing the compound in liposome-entrapped form.
- the size, lipid composition, and extent compound loading of the drug are selected, according to the desired release rates and total release times, as con ⁇ sidered in Section III above.
- the composition is injected intravenously to a subject at a dose which contains an amount of the compound which is at least 3, and typically 5-20 times the therapeutically effec ⁇ tive dose.
- a therapeutically effective dose of a compound is 10 ⁇ g/Kg body weight
- the liposome com- position would be injected at a liposome dose of at least 30 ⁇ g compound/Kg, and typically between 50-200 ⁇ g compound/Kg body weight.
- the amount of material which can be injected is generally limited by the maximum tolerated dose of free compound, since 5-20% or more of the compound may be in free (non-entrapped) form when the composition is admi ⁇ nistered.
- the maximum tolerated dose of a compound in free form is 2 ⁇ g/Kg body weight
- the lipo ⁇ some composition contains 10% non-entrapped compound
- the highest dose of liposome composition which can be given is 20 ⁇ g/Kg body weight.
- Figure 13 shows the effect, measured in percent predosage urine flow, of IV injection of free vaso ⁇ pressin at dose levels of 0.2 ⁇ g (solid squares), 0.8 ⁇ g (solid triangles) and 2.0 ⁇ g (solid circles) .
- the reduction in urine flow is maximum after 1 day, but returns to control levels (open circles) by day 2.
- Figure 14 shows the effect on urine flow by vasopressin administered IV in PEG-liposomes, at dosage levels of 2 ⁇ g (solid squares) , 8 ⁇ g (solid triangles) and 24 ⁇ g (solid cir ⁇ cles) .
- a pronounced reduction in urine flow was observed within one day, with a slight rebound toward control values by day 2 — an effect likely due, in part, to free peptide in the liposome formulation.
- a marked reduction in urine flow was observed for at least 7 days following IV administration. It is noted that the long-term therapeutic effect is saturated at an 8 ⁇ g dose, with no further effect observed at 24 ⁇ g.
- the long-live liposome composition of the invention is also effective for slow release of a liposome- entrapped compound from a subcutaneous (SubQ) site into the bloodstream.
- a subcutaneous site into the bloodstream.
- therapeutic effects of up to 3 weeks or more can be achieved by a single subcutaneous injection of the liposome composition of the invention.
- the experimental model used to demonstrate this method is the vasopressin model described above, and detailed in Example 17. Briefly, a treatment method involving SubQ injection of free vasopressin was compared, for duration of physiological effect, with vasopressin administered SubQ in PEG-liposomes.
- Figure 18A shows the depression in urine production observed with SubQ administration of free vasopressin at doses of 2 ⁇ g
- FIG. 18B shows the effect of SubQ administration of the peptide in PEG liposomes. The lowest does administered, 25 ⁇ g (closed triangles) gave a slight prolongation of activity, to about 8 days. A vasopressin dose of 100 ⁇ g (closed circles) showed a significant reduction in urine output out to about 20 days. An even longer effect, of at least 24 days, was observed at a dose of 400 ⁇ g (closed squares) .
- the treatment method employing vasopressin is designed for treatment of diabetes insipidus, by long-term administration of vasopressin from a SubQ site. More generally, the method is designed for extending to at least one week, the period of effective activity of an therapeutic compound which can be administered intravenously in a therapeutically effective amount.
- the method utilizes liposomes (i) composed of vesicle-forming lipids and between 1-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer, and (ii) having a selected mean particle diameter in the size range preferably between about 0.07-.15 microns, and having the compound in liposome-entrapped form.
- the liposome composition is administered subcutaneously at a dose of the composition which contains an amount of the liposome-entrapped compound which is at least ten times the therapeutically effective intravenously administered amount.
- the method can be used for therapeutic delivery of the compound over a several- week period.
- the ability of the liposome composition of the invention to produce a long-term therapeutic effect from a SubQ site suggests that the liposomes taken up from this site through the lymphatics may be able to successfully evade the normal lymphatic clearance mechanisms, including Kupfer cells.
- This mechanism is supported by studies on araC administration by the interperitoneal (IP) route by PEG-liposomes. Briefly, it was found that PEG-liposomes containing entrapped araC and administered by IP route produced a 250-300% increase in survial in animals having L1210 leukemias, compared with about 120% increase in survival with the free drug given by the IP route. The results suggests that PEG-liposomes are capable of migrating from the peritoneum through the lymphatics into the bloodstream.
- Cholesterol Cholesterol (Choi) was obtained from Sigma (St. Louis, MO) .
- Sphingomyelin (SM) egg phosphatidylcholine (lecithin or PC), partially hydrogenated PC having the composition IV40, IV30, IV20, IV10, and IV1, phosphatidylglycerol (PG) , phospha- tidylethanolamine (PE) , dipalmitoyl-phosphatidyl glycerol (DPPG) , dipalmitoyl PC (DPPC) , dioleyl PC (DOPC) and distear- oyl PC (DSPC) were obtained from Avanti Polar Lipids (Birming ⁇ ham, AL) or Austin Chemical Co (Chicago, II) .
- Cyanuric chloride (5.5 g; 0.03 mol) was dissolved in 400 ml of anhydrous benzene containing 10 g of anhydrous sodium carbonate, and PEG-1900 (19 g; 0.01 mol) was added and the mixture was stirred overnight at room temperature. The solu ⁇ tion was filtered, and 600 ml of petroleum ether (boiling range, 35-60°) was added slowly with stirring. The finely divided precipitate was collected on a filter and redissolved in 400 ml of benzene.
- the activated PEG was analyzed for nitrogen and an appropriate correction was applied in selecting the quantity of reactant to use in further synthetic steps.
- the quantity of material used in the next synthetic step was increased by 100/20, or 5-fold.
- the product contained 50% of the theoretical amount of nitrogen only 100/50 or a 2-fold increase was needed.
- the solid compound was taken up in 24 ml of ethanol/- chloroform; 50/50 chloroform and centrifuged to remove insoluble material. Evaporation of the clarified solution to dryness under vacuum afforded 21 mg (7.62 ' micromoles) of colorless solid.
- the reaction mixture was cooled and the clear solution formed at room temperature.
- the solution was diluted to 50.0 ml with dry benzene and stored in the refrigerator as a 100 micromole/ml stock solution of the imidazole carbamate of PEG ether 1900.
- the solvent from the remaining reaction mixture was evapo rated under vacuum.
- the residue was taken up in 10 m methylene chloride and placed at the top of a 21 mm x 270 m chromatographic absorption column packed with Merck Kieselge 60 (70-230 mesh silica gel) , which has been first rinsed wit methylene chloride.
- the mixture was passed through th column, in sequence, using the following solvents.
- Air from the reaction vessel was displaced with nitrogen.
- the vessel was closed and heated in a sand bath 110°C for 22 hours.
- the solvent was evaporated under vacuum to obtain 1.58 grams of brownish- colored oil.
- the crude product was dissolved in 3 ml of the same solvent and transferred to the top of the chromatography column.
- the chromatogram was developed with the same solvent and sequential 30 ml portions of effluent were assayed each by TLC.
- the TLC assay system used silica gel coated glass plates, with solvent combination butanone/acetic acid/water; 40/25/5; v/v/v. Iodine vapor absorption served for visualization.
- the desired N-1-trimethylsilyloxy polyethylene glycol 1500 PE was a chief constituent of the 170-300 ml portions of column effluent. When evaporated to dryness under vacuum these portions afforded 111 mg of pale yellow oil of compound.
- PE compound was dissolved in 2 ml of tetrahydrofuran. To this, 6 ml acetic acid and 2 ml water was added. The resulting solution was let to stand for 3 days at 23°C. The solvent from the reaction mixture was evaporated under vacuum and dried to constant weight to obtain 75 mg of pale yellow wax. TLC on Si-C18 reversed-phase plates. developed with a mixture of 4 volumes ethanol, 1 volume water indicated that some free PE and some polyglycol-like materia formed during the hydrolysis.
- N-Polyethylene glycol 1500 P.E. by fluorid deprotection.
- 500 mg of crude N-1-trimethylsilyloxy polyethylene glyco PE was dissolved in 5 ml tetrahydrofuran and 189 mg (0.60 millimoles) of tetrabutyl ammonium fluoride was added an agitated until dissolved.
- the reactants were let to stan over night at 20°C.
- the solvent was evaporated under reduced pressure and th residue was dissolved in 10 ml chloroform, washed with tw successive 10 ml portions of water, and centrifuged t separate chloroform and water phases.
- the chloroform phas was evaporated under vacuum to obtain 390 mg of orange-brown wax, which was determined to be impure N-polyethylene glycol 1500 PE compound.
- the wax was re-dissolved in 5 ml chloro ' form and trans- ferred to the top of a 21 X 270 mm column of silica gel moistened with chloroform.
- the column was developed by passing 100 ml of solvent through the column.
- the Table 2 solvents were used in sequence:
- the tube was cooled to room temperature, and 6 ml of chloroform added.
- the chloroform solution wa washed with three successive 6 ml volumes of water, centrifuged after each wash, and the phases separated with Pasteur pipette.
- the remaining chloroform phase was filtere with suction to remove suspended distearolyphosphatidyl ethanola ine.
- the filtrate was dried under vacuum to obtai 212 mg of semi-crystalline solid.
- This solid was dissolved in 15 ml of a mixture of volumes ethanol with 1 volume water and passed through a 50 m deep and 21 mm diameter bed of H + Dowex 50 cation exchang resin, and washed with 100 ml of the same solvent.
- Phosphate analysis suggests a molecular weight of 924,000.
- Example 5 Preparation of REVs and MLVs A. Sized REVs A total of 15 ⁇ moles of the selected lipid components, in the mole ratios indicated in the examples below, were dis ⁇ solved in chloroform and dried as a thin film by rotary evapo ⁇ ration. This lipid film was dissolved in 1 ml of diethyl ether washed with distilled water. To this lipid solution was added 0.34 ml of an aqueous buffer solution containing 5 ⁇ i Tris, 100 mM NaCl, 0.1 mM EDTA, pH 7.4, and the mixture was emulsified by sonication for 1 minute, maintaining the tempe rature of the solution at or below room temperature. Wher the liposomes were prepared to contain encapsulated [1251] tyraminyl-inulin, such was included in the phosphate buffer at a concentration of about 4 ⁇ Ci/ml buffer.
- the ether solvent was removed under reduced pressure at room temperature, and the resulting gel was taken up in 0.1 ml of the above buffer, and shaken vigorously.
- the resulting REV suspension had particle sizes, as determined by microscopic examination, of between about 0.1 to 20 microns, and was com ⁇ posed predominantly of relatively large (greater than 1 micron) vesicles having one or only a few bilayer lamellae.
- the liposomes were extruded twice through a polycarbonate filter (Szoka, 1978), having a selected pore size of 0.4 microns or 0.2 microns. Liposomes extruded through the 0.4 micron filter averaged 0.17+ (0.05) micron diameters, and through the 0.2 micron filter, 0.16 (0.05) micron diameters. Non-encapsulated [1251] tyraminyl-inulin was removed by passing the extruded liposomes through Sephadex G-50 (Phar ⁇ macia) .
- Multilamellar vesicle (MLV) liposomes were prepared according to standard procedures by dissolving a mixture of lipids in an organic solvent containing primarily CHC1 3 and drying the lipids as a thin film by rotation under reduced pressure.
- a radioactive label for the lipid phase was added to the lipid solution before drying.
- the lipid film was hydrated by addition of the desired aqueous phase and 3 mm glass beads followed by agitation with a vortex and shaking above the phase transition temperature of the phospholipid component for at least 1 hour.
- a radioactive label for the aqueous phase was included in the buffer.
- the hydrated lipid was repeatedly frozen and thawed three times to provide for ease of the following extrusion step.
- the size of the liposome samples was controlled by extru ⁇ sion through defined pore polycarbonate filters using pres ⁇ surized nitrogen gas.
- the ' liposomes were extruded one time through a filter with pores of 0.4 ⁇ m and then ten times through a filter with pores of 0.1 ⁇ m.
- the liposomes were extruded three times through a filter with 0.2 ⁇ m pores followed by repeated extrusion with 0.05 ⁇ m pores until the mean diameter of the particles was below 100 nm as determined by DLS.
- Unencapsu- lated aqueous components were removed by passing the extruded sample through a gel permeation column separating the lipo ⁇ somes in the void volume from the small molecules in the included volume.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and l-palmitoyl-2-oleyl-PE (POPE) was prepared as in Example 2.
- the PEG-POPE lipid was combined with and partially hydrogen- ated egg PC (PHEPC) in a lipid:lipid mole ratio of about 0.1:2, and the lipid mixture was hydrated and extruded through a 0.1 micron polycarbonate membrane, as described in Example 4, to produce MLVs with average size about 0.1 micron.
- the MLV lipids included a small amount of radiolabeled lipid marker 14 C-cholesteryl oleate, and the encapsulated marker 3 H- inulin.
- the liposome composition was injected and the percent initial injected dose in mice was determined as described in Example 4, at 1, 2, 3, 4, and 24 after injection.
- the time course of loss of radiolabeled material is seen in Figure which is a plot of percent injected dose for encapsulate inulin (solid circles), inulin marker corrected to the initia injection point of 100% (open circles) , and lipid marke (closed triangles), over a 24-hour period post injection. A seen, both lipid and encapsulated markers showed greater tha 10% of original injected dose after 24 hours.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and distearylPE (DSPE) was prepared as in Example 2.
- the PEG-PE lipids were formulated with selected lipids from among sphin- gomyelin (SM) , fully hydrogenated soy PC (PC) , cholesterol (Choi) , partially hydrogenated soy PC (PHSPC) , and partially hydrogenated PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4.
- SM sphin- gomyelin
- PC fully hydrogenated soy PC
- PHSPC partially hydrogenated soy PC
- PC lipids identified as PC IV1, IV10, IV20, IV30, and IV40 in Table 4.
- the lipid components were mixed in the molar ratios shown at the left in Table 5, and used to form MLVs sized to 0.1 micron as described in Example 4.
- the blood and L+S (RES) values were used to calculate a blood/RES value for each composition.
- the column at the right in Table 4 shows total amount of radioactivity recovered.
- the two low total recovery values in the table indicate anomalous clearance behavior.
- the results from the table demonstrate that the blood/RES ratios are largely independent of the fluidity, or degree of saturation of the phospholipid components forming the lipo ⁇ somes. In particular, there was no systematic change in blood/RES ratio observed among liposomes containing largely saturated PC components (e.g., IV1 and IV10 PC's), largely unsaturated PC components (IV40) , and intermediate-saturation components (e.g., IV20) .
- largely saturated PC components e.g., IV1 and IV10 PC's
- IV40 largely unsaturated PC components
- IV20 intermediate-saturation components
- the PEG-PE lipids were formulated with selected lipids from among sphin- gomyelin (SM) , fully hydrogenated soy PC (PC) , and cholesterol
- Methoxy-ethyoxy-cholesterol was prepared by coupling methoxy ethanol to cholesterol via the trifluorosulfonate coupling method described in Section I.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6.
- the PEG-PE lipids were formulated with selected lipids from among distearylPC (DSPC) , partially hydrogenated soy PC (PHSPC) , cholesterol, and ethoxylated cholesterol, as indicated at the right in Table 7.
- DSPC distearylPC
- PHSPC partially hydrogenated soy PC
- cholesterol ethoxylated cholesterol
- Example 9 Effect of Charged Lipid Components on Blood/RES Ratios in PEG-PE Liposomes
- PEG-PE composed of methoxy PEG, molecular weight 1900 and was derivatized DSPE as described in Example 6.
- the PEG- PE lipids were formulated with lipids selected from among egg PG (PG) , partially hydrogenated egg PC (PHEPC) , and choleste ⁇ rol (Choi), as indicated in the Figure 6.
- the two formula ⁇ tions shown in the figure contained about 4.7 mole percent (triangles) or 14 mole percent (circles) PG.
- the lipids were prepared as MLVs, sized to 0.1 micron as in Example 4.
- the percent of injected liposome dose present 0.25, 1, 2, 4, and 24 hours after injection are plotted for both formula ⁇ tions in Figure 6. As seen, the percent PG in the composition had little or no effect on liposome retention in the bloodstr ⁇ eam. The rate of loss of encapsulated marker seen is also similar to that observed for similarly prepared liposomes containing no PG.
- PEG-DSPE prepared as above with PEG-1900, was formulated with partially hydrogenated egg PC (PHEPC) , and cholesterol (Choi), at a mole ratio of 0.15: 1.85: 1.
- PHEPC partially hydrogenated egg PC
- Choi cholesterol
- the liposomes were sized by extrusion through 0.25, 0.15 or 0.1 micron polycarbo ⁇ nate filters, to produce liposome sizes of about 0.4, 0.2, and 0.1 microns, respectively.
- Non-encapsulated 3 H-inulin was removed by gel filtration.
- each of the three liposome were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 10. All three formulations show long blood half- lives, as evidence by at least about 10% liposome marker remaining after 24 hours.
- the 0.1 micron formulation (solid squares) is longer lived than the 0.2 micron formulation (solid circles) which is in turn longer lived than the 0.4 micron formulation.
- Example 11 Effect of Other Hydrophilic Polymers on Blood Lifetime Polylactic acid-DSPE or polyglycolic acid-DSPE, prepared as above, was formulated with lipids selected from among hydrogenated soy PC (HSPC) , and cholesterol (Choi) , at a weight ratio of either 2: 3.5: 1 or 1: 3.5: 1.
- the liposomes were sized by extrusion through a 0.1 micron polycarbonate filter.
- the liposomes were labeled by Ga-DF as described in Example 5.
- These liposome formulations were injected intravenously, and the percent of injected liposome marker in the blood was measured at 1, 2, 3, 4, and 24 hours, with the results shown in Figure 11.
- PEG-PE composed of methoxy PEG, molecular weight 1900 and distearyl PE (DSPE) was prepared as in Example 2.
- the PEG-PE lipids were formulated with PHEPC, and cholesterol, in a mole ratio of 0.15:1.85:1.
- a second lipid mixture contained the same lipids, but without PEG-PE.
- Liposomes were prepared from the two lipid mixtures as described in Example 5, by lipid hydration in the presence of DF followed by sizing to 0.1 micron, removal of non-entrapped DF by gel filtration, and Ga labeling as described in Example 5. Both compositions contained 10 ⁇ M lipid/ml in 0.15 M NaCl, 0.5 mM desferal.
- the two liposome compositions (0.4 ml) were injected IV in animals, as described in Example 6. At time 0.25, 1, 3 or 5, and 24 hours after injection, blood samples were removed and assayed for amount inulin remaining in the blood, expressed as a percentage of the amount measured immediately after injection. The results are shown in Figure 9. As seen, the PEG-coated liposomes have a blood halflife of about 11 hours, and nearly 30% of the injected material is present in the blood after 24 hours. By contrast, uncoated liposomes showed a halflife in the blood of less than 1 hour. At 24 hours, the amount of injected material was undetectable.
- the vein was nicked and a bevelled 6-inch section of poly ⁇ ethylene catheter tubing (PE_50 Clay-Adams) filled with normal saline (0.9%) or 5% dextrose was inserted into the vein. Correct placement was verified by venous drawback and flush using a 1 cc syringe. The catheter was anchored loosely to the vein by passing a small tie under the vessel and knotting it around the cannula.
- PE_50 Clay-Adams poly ⁇ ethylene catheter tubing
- test solution 150-1000 ⁇ l of test solution was administered intravenously.
- the dose volume administered was adjusted to give the desired total amount of vasopressin, for example 0.2, 0.8, and 3 ⁇ g of aqueous vaso- pressin.
- the venous catheter was then removed, the femoral vein was tied off, and both leg incisions were closed. The animals were allowed to regain consciousness.
- Figure 12 shows the percent predosage urine flow in animals treated with saline (open circles) or 0.2 ⁇ g (solid squares) 0.8 ⁇ g (solid triangles), and 2 ⁇ g (solid circles) vasopressin solution.
- urine production showed a dose-dependent drop.
- urine production was substantially back to control levels.
- lipid composition used in preparing the liposomes was PEG-DSPE, PC, sphingomyelin, and cholesterol, in a mole ratio 0.2: 1: 1: 1.
- Lipid mixtures for a 1 ml final volume of liposomes with a phospholipid concentration of 10 ⁇ mol/ml were dissolved in chloroform and evaporated to dryness under reduced pressure. After residual solvent was removed by high vacuum for 1 hour the mixture was dissolved in ethyl ether freshly washed with phosphate buffer at pH 7.
- aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing sufficient arginine vasopressin to give a final drug concentration of 510 ⁇ g/ml was added to the lipids in ether.
- a trace amount of 3 H-labeled vasopressin was added to the vasopressin solution for determination of protein concentrations.
- the ether was removed by controlled rotoevaporation, and additional drug-free buffer added to give a 1 ml solution immediately after gel dispersion.
- the vasopressin content of the resulting liposomes was determined by separating free from liposome-bound by gel filtration on Bio-Gel A15.
- the liposomes were extruded through 0.4 ⁇ m Nuclepore filters (Olsen et al., 1979) and particle size distribution measured by dynamic light scattering with a Nicomp model 200. Mean diameter ranged between 0.2 ⁇ m and 0.5 ⁇ m and showed a low polydispersity. Unbound vasopressin was removed by dialysis and monitored by gel chromatography as above.
- PEG-liposome preparations from above were administered intravenously to rats prepared as in Example 13, at liposomal doses 2 ⁇ g (solid squares) 8 ⁇ g (solid triangles) , and 24 ⁇ g (closed circles) vasopressin solution.
- Percent predosage urine flow was measured as above, with the results shown in Figure 14.
- the data show the substantially the same dose- dependent depression in urine production in the first day after drug administration, presumably resulting predominantly from non-entrapped vasopressin in the lipsome formulations. In contrast to free peptide administration, however, all three formulation produced a significant inhibition in urine production with respect to control (open circles) over a 2-8 day period after liposome administration.
- Example 15 Treatment with PEG-Liposomal Vasopressin: Effect of Liposome Cholesterol Concentration Large unilamellar liposomes were prepared as in Example 14, with liposomes containing either 33, 16, or 0 mole percent cholesterol. Vasopressin encapsulation, lipsome sizing, and free peptide removal was carried out as in Example 14.
- the three PEG-liposome preparations were administered intravenously to rats prepared as in Example 13, at liposomal doses giving 8 ⁇ g vasopressin, and the percent predosage urine production was measured over a 9 day period following liposome administration.
- the results are shown in Figure 15, for saline control (open circles) and PEG-liposomes with 0 (solid squares) , 16 (solid triangles) , and 33 (solid circles) mole percent cholesterol.
- the day-1 response shows a marked dependence on percent cholesterol, with the greatest effect on urine flow being produced in liposomes with the lowest mole ratio of choleste ⁇ rol.
- This result is consistent with in vitro stability studies of vasopressin release from PEG-liposomes in serum: In the presence of serum, little release of vasopressin was seen in liposomes containing greater than 30 mole percent cholesterol. By contrast, formulations containing reduced amounts of cholesterol showed increasingly higher release rates of encapsulated peptide. Thus, it would appear that the significantly higher diuretic effect seen after 1 day with low and no cholesterol formulations is due to the presence of free peptide released from the liposomes in serum.
- Example 16 Blood Clearance Kinetics of M-CSF from PEG-Liposomes A lipid film containing PEG-DSPE, PHEPC IV-40, cholesterol, and ⁇ -tocopherol, in a mole ratio 5:61:33:1, was hydrated with distilled water, and the resulting MLVs were sonicated for 30 minutes to form SUVs. M-CSF was concentrated and a portion of the protein was labeled with U125I-iodine.
- Equal volumes (2 ml) of the protein solution and SUVs were mixed, and the mixture was frozen in an acetone/dry bath, and lyophilized overnight.
- the dried material was rehydrated in 0.8 ml of distilled water, and the resulting liposome suspension was extruded 1 time through a 0.4 ⁇ polycarbonate filter, and 3 times through a 0.2 ⁇ filter.
- the sized liposomes were diluted to 10 ml in distilled water, washed washed two times with high speed centrifugation, and the washed pellet was resuspended in 0.9 ⁇ l of sterile buffer, to a final concentration of 40 ⁇ ol lipid/ml and between 0.5 and 1.25 mg protein/ml.
- PEG-liposome preparations from above were administered intravenously to animals as in Example 6, and the blood levels of M-CSF were measured at 1, 2, 4, and 24 hours after rats prepared as in Example 14, at liposomal doses 2 ⁇ g (solid squares) 8 ⁇ g (solid triangles) , and 24 ⁇ g (closed circles) vasopressin solution. Similar measurements were made for an equivalent amount of M-CSF administered in solution form.
- the plasma kinetics for the PEG-liposome formulation containing 30 mole percent cholesterol are shown in Figure 15. The data show rapid clearance of free protein (solid triangles) with less than 1% protein remaining in the blood at 24 hours, compared with about 8% for liposome-associated protein (solid circles) .
- Percent liposomes remaining in the bloodstream was slightly greater than 10%.
- a comparison of the clearance of rates of the lipid and pro ⁇ tein markers indicates that about 20% of the protein marker was released from the liposomes by 24 hours post injection.
- the plasma kinetics obtained with cholesterol-free PEG- liposomes is shown in Figure 16.
- Percent liposomes remaining after 24 hours was about 8.5 (solid triangles) compared with about 4.5% for liposome-associated M-CSF.
- the radioactive counts in the liposome lipid marker and in the encapsulated protein were normalized to 100% initial values, and the percent injected dose released into the blood ⁇ stream over time was then determined from the ' difference be- tween the normalized protein and normalized liposome marker radioactivity levels.
- a plot of the calculated values of percent protein released at 1, 2, 4, and 24 hours post injec ⁇ tion is shown in Figure 17.
- the plot for the cholesterol-free formulation shows a protein release peak at 2 hours, with a gradual decline in amount released in the 2-24 hour period in the no-cholesterol formulation (solid triangles) .
- the amount of protein released from the liposomes at 24 hours was between 3-4 percent of the total administered.
- the plot for the formulation containing 30 mole percent cholesterol shows a gradual increase in release protein release rate over 24 hours.
- the amount of protein released from the liposomes at 24 hours was about 3 percent of the total administered.
- both formulations showed relatively high levels of protein release (3% or greater) at 24 hours.
- Example 17 Subcutaneously Administered Liposomes
- the lipid composition of the thin film was PEG- DSPE, HEPC, and cholesterol, in a mole ratio 0.15:1.85:1.
- the thin film was hydrated with an aqueous buffer (5 mM Tris, 100 mM NaCl, 0.1 mM EDTA) containing arginine vasopressin at 7.5 mgs/ml.
- the MLVs were sized by repeated extrusion through a 0.1 micron polycarbonate membrane, and free (non-encapsulated) peptide was removed by gel filtration, as in Example 15. The final concentration of PEG-liposomes in the suspension was 100 ⁇ M/ml.
- Vasopressin in free form was administered subcutaneously (1 ml) to Brattleboro rats, as in Example 13.
- the site of subcutaneous injection was the dorsal neck region.
- the doses administered were 2 ⁇ g (solid triangles) , 25 ⁇ g (solid circles) , 50 ⁇ g (solid squares) , and 100 ⁇ g (solid diamonds) .
- the percent of predosage urine flow observed is plotted in Figure 18A.
- the percent of predosage urine flow observed is plotted in Figure 18B.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019920700919A KR920703013A (en) | 1989-10-20 | 1990-10-19 | Liposomal Microretent Compositions and Methods |
DE69015207T DE69015207T2 (en) | 1989-10-20 | 1990-10-19 | LIPOSOME MICRORESERVOIR COMPOSITION AND METHOD. |
KR1019920700918A KR0134982B1 (en) | 1989-10-20 | 1990-10-19 | Lipsome microreservoir composition and method |
EP90916409A EP0496813B1 (en) | 1989-10-20 | 1990-10-19 | Liposome microreservoir composition and method |
NO92921213A NO921213L (en) | 1989-10-20 | 1992-03-27 | LIPOSOM MICROR RESERVE COMPOSITION AND PROCEDURE |
FI921763A FI921763A0 (en) | 1989-10-20 | 1992-04-21 | MIKRORESERVOARKOMPOSITION OCH FOERFARANDE FOER LIPOSOM. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US425,224 | 1989-10-20 | ||
US07/425,224 US5013556A (en) | 1989-10-20 | 1989-10-20 | Liposomes with enhanced circulation time |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991005545A1 true WO1991005545A1 (en) | 1991-05-02 |
Family
ID=23685679
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006034 WO1991005545A1 (en) | 1989-10-20 | 1990-10-19 | Liposome microreservoir composition and method |
PCT/US1990/006211 WO1991005546A1 (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/006211 WO1991005546A1 (en) | 1989-10-20 | 1990-10-19 | Solid tumor treatment method and composition |
Country Status (18)
Country | Link |
---|---|
US (2) | US5013556A (en) |
EP (2) | EP0496813B1 (en) |
JP (4) | JP3571335B2 (en) |
KR (2) | KR920703013A (en) |
AT (2) | ATE115401T1 (en) |
AU (2) | AU642679B2 (en) |
CA (2) | CA2067178C (en) |
DE (3) | DE19675048I2 (en) |
DK (1) | DK0496835T3 (en) |
ES (1) | ES2071976T3 (en) |
FI (2) | FI105151B (en) |
GR (1) | GR3017060T3 (en) |
HK (1) | HK14097A (en) |
IL (2) | IL96069A (en) |
LU (1) | LU88854I2 (en) |
NL (1) | NL960031I2 (en) |
NO (3) | NO304637B1 (en) |
WO (2) | WO1991005545A1 (en) |
Cited By (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994007537A1 (en) * | 1992-10-05 | 1994-04-14 | Stichting Voor De Technische Wetenschappen | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
WO1994007466A1 (en) * | 1992-10-07 | 1994-04-14 | Liposome Technology, Inc. | Compositions for treatmewnt of inflamed tissues |
WO1994020073A1 (en) * | 1993-03-03 | 1994-09-15 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
WO1996010391A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
WO1997021429A1 (en) * | 1995-12-11 | 1997-06-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid |
WO1998008489A1 (en) * | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
WO1998016202A2 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome composition and method |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
WO1999027908A1 (en) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US6096720A (en) * | 1995-08-01 | 2000-08-01 | Novartis Ag | Liposomal oligonucleotide compositions |
WO2000066126A2 (en) * | 1999-04-29 | 2000-11-09 | Alza Corporation | Liposome compositions for improved drug retention |
WO2001011069A1 (en) | 1999-08-06 | 2001-02-15 | Celltech R&D Limited | Freeze/thawed lipid complexes and their preparation |
US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6316024B1 (en) | 1996-10-11 | 2001-11-13 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
EP1651187A2 (en) * | 2003-07-31 | 2006-05-03 | The Board Of Regents, The University Of Texas System | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
US7358068B2 (en) | 2002-09-13 | 2008-04-15 | Replicor, Inc. | Antiviral oligonucleotides |
EP2003207A2 (en) | 2000-01-18 | 2008-12-17 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2140872A2 (en) | 2008-07-02 | 2010-01-06 | Kenneth Wileford | Composition for the treatment of skin conditions comprising sea water with additional magnesium |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
EP2174945A1 (en) | 2001-08-01 | 2010-04-14 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2010042281A2 (en) | 2008-08-25 | 2010-04-15 | Excaliard Pharmaceuticals | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
US7718632B2 (en) | 2007-06-15 | 2010-05-18 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
WO2010068816A1 (en) | 2008-12-10 | 2010-06-17 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
EP2221376A2 (en) | 2001-06-21 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
EP2246443A1 (en) | 2001-05-14 | 2010-11-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2270231A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2270230A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
EP2272985A1 (en) | 2001-08-07 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2280019A1 (en) | 2001-07-25 | 2011-02-02 | ISIS Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US7888498B2 (en) | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
EP2284267A2 (en) | 2003-08-18 | 2011-02-16 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US7960350B2 (en) | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
EP2332955A2 (en) | 2001-07-30 | 2011-06-15 | ISIS Pharmaceuticals, Inc. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
EP2336318A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336319A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
EP2388318A1 (en) | 2001-12-10 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
EP2392583A1 (en) | 2006-05-19 | 2011-12-07 | Alnylam Europe AG. | RNAi modulation of Aha and therapeutic uses thereof |
US8148344B2 (en) | 2008-03-27 | 2012-04-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for mediating RNAi in vivo |
WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
EP2468865A1 (en) | 2004-02-06 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
WO2012177906A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
WO2012177947A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
EP2617828A1 (en) | 2007-12-10 | 2013-07-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor VII gene |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
WO2013155204A2 (en) | 2012-04-10 | 2013-10-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
EP2690175A2 (en) | 2008-09-02 | 2014-01-29 | Alnylam Pharmaceuticals | Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
EP2712926A2 (en) | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
WO2014107731A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
WO2014160871A2 (en) | 2013-03-27 | 2014-10-02 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
EP2810643A2 (en) | 2009-08-14 | 2014-12-10 | Alnylam Pharmaceuticals Inc. | Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus |
US8926955B2 (en) | 2008-12-22 | 2015-01-06 | Creabilis S.A. | Synthesis of polymer conjugates of indolocarbazole compounds |
WO2015050990A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
EP2937418A1 (en) | 2008-10-20 | 2015-10-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP2944646A1 (en) | 2005-09-29 | 2015-11-18 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016094897A1 (en) | 2014-12-12 | 2016-06-16 | The Jackson Laboratory | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
EP3109321A1 (en) | 2008-09-25 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
WO2017015109A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP3456827A2 (en) | 2010-06-02 | 2019-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
WO2020037125A1 (en) | 2018-08-16 | 2020-02-20 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
WO2020113135A1 (en) | 2018-11-29 | 2020-06-04 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
EP3674409A1 (en) | 2011-03-29 | 2020-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
EP3693463A1 (en) | 2013-10-04 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2021046122A1 (en) | 2019-09-03 | 2021-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP3797789A1 (en) | 2015-01-20 | 2021-03-31 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021207167A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Families Citing this family (1493)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5882330A (en) * | 1984-05-25 | 1999-03-16 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5456663A (en) * | 1984-05-25 | 1995-10-10 | Lemelson; Jerome H. | Drugs and methods for treating diseases |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
JPH0720857B2 (en) * | 1988-08-11 | 1995-03-08 | テルモ株式会社 | Liposome and its manufacturing method |
US6132763A (en) * | 1988-10-20 | 2000-10-17 | Polymasc Pharmaceuticals Plc | Liposomes |
GB8824593D0 (en) * | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Liposomes |
US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
US5843473A (en) * | 1989-10-20 | 1998-12-01 | Sequus Pharmaceuticals, Inc. | Method of treatment of infected tissues |
US5527528A (en) * | 1989-10-20 | 1996-06-18 | Sequus Pharmaceuticals, Inc. | Solid-tumor treatment method |
US20010051183A1 (en) * | 1989-10-20 | 2001-12-13 | Alza Corporation | Liposomes with enhanced circulation time and method of treatment |
US5620689A (en) * | 1989-10-20 | 1997-04-15 | Sequus Pharmaceuuticals, Inc. | Liposomes for treatment of B-cell and T-cell disorders |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5656211A (en) * | 1989-12-22 | 1997-08-12 | Imarx Pharmaceutical Corp. | Apparatus and method for making gas-filled vesicles of optimal size |
US5441746A (en) * | 1989-12-22 | 1995-08-15 | Molecular Bioquest, Inc. | Electromagnetic wave absorbing, surface modified magnetic particles for use in medical applications, and their method of production |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US6001335A (en) * | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5733572A (en) * | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5773024A (en) * | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
US5882678A (en) * | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
US5162361A (en) * | 1990-04-10 | 1992-11-10 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Method of treating diseases associated with elevated levels of interleukin 1 |
US6465188B1 (en) * | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Nucleic acid ligand complexes |
US20060084797A1 (en) * | 1990-06-11 | 2006-04-20 | Gilead Sciences, Inc. | High affinity TGFbeta nucleic acid ligands and inhibitors |
US20030113369A1 (en) * | 1991-01-16 | 2003-06-19 | Martin Francis J. | Liposomes with enhanced circulation time and method of treatment |
US5874062A (en) * | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
JP3220180B2 (en) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | Drug-containing protein-bound liposomes |
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
EP1236473A3 (en) | 1992-04-03 | 2003-01-15 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system |
ZA933926B (en) * | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
EP0656368B2 (en) * | 1992-08-05 | 2003-06-04 | Meito Sangyo Kabushiki Kaisha | Small-diameter composite composed of water-soluble carboxypolysaccharide and magnetic iron oxide |
DE4236237A1 (en) * | 1992-10-27 | 1994-04-28 | Behringwerke Ag | Prodrugs, their preparation and use as medicines |
US6764693B1 (en) * | 1992-12-11 | 2004-07-20 | Amaox, Ltd. | Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants |
JP3351476B2 (en) * | 1993-01-22 | 2002-11-25 | 三菱化学株式会社 | Phospholipid derivatives and liposomes containing the same |
AU6368394A (en) * | 1993-03-23 | 1994-10-11 | Liposome Technology, Inc. | Polymer-polypeptide composition and method |
US6326353B1 (en) * | 1993-03-23 | 2001-12-04 | Sequus Pharmaceuticals, Inc. | Enhanced circulation effector composition and method |
US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
US20050181976A1 (en) * | 1993-05-10 | 2005-08-18 | Ekwuribe Nnochiri N. | Amphiphilic oligomers |
US5681811A (en) * | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US6191105B1 (en) | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
DE1118326T1 (en) * | 1993-05-21 | 2002-04-18 | Liposome Co Inc | Reduction of physiological counter-reactions induced by liposomes |
DE69424680T2 (en) * | 1993-10-25 | 2000-09-28 | Liposome Co Inc | LIPOSOMAL DEFENSINE |
US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US5468499A (en) * | 1993-11-15 | 1995-11-21 | Ohio State University | Liposomes containing the salt of phosphoramide mustard and related compounds |
US7083572B2 (en) * | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
WO1995016464A1 (en) * | 1993-12-14 | 1995-06-22 | Johns Hopkins University School Of Medicine | Controlled release of pharmaceutically active substances for immunotherapy |
US6773719B2 (en) | 1994-03-04 | 2004-08-10 | Esperion Luv Development, Inc. | Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US20010055581A1 (en) * | 1994-03-18 | 2001-12-27 | Lawrence Tamarkin | Composition and method for delivery of biologically-active factors |
US5736121A (en) * | 1994-05-23 | 1998-04-07 | Imarx Pharmaceutical Corp. | Stabilized homogenous suspensions as computed tomography contrast agents |
DE4423131A1 (en) * | 1994-07-01 | 1996-01-04 | Bayer Ag | New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4 |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5512294A (en) * | 1994-08-05 | 1996-04-30 | Li; King C. | Targeted polymerized liposome contrast agents |
US6132764A (en) * | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US6471956B1 (en) | 1994-08-17 | 2002-10-29 | The Rockefeller University | Ob polypeptides, modified forms and compositions thereto |
US6001968A (en) * | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
US6124439A (en) * | 1994-08-17 | 2000-09-26 | The Rockefeller University | OB polypeptide antibodies and method of making |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US6048837A (en) * | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6124448A (en) * | 1994-08-17 | 2000-09-26 | The Rockfeller University | Nucleic acid primers and probes for the mammalian OB gene |
US5885613A (en) * | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
DE69527206T2 (en) * | 1994-09-30 | 2003-02-27 | Inex Pharmaceuticals Corp | AGENT FOR INSERTING POLYANIONIC MATERIALS IN CELLS |
DK0785773T3 (en) * | 1994-10-14 | 2001-01-29 | Liposome Co Inc | Etherlipid liposomes and their therapeutic use |
CN1080575C (en) * | 1994-10-14 | 2002-03-13 | 蛋白质传送股份有限公司 | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US6214388B1 (en) * | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
US5827531A (en) * | 1994-12-02 | 1998-10-27 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microcapsules and methods for making |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
IL112834A (en) * | 1995-03-01 | 2000-12-06 | Yeda Res & Dev | Pharmaceutical compositions for controlled release of soluble receptors |
US5658588A (en) * | 1995-03-31 | 1997-08-19 | University Of Cincinnati | Fibrinogen-coated liposomes |
GB9509016D0 (en) * | 1995-05-03 | 1995-06-21 | Royal Free Hosp School Med | Tissue entrapment |
US8071737B2 (en) * | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
US5997898A (en) * | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
EP1489184A1 (en) * | 1995-06-07 | 2004-12-22 | Inex Pharmaceutical Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
US6033645A (en) * | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
US6107332A (en) | 1995-09-12 | 2000-08-22 | The Liposome Company, Inc. | Hydrolysis-promoting hydrophobic taxane derivatives |
US6051600A (en) * | 1995-09-12 | 2000-04-18 | Mayhew; Eric | Liposomal hydrolysis-promoting hydrophobic taxane derivatives |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US5858397A (en) * | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
WO1997013501A1 (en) * | 1995-10-11 | 1997-04-17 | Kevin Jon Williams | Liposomal compositions and methods of using them |
US6936439B2 (en) * | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
US20030040467A1 (en) * | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
US5626654A (en) | 1995-12-05 | 1997-05-06 | Xerox Corporation | Ink compositions containing liposomes |
US6392069B2 (en) | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
EP0885299B1 (en) | 1996-01-08 | 2005-10-26 | Genentech, Inc. | Ob receptor and ligands |
US6096336A (en) * | 1996-01-30 | 2000-08-01 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
US5908624A (en) * | 1996-06-27 | 1999-06-01 | Albany Medical College | Antigenic modulation of cells |
US6667053B1 (en) | 1996-02-16 | 2003-12-23 | Elan Pharmaceuticals, Inc. | D and L etherlipid stereoisomers and liposomes |
US6007839A (en) * | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US5965159A (en) | 1996-02-16 | 1999-10-12 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
US5942246A (en) * | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
USRE39042E1 (en) * | 1996-02-16 | 2006-03-28 | The Liposome Company, Inc. | Etherlipid-containing multiple lipid liposomes |
CA2250219C (en) | 1996-03-28 | 2008-10-07 | Hayat Onyuksel | Materials and methods for making improved liposome compositions |
AU736301B2 (en) | 1996-05-01 | 2001-07-26 | Imarx Therapeutics, Inc. | Methods for delivering compounds into a cell |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050042647A1 (en) * | 1996-06-06 | 2005-02-24 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
US5919480A (en) | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
US7368129B1 (en) | 1996-08-14 | 2008-05-06 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6284267B1 (en) | 1996-08-14 | 2001-09-04 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
US6159462A (en) * | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
DE69725747T2 (en) * | 1996-08-23 | 2004-07-29 | Sequus Pharmaceuticals, Inc., Menlo Park | LIPOSOME CONTAINING CISPLATIN |
US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
US5846517A (en) * | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
ATE366588T1 (en) * | 1996-09-11 | 2007-08-15 | Imarx Pharmaceutical Corp | METHOD FOR DIAGNOSTIC IMAGING OF THE KIDNEY REGION USING A CONTRAST AGENT AND A VASODILATOR |
JP2001503396A (en) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | Therapeutic liposome compositions and methods |
US6339069B1 (en) | 1996-10-15 | 2002-01-15 | Elan Pharmaceuticalstechnologies, Inc. | Peptide-lipid conjugates, liposomes and lipsomal drug delivery |
IL130823A (en) * | 1996-10-15 | 2005-12-18 | Elan Pharm Inc | Peptide-lipid conjugates, liposomes drug delivery |
US6264917B1 (en) * | 1996-10-28 | 2001-07-24 | Nycomed Imaging As | Targeted ultrasound contrast agents |
US20070036722A1 (en) * | 1996-10-28 | 2007-02-15 | Pal Rongved | Separation processes |
US6261537B1 (en) | 1996-10-28 | 2001-07-17 | Nycomed Imaging As | Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors |
US6331289B1 (en) | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
US6207186B1 (en) * | 1997-02-14 | 2001-03-27 | The Regents Of The University Of California | Lamellar gels and methods for making and using |
US6143276A (en) * | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
AU741145B2 (en) | 1997-04-03 | 2001-11-22 | Eisai Inc. | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same |
ES2361267T3 (en) | 1997-04-07 | 2011-06-15 | Genentech Inc. | PROCEDURE FOR THE PRODUCTION OF HUMANIZED ANTIBODIES THROUGH RANDOM MUTAGENESIS. |
JP3957765B2 (en) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | Anti-VEGF antibody |
WO1998044910A1 (en) | 1997-04-09 | 1998-10-15 | Philipp Lang | NEW TECHNIQUE TO MONITOR DRUG DELIVERY NONINVASIVELY $i(IN VIVO) |
US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
JP4656675B2 (en) * | 1997-05-14 | 2011-03-23 | ユニバーシティー オブ ブリティッシュ コロンビア | High rate encapsulation of charged therapeutic agents in lipid vesicles |
DE19724796A1 (en) * | 1997-06-06 | 1998-12-10 | Max Delbrueck Centrum | Antitumor therapy agents |
US6663899B2 (en) * | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
US6217886B1 (en) | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
EP1014946B1 (en) | 1997-09-18 | 2010-04-07 | Pacira Pharmaceuticals, Inc. | Sustained-release liposomal anesthetic compositions |
US7229841B2 (en) * | 2001-04-30 | 2007-06-12 | Cytimmune Sciences, Inc. | Colloidal metal compositions and methods |
ES2384094T3 (en) | 1997-11-14 | 2012-06-29 | Pacira Pharmaceuticals, Inc. | Production of multivesicular liposomes |
DE69837897T2 (en) | 1997-11-21 | 2008-03-06 | Genentech Inc., San Francisco | A33 related antigens and their pharmaceutical uses |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US6787132B1 (en) * | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
EP1947119A3 (en) | 1997-12-12 | 2012-12-19 | Genentech, Inc. | Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent |
US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
EP1053009B1 (en) | 1998-02-04 | 2004-09-22 | Genentech, Inc. | Use of heregulin as an epithelial cell growth factor |
CA2319433C (en) * | 1998-02-09 | 2008-04-22 | Bracco Research S.A. | Targeted delivery of biologically active media |
US6312685B1 (en) | 1998-03-13 | 2001-11-06 | Timothy C. Fisher | Red blood cells covalently bound with two different polyethylene glycol derivatives |
US6942859B2 (en) | 1998-03-13 | 2005-09-13 | University Of Southern California | Red blood cells covalently bound with polymers |
ES2389387T3 (en) | 1998-03-17 | 2012-10-25 | Genentech, Inc. | Homologous VEGF and BMP1 polypeptides |
US6433012B1 (en) * | 1998-03-25 | 2002-08-13 | Large Scale Biology Corp. | Method for inhibiting inflammatory disease |
KR20010042168A (en) * | 1998-03-25 | 2001-05-25 | 바이오소스 테크놀로지스 인코포레이티드 | Benzoates derivatives for inhibiting angiogenesis |
US6858706B2 (en) | 1998-04-07 | 2005-02-22 | St. Jude Children's Research Hospital | Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof |
CA2329768C (en) * | 1998-04-27 | 2008-06-10 | Opperbas Holding B.V. | Pharmaceutical composition comprising factor viii and neutral liposomes |
US6986902B1 (en) * | 1998-04-28 | 2006-01-17 | Inex Pharmaceuticals Corporation | Polyanionic polymers which enhance fusogenicity |
US6448224B1 (en) | 1998-05-06 | 2002-09-10 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6331407B1 (en) | 1998-05-06 | 2001-12-18 | St. Jude Children's Research Hospital | Antibiotics and methods of using the same |
US6169078B1 (en) * | 1998-05-12 | 2001-01-02 | University Of Florida | Materials and methods for the intracellular delivery of substances |
EP1865061A3 (en) | 1998-05-15 | 2007-12-19 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
EP3112468A1 (en) | 1998-05-15 | 2017-01-04 | Genentech, Inc. | Il-17 homologous polypeptides and therapeutic uses thereof |
DE69936382T3 (en) | 1998-05-15 | 2011-07-07 | Genentech, Inc., Calif. | THERAPEUTIC USES OF IL-17 HOMOLOGOUS POLYPEPTIDE |
AU4561199A (en) | 1998-06-12 | 1999-12-30 | Genentech Inc. | Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method |
US6200598B1 (en) * | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
US20040229363A1 (en) * | 1998-06-24 | 2004-11-18 | Ed Nolan | High efficiency transfection based on low electric field strength, long pulse length |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
IL140899A0 (en) | 1998-07-17 | 2002-02-10 | Skyepharma Inc | Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
CA2346879A1 (en) * | 1998-09-16 | 2000-04-27 | Alza Corporation | Liposome-entrapped topoisomerase inhibitors |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6419709B1 (en) | 1998-10-02 | 2002-07-16 | Guilford Pharmaceuticals, Inc. | Biodegradable terephthalate polyester-poly(Phosphite) compositions, articles, and methods of using the same |
US6153212A (en) * | 1998-10-02 | 2000-11-28 | Guilford Pharmaceuticals Inc. | Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same |
DE69934425T2 (en) * | 1998-10-23 | 2007-09-27 | Amgen Inc., Thousand Oaks | THROMBOPOIETIN SUBSTITUTE |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1950300A3 (en) | 1998-11-18 | 2011-03-23 | Genentech, Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
AU1740900A (en) * | 1998-11-20 | 2000-06-13 | Genentech Inc. | Method of inhibiting angiogenesis |
US6773911B1 (en) | 1998-11-23 | 2004-08-10 | Amgen Canada Inc. | Apoptosis-inducing factor |
EP2075335A3 (en) | 1998-12-22 | 2009-09-30 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
EP2016953A3 (en) | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
US6350464B1 (en) | 1999-01-11 | 2002-02-26 | Guilford Pharmaceuticals, Inc. | Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
US6818227B1 (en) * | 1999-02-08 | 2004-11-16 | Alza Corporation | Liposome composition and method for administration of a radiosensitizer |
US6537585B1 (en) | 1999-03-26 | 2003-03-25 | Guilford Pharmaceuticals, Inc. | Methods and compositions for treating solid tumors |
US6379698B1 (en) | 1999-04-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Fusogenic lipids and vesicles |
US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
CA2270600A1 (en) | 1999-05-03 | 2000-11-03 | Infectio Recherche Inc. | Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania |
EP1645290A1 (en) | 1999-05-07 | 2006-04-12 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
WO2000067760A1 (en) * | 1999-05-11 | 2000-11-16 | Sankyo Company, Limited | Liposome preparation of fat-soluble antitumor drug |
US20040229779A1 (en) * | 1999-05-14 | 2004-11-18 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040023874A1 (en) * | 2002-03-15 | 2004-02-05 | Burgess Catherine E. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US6974684B2 (en) * | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040067490A1 (en) * | 2001-09-07 | 2004-04-08 | Mei Zhong | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
DE60043322D1 (en) | 1999-06-15 | 2009-12-24 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids for their coding |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
US7169889B1 (en) | 1999-06-19 | 2007-01-30 | Biocon Limited | Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin |
AU780194B2 (en) * | 1999-06-24 | 2005-03-10 | Kyowa Hakko Kirin Co., Ltd. | Method of regulating leakage of drug encapsulated in liposomes |
CN100340575C (en) | 1999-06-25 | 2007-10-03 | 杰南技术公司 | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US6352996B1 (en) | 1999-08-03 | 2002-03-05 | The Stehlin Foundation For Cancer Research | Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs |
DE60042693D1 (en) | 1999-08-27 | 2009-09-17 | Genentech Inc | DOSAGE FOR TREATMENT WITH ANTI ERBB2 ANTIBODIES |
NZ523206A (en) * | 1999-08-31 | 2004-12-24 | Genentech Inc | Antibodies that bind to tumor gene sequences |
KR20010085996A (en) * | 1999-09-03 | 2001-09-07 | 스티븐 엠. 오드레 | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
AU7868400A (en) * | 1999-10-08 | 2001-04-23 | Alza Corporation | Neutral-cationic lipid for nucleic acid and drug delivery |
IT1315253B1 (en) * | 1999-10-22 | 2003-02-03 | Novuspharma Spa | LIPOSOMIAL PREPARATION OF 6,9-BIS- (2-AMINOXYL) AMINO | BENZOG | ISOCHINOLIN-5,10-DIONE DIMALEATO |
US7067111B1 (en) * | 1999-10-25 | 2006-06-27 | Board Of Regents, University Of Texas System | Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
ES2629683T3 (en) | 1999-11-30 | 2017-08-14 | Mayo Foundation For Medical Education And Research | B7-H1, a new immunoregulatory molecule |
CA2491610A1 (en) | 1999-12-01 | 2001-06-07 | Kevin P. Baker | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6593308B2 (en) * | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
US20030147944A1 (en) * | 1999-12-10 | 2003-08-07 | Mayer Lawrence D | Lipid carrier compositions with protected surface reactive functions |
DK1897944T3 (en) | 1999-12-23 | 2011-10-24 | Genentech Inc | IL-17 homologous polypeptides and their therapeutic use |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
JP2003520210A (en) * | 2000-01-05 | 2003-07-02 | イマレックス セラピューティクス, インコーポレイテッド | Pharmaceutical formulations for delivery of drugs with low water solubility |
DE60137829D1 (en) | 2000-01-13 | 2009-04-16 | Genentech Inc | HUMAN STRA6 POLYPEPTIDE |
AU3467001A (en) * | 2000-01-28 | 2001-08-07 | Alza Corp | Liposomes containing an entrapped compound in supersaturated solution |
US20030176385A1 (en) * | 2000-02-15 | 2003-09-18 | Jingfang Ju | Antisense modulation of protein expression |
JP4922824B2 (en) * | 2000-04-03 | 2012-04-25 | 参天製薬株式会社 | Delivery substance and drug delivery system using the same |
ES2637801T3 (en) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Multivalent antibodies and uses thereof |
WO2001076644A2 (en) * | 2000-04-12 | 2001-10-18 | Liplasome Pharma A/S | Lipid-based systems for targeting diagnostic agents |
WO2001081376A2 (en) | 2000-04-21 | 2001-11-01 | Amgen Inc. | Apo-ai/aii peptide derivatives |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US7030219B2 (en) * | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
AU2001258106A1 (en) * | 2000-05-11 | 2001-11-20 | Celator Technologies Inc. | Lipid carrier compositions for improved drug retention |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
AU6531101A (en) | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2410906C (en) | 2000-06-02 | 2012-10-02 | Board Of Regents, The University Of Texas System | Ethylenedicysteine (ec)-drug conjugates |
US20030072794A1 (en) * | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
WO2001097858A2 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
EP2275549A1 (en) | 2000-06-23 | 2011-01-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
CA2648046A1 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
US20040023259A1 (en) * | 2000-07-26 | 2004-02-05 | Luca Rastelli | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
ATE412009T1 (en) | 2000-08-24 | 2008-11-15 | Genentech Inc | METHOD FOR INHIBITING IL-22 INDUCED PAP1 |
EP1944317A3 (en) | 2000-09-01 | 2008-09-17 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US20030133972A1 (en) * | 2000-10-11 | 2003-07-17 | Targesome, Inc. | Targeted multivalent macromolecules |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
JP4198990B2 (en) | 2000-10-18 | 2008-12-17 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | E-selectin / L-selectin ligand polypeptide of hematopoietic cells and use thereof |
AU2002225878A1 (en) * | 2000-11-02 | 2002-05-15 | Smith Kline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
DE10056136A1 (en) * | 2000-11-07 | 2002-05-16 | Nemod New Modalities | Inhibiting leukocyte or tumor cell adhesion to vascular endothelial cells e.g. for combating inflammation or metastasis, using e.g. pregnancy proteins or selectin binding liposomes containing calcium-binding compound |
US20020132982A1 (en) * | 2000-11-30 | 2002-09-19 | Balasubramanian Sathyamangalam V. | AHF associated dispersion system and method for preparation |
US7625584B2 (en) * | 2000-11-30 | 2009-12-01 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
WO2002061036A2 (en) * | 2000-11-30 | 2002-08-08 | The Research Foundation Of State University Of New York | Method of complexing a protein by the use of a dispersed system and proteins thereof |
US8110218B2 (en) * | 2000-11-30 | 2012-02-07 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein-lipid complexes |
WO2002056829A2 (en) * | 2000-12-18 | 2002-07-25 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified daptomycin |
WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
US20060014674A1 (en) | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
US6964849B2 (en) | 2001-01-11 | 2005-11-15 | Curagen Corporation | Proteins and nucleic acids encoding same |
US20040043928A1 (en) * | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
AR035779A1 (en) | 2001-02-06 | 2004-07-14 | Genetics Inst Llc | FUSION POLYPEPTIDES DERIVED FROM GLICOPROTEIN IB PLATE ALFA AND METHODS OF USE OF THE SAME |
US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
AU2002245629A1 (en) * | 2001-03-08 | 2002-09-24 | Targesome, Inc. | Stabilized therapeutic and imaging agents |
HUP0303616A3 (en) * | 2001-03-26 | 2006-07-28 | Alza Corp Mountain View | Liposome composition for improved intracellular delivery of a therapeutic agent |
US20040126900A1 (en) * | 2001-04-13 | 2004-07-01 | Barry Stephen E | High affinity peptide- containing nanoparticles |
WO2002087541A1 (en) * | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
AU2002256398A2 (en) * | 2001-04-30 | 2002-11-11 | Targeted Genetics Corporation | Lipid-comprising drug delivery complexes and methods for their production |
GB0111279D0 (en) * | 2001-05-10 | 2001-06-27 | Nycomed Imaging As | Radiolabelled liposomes |
EE05294B1 (en) | 2001-05-11 | 2010-04-15 | Amgen Inc. | TALL-1 binding agent composition |
EP1389182A1 (en) * | 2001-05-15 | 2004-02-18 | Transgene S.A. | Complexes for transferring substances of interest into a cell |
AU2002310046A1 (en) * | 2001-05-22 | 2002-12-03 | Duke University | Compositions and methods for inhibiting metastasis |
US20020197253A1 (en) * | 2001-05-22 | 2002-12-26 | Cheek Dennis J. | Compositions and methods for promoting or inhibiting NDPK |
EP2340849A1 (en) | 2001-05-30 | 2011-07-06 | Genentech, Inc. | Anti-NGF antibodies for the treatment of various disorders |
CA2447990C (en) * | 2001-05-31 | 2012-01-31 | Skyepharma Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6713452B2 (en) | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US7713932B2 (en) | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
US20070160576A1 (en) | 2001-06-05 | 2007-07-12 | Genentech, Inc. | IL-17A/F heterologous polypeptides and therapeutic uses thereof |
JP2005501011A (en) * | 2001-06-08 | 2005-01-13 | ユタ ベンチャー ザ セカンド リミテッド パートナーシップ | Tissue-specific inner membrane protein |
KR100788092B1 (en) | 2001-06-20 | 2007-12-21 | 제넨테크, 인크. | Compositions and Methods for the Diagnosis and Treatment of Tumor |
US7803915B2 (en) * | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
US20050107595A1 (en) * | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CN1827766B (en) | 2001-06-28 | 2010-08-25 | 徐荣祥 | In vitro cell cultivation method |
US20030087274A1 (en) * | 2001-07-05 | 2003-05-08 | Anderson David W. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US20040029790A1 (en) * | 2001-07-05 | 2004-02-12 | Meera Patturajan | Novel human proteins, polynucleotides encoding them and methods of using the same |
US20030134892A1 (en) * | 2001-07-19 | 2003-07-17 | Wenbin Dang | Compositions for treatment of head and neck cancers, and methods of making and using the same |
WO2003007914A2 (en) * | 2001-07-19 | 2003-01-30 | Guilford Pharmaceuticals, Inc. | Biocompatible polymer containing composition for treatment of prostate cancers |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
CA2456092A1 (en) * | 2001-07-29 | 2003-02-13 | Yissum Research Development Company Of The Hebrew University In Jerusalem | Osteogenic growth oligopeptides as stimulants of hematopoiesis |
US20040030096A1 (en) * | 2001-08-02 | 2004-02-12 | Linda Gorman | Novel human proteins, polynucleotides encoding them and methods of using the same |
US20030059375A1 (en) * | 2001-08-20 | 2003-03-27 | Transave, Inc. | Method for treating lung cancers |
US20030211040A1 (en) | 2001-08-31 | 2003-11-13 | Paul Greengard | Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain |
US20040235068A1 (en) * | 2001-09-05 | 2004-11-25 | Levinson Arthur D. | Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders |
US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
US6913903B2 (en) | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7166571B2 (en) * | 2001-09-07 | 2007-01-23 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
US7547673B2 (en) * | 2001-09-13 | 2009-06-16 | The Johns Hopkins University | Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production |
DE60238143D1 (en) | 2001-09-18 | 2010-12-09 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS OF TUMORS |
US7981863B2 (en) | 2001-09-19 | 2011-07-19 | Neuronova Ab | Treatment of Parkinson's disease with PDGF |
CN1635873A (en) * | 2001-09-28 | 2005-07-06 | 埃斯佩里安医疗公司 | Methods and apparatus for extrusion of vesicles at high pressure |
DE10148065A1 (en) * | 2001-09-28 | 2003-04-17 | Max Planck Gesellschaft | (Ester) -lysolecithins in liposomes |
US20030199442A1 (en) * | 2001-10-09 | 2003-10-23 | Alsobrook John P. | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
IL161733A0 (en) | 2001-11-02 | 2005-11-20 | Insert Therapeutics Inc | Methods and compositions for therapeutic use of rna interference |
AU2002340662B2 (en) * | 2001-11-07 | 2008-07-03 | Tekmira Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
US20040219201A1 (en) * | 2001-12-06 | 2004-11-04 | Yechezkel Barenholz | Tempamine compositions and methods of use |
MXPA04006554A (en) | 2002-01-02 | 2005-03-31 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor. |
WO2003057165A2 (en) | 2002-01-04 | 2003-07-17 | The Rockefeller University | COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
EP1487273B1 (en) * | 2002-02-13 | 2009-01-21 | Immunology Laboratories, Inc. | Compositions and methods for treatment of microbial infections |
JP2005535290A (en) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | Compositions and methods for the treatment of immune related diseases |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US20090042291A1 (en) * | 2002-03-01 | 2009-02-12 | Xencor, Inc. | Optimized Fc variants |
US20100311954A1 (en) * | 2002-03-01 | 2010-12-09 | Xencor, Inc. | Optimized Proteins that Target Ep-CAM |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
US20040009216A1 (en) * | 2002-04-05 | 2004-01-15 | Rodrigueza Wendi V. | Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease |
EP2011886A3 (en) | 2002-04-16 | 2009-02-11 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
AU2003233008B2 (en) * | 2002-04-22 | 2008-04-24 | Recopharma Ab | Fusion polypeptides and methods for inhibiting microbial adhesion |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
WO2005056606A2 (en) * | 2003-12-03 | 2005-06-23 | Xencor, Inc | Optimized antibodies that target the epidermal growth factor receptor |
EP2305710A3 (en) | 2002-06-03 | 2013-05-29 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2003236521A1 (en) * | 2002-06-13 | 2003-12-31 | Nobex Corporation | Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus |
EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
DE60335469D1 (en) * | 2002-07-02 | 2011-02-03 | Univ Texas | RADIOACTIVELY MARKED COMPOUNDS AND LIPOSOME AND THEIR MANUFACTURING AND APPLICATION METHOD |
US20040247661A1 (en) * | 2002-07-03 | 2004-12-09 | Dov Michaeli | Liposomal vaccine |
US20050169979A1 (en) * | 2002-07-03 | 2005-08-04 | Dov Michaeli | Liposomal vaccine |
AU2003267984A1 (en) * | 2002-07-03 | 2004-01-23 | Receptor Biologix, Inc. | Liposomal vaccine |
WO2004004649A2 (en) | 2002-07-08 | 2004-01-15 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
RU2338751C2 (en) | 2002-07-15 | 2008-11-20 | Дженентек, Инк. | MEANS OF IDENTIFICATION OF TUMOURS, ACQUISITIVE TO TREATMENT BY ANTIBODIES AGAINST ErbB2 |
US7625563B2 (en) * | 2002-07-15 | 2009-12-01 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
ATE491725T1 (en) * | 2002-07-15 | 2011-01-15 | Univ Texas | ANTIBODIES BOUND TO ANIONIC PHOSPHOLIPIDES AND AMINOPHOSPHOLIPIDES AND THEIR USE IN THE TREATMENT OF VIRUS INFECTIONS |
US7615223B2 (en) * | 2002-07-15 | 2009-11-10 | Board Of Regents, The University Of Texas System | Selected immunoconjugates for binding to aminophospholipids |
US7622118B2 (en) * | 2002-07-15 | 2009-11-24 | Board Of Regents, The University Of Texas System | Cancer treatment methods using selected antibodies to aminophospholipids |
US7714109B2 (en) * | 2002-07-15 | 2010-05-11 | Board Of Regents, The University Of Texas System | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids |
US7572448B2 (en) * | 2002-07-15 | 2009-08-11 | Board Of Regents, The University Of Texas System | Combined cancer treatment methods using selected antibodies to aminophospholipids |
US7678386B2 (en) * | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
EP1546184A4 (en) * | 2002-07-16 | 2006-08-23 | Univ South Florida | Human immunosuppressive protein |
US20040161423A1 (en) * | 2002-07-18 | 2004-08-19 | Sanjeev Kumar (Mendiratta) | Polymer modified anti-angiogenic serpins |
US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
MXPA05001312A (en) * | 2002-08-02 | 2005-08-03 | Transave Inc | Platinum aggregates and process for producing the same. |
CA2495251C (en) | 2002-08-14 | 2018-03-06 | Macrogenics, Inc. | Fc.gamma.riib-specific antibodies and methods of use thereof |
EP1393720A1 (en) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesicle-encapsulated corticosteroids for treatment of cancer |
PL376536A1 (en) | 2002-08-28 | 2006-01-09 | Immunex Corporation | Compositions and methods for treating cardiovascular disease |
AR036316A1 (en) * | 2002-08-29 | 2004-08-25 | Monte Verde S A | A PHARMACEUTICAL COMPOSITION OF SMALL SIZE LIPOSOMES AND PREPARATION METHOD |
US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
AU2003268531A1 (en) | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
WO2004024072A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel compositions and methods for the treatment of immune related diseases |
WO2004024068A2 (en) | 2002-09-11 | 2004-03-25 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
JP2006515165A (en) | 2002-09-16 | 2006-05-25 | ジェネンテック・インコーポレーテッド | Novel compositions and methods for the treatment of immune related diseases |
US6919426B2 (en) | 2002-09-19 | 2005-07-19 | Amgen Inc. | Peptides and related molecules that modulate nerve growth factor activity |
WO2004028479A2 (en) | 2002-09-25 | 2004-04-08 | Genentech, Inc. | Nouvelles compositions et methodes de traitement du psoriasis |
ES2562177T3 (en) | 2002-09-27 | 2016-03-02 | Xencor Inc. | Optimized Fc variants and methods for their generation |
US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
EP1545615A4 (en) * | 2002-10-04 | 2006-03-01 | Rinat Neuroscience Corp | Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists |
UA80447C2 (en) * | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
DK1556083T3 (en) * | 2002-10-08 | 2011-04-04 | Rinat Neuroscience Corp | Method of treating post-operative pain by administration of an antibody to nerve growth factor and composition containing the same |
US7255860B2 (en) | 2002-10-08 | 2007-08-14 | Rinat Neuroscience Corp. | Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody |
KR20050071564A (en) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
EP1560597A4 (en) * | 2002-10-29 | 2007-06-27 | Pharmacia Corp | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
JP2006517785A (en) | 2002-10-29 | 2006-08-03 | ジェネンテック・インコーポレーテッド | Novel compositions and methods for the treatment of immune related diseases |
US8604183B2 (en) | 2002-11-05 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
CA2504720C (en) | 2002-11-05 | 2013-12-24 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
AU2003295401B2 (en) | 2002-11-08 | 2010-04-29 | Genentech, Inc. | Compositions and methods for the treatment of natural killer cell related diseases |
US20040093198A1 (en) * | 2002-11-08 | 2004-05-13 | Carbon Design Systems | Hardware simulation with access restrictions |
US20040152769A1 (en) * | 2002-11-09 | 2004-08-05 | Ekwuribe Nnochiri Nkem | Modified carbamate-containing prodrugs and methods of synthesizing same |
US20050158375A1 (en) * | 2002-11-15 | 2005-07-21 | Toshikiro Kimura | Pharmaceutical composition containing liposomes for treating cancer |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
AU2003297583B2 (en) | 2002-11-26 | 2010-01-14 | Biocon, Ltd | Modified naturetic compounds, conjugates, and uses thereof |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
WO2004056323A2 (en) * | 2002-12-19 | 2004-07-08 | Alza Corporation | Method of treating angiogenic tissue growth |
US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
CA2511598C (en) | 2002-12-24 | 2016-09-13 | Rinat Neuroscience Corp. | Anti-ngf antibodies and methods using same |
US7569364B2 (en) | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
CA2511464C (en) | 2002-12-31 | 2011-08-23 | Bharat Serums & Vaccines Ltd. | Non-pegylated long-circulating liposomes |
ATE426575T1 (en) * | 2003-01-07 | 2009-04-15 | Univ Ramot | PEPTIDE ANOSTRUCTURES CONTAINING FOREIGN MATERIAL AND METHOD FOR PRODUCING THE SAME |
JPWO2004063216A1 (en) * | 2003-01-10 | 2006-06-15 | アステラス製薬株式会社 | Conjugates for blood retention and cancer tissue specific drug delivery |
US7169892B2 (en) | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
EP1597366B1 (en) | 2003-02-11 | 2012-11-21 | Antisense Therapeutics Ltd | Modulation of insulin like growth factor i receptor expression |
CA2516454A1 (en) | 2003-02-19 | 2004-09-02 | Rinat Neuroscience Corp. | Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US7968115B2 (en) | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
WO2004087097A2 (en) * | 2003-03-31 | 2004-10-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
MXPA05010499A (en) | 2003-03-31 | 2006-05-25 | Johnson & Johnson | Lipid particles having asymmetric lipid coating and method of preparing same. |
JP4869064B2 (en) | 2003-04-04 | 2012-02-01 | ジェネンテック, インコーポレイテッド | High concentration antibody and protein preparation |
NZ587776A (en) | 2003-04-09 | 2012-03-30 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor using anti-CD20 antibody |
PL1633440T3 (en) * | 2003-04-15 | 2008-12-31 | Opperbas Holding Bv | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US20060246104A1 (en) * | 2003-04-16 | 2006-11-02 | Massia Stephen P | Stable rgd peptidomimetic composition |
AU2004231740A1 (en) * | 2003-04-17 | 2004-11-04 | The Trustees Of Columbia University In The City Ofnew York | Desmoglein 4 is a novel gene involved in hair growth |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
CA2525464A1 (en) | 2003-05-12 | 2004-11-25 | Qun Yin | Novel poly(ethylene glycol) modified compounds and uses thereof |
EP2204193A3 (en) | 2003-05-12 | 2010-08-18 | Affymax, Inc. | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds |
RS20181002A1 (en) | 2003-05-30 | 2018-12-31 | Genentech Inc | Treatment with anti-vegf antibodies |
EP1629014A2 (en) * | 2003-05-30 | 2006-03-01 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
EP2241572A3 (en) | 2003-06-03 | 2011-04-06 | Eli Lilly And Company | Modulation of survivin expression |
KR20060012661A (en) * | 2003-06-04 | 2006-02-08 | 캔지, 인크. | Methods and compositions for interferon therapy |
DK1636593T5 (en) | 2003-06-06 | 2009-07-27 | Genentech Inc | Modulating the interaction between HGF-beta chain and c-met |
RU2403262C2 (en) | 2003-06-11 | 2010-11-10 | Уайт | Isolated glycoprotein ib alpha polypeptide of human thrombocytes, fused protein, dna molecule (versions), expression vector (versions), cell (versions), polypeptide expression method, fused protein expression method, pharmaceutical composition (versions), method of inhibiting boding of blood cells to biological tissue in biological system, method of inhibiting bonding of protein to biological tissue in biological system and disorder treatment method |
US7939058B2 (en) * | 2003-07-03 | 2011-05-10 | University Of Southern California | Uses of IL-12 in hematopoiesis |
DE602004028837D1 (en) | 2003-07-03 | 2010-10-07 | Univ New Jersey Med | GENES AS DIAGNOSTIC TOOLS FOR AUTISM |
KR100945327B1 (en) | 2003-07-08 | 2010-03-08 | 제넨테크, 인크. | Il-17a/f heterologous polypeptides and therapeutic uses thereof |
WO2005007196A2 (en) * | 2003-07-16 | 2005-01-27 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
CN100431525C (en) * | 2003-07-17 | 2008-11-12 | 台湾东洋药品工业股份有限公司 | Production method of liposome suspended liquid and products thereof |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005016348A1 (en) * | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
US20050054614A1 (en) * | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
WO2005037911A2 (en) * | 2003-08-26 | 2005-04-28 | Smithkline Beecham Corporation | Heterofunctional copolymers of glycerol and polyethylene glycol, their conjugates and compositions |
US8986731B2 (en) * | 2003-08-26 | 2015-03-24 | Biolitec Pharma Marketing Ltd | Pegylated liposomal formulations of hydrophobic photosensitizers for photodynamic therapy |
US8846079B1 (en) | 2004-12-01 | 2014-09-30 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
US11324698B2 (en) | 2003-08-28 | 2022-05-10 | Vgsk Technologies, Inc. | Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal |
US20060115523A1 (en) * | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
KR20070019941A (en) * | 2003-09-03 | 2007-02-16 | 교와 핫꼬 고교 가부시끼가이샤 | Compound modified with glycerol derivative |
US20050233435A1 (en) * | 2003-09-04 | 2005-10-20 | Nyu Medical Center | Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
NZ581166A (en) * | 2003-09-15 | 2011-06-30 | Protiva Biotherapeutics Inc | Polyethyleneglycol-modified lipid compounds and uses thereof |
EP2256201A3 (en) | 2003-09-18 | 2012-07-04 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E expression |
CA2540407A1 (en) * | 2003-09-25 | 2005-03-31 | Tel Aviv University Future Technology Development L.P. | Compositions and methods using same for treating amyloid-associated diseases |
US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US7625707B2 (en) * | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
DK1678194T3 (en) | 2003-10-10 | 2013-10-07 | Alchemia Oncology Pty Ltd | MODULATING SYNTHESIS AND DEGRADING HYALURONANE IN THE TREATMENT OF DISEASE |
JP2007509040A (en) * | 2003-10-11 | 2007-04-12 | イネックス ファーマシューティカルズ コーポレイション | Methods and compositions for enhancing innate immunity and antibody-dependent cytotoxicity |
TW200517114A (en) | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
EP1677765A1 (en) * | 2003-10-24 | 2006-07-12 | Alza Corporation | Preparation of lipid particles |
WO2005040163A1 (en) * | 2003-10-28 | 2005-05-06 | Dr. Reddy's Laboratories Ltd | Heterocyclic compounds that block the effects of advanced glycation end products (age) |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
US7915227B2 (en) * | 2003-11-14 | 2011-03-29 | Het Nederlands Kanker Instituut | Pharmaceutical formulations employing short-chain sphingolipids and their use |
US20050129753A1 (en) * | 2003-11-14 | 2005-06-16 | Gabizon Alberto A. | Method for drug loading in liposomes |
EP2412725A3 (en) | 2003-11-17 | 2012-04-25 | Genentech, Inc. | Antibodies against CD79b for the treatment of tumor of hematopoeitic origin |
US7750123B2 (en) * | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
US9050378B2 (en) * | 2003-12-10 | 2015-06-09 | Board Of Regents, The University Of Texas System | N2S2 chelate-targeting ligand conjugates |
US20050233960A1 (en) | 2003-12-11 | 2005-10-20 | Genentech, Inc. | Methods and compositions for inhibiting c-met dimerization and activation |
EP1700121A4 (en) | 2003-12-23 | 2008-09-03 | Rinat Neuroscience Corp | Agonist anti-trkc antibodies and methods using same |
EP3476861A1 (en) | 2004-01-07 | 2019-05-01 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
CA2553426A1 (en) * | 2004-01-15 | 2005-08-04 | Alza Corporation | Liposome composition for delivery of therapeutic agents |
JP2007520222A (en) | 2004-01-20 | 2007-07-26 | アイシス ファーマシューティカルズ インコーポレイテッド | Regulation of glucocorticoid receptor expression |
US7468431B2 (en) | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
CA2559853A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
US8784881B2 (en) | 2004-03-05 | 2014-07-22 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of diseases |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
CN1679957B (en) * | 2004-03-15 | 2010-06-09 | 尼普洛株式会社 | A pharmaceutical composition containing liposomes for treating a cancer |
WO2005089268A2 (en) | 2004-03-15 | 2005-09-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of rna by rnase h |
US20070065522A1 (en) * | 2004-03-18 | 2007-03-22 | Transave, Inc. | Administration of high potency platinum compound formulations by inhalation |
CN1976711A (en) * | 2004-03-18 | 2007-06-06 | 特兰萨维股份有限公司 | Administration of cisplatin by inhalation |
WO2005092388A1 (en) * | 2004-03-26 | 2005-10-06 | Terumo Kabushiki Kaisha | Liposome preparation |
AU2005231692B2 (en) * | 2004-03-26 | 2011-01-27 | Curis, Inc. | RNA interference modulators of Hedgehog signaling and uses thereof |
US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US7794713B2 (en) | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
ES2338344T3 (en) * | 2004-04-07 | 2010-05-06 | Rinat Neuroscience Corporation | PROCESS OF BONE CANCER TREATMENT THROUGH THE ADMINISTRATION OF AN ANTAGONIST OF THE NEURONAL GROWTH FACTOR. |
US20150017671A1 (en) | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
WO2005115453A2 (en) * | 2004-04-16 | 2005-12-08 | Genentech, Inc. | Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies |
ES2616047T3 (en) | 2004-05-03 | 2017-06-09 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug administration |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
ES2605792T3 (en) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinone used as a human phosphatidylinositol 3-kinase delta inhibitor |
EP1750673B1 (en) * | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
AU2005250369A1 (en) * | 2004-05-18 | 2005-12-15 | Genentech, Inc. | M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein |
US20050260260A1 (en) * | 2004-05-19 | 2005-11-24 | Edward Kisak | Liposome compositions for the delivery of macromolecules |
CA2566174A1 (en) * | 2004-05-21 | 2005-12-01 | Transave, Inc. | Treatment of lung diseases and pre-lung disease conditions |
JP2008500338A (en) * | 2004-05-25 | 2008-01-10 | イコス・コーポレイション | Method for treating and / or preventing abnormal proliferation of hematopoietic cells |
WO2005115384A2 (en) * | 2004-05-25 | 2005-12-08 | Metabolex, Inc. | Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation |
RU2006145872A (en) * | 2004-05-25 | 2008-06-27 | Метаболекс, Инк. (Us) | SUBSTITUTED TRIAZOLES AS PPAR MODULATORS AND METHODS FOR PRODUCING THEM |
ES2623362T3 (en) * | 2004-05-28 | 2017-07-11 | Human Biomolecular Research Institute | Metabolically stable pain relievers and pain medications |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
EP1765416A4 (en) * | 2004-06-03 | 2010-03-24 | Isis Pharmaceuticals Inc | Double strand compositions comprising differentially modified strands for use in gene modulation |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
US20080261904A1 (en) * | 2004-06-03 | 2008-10-23 | Balkrishen Bhat | Chimeric Gapped Oligomeric Compounds |
NZ604082A (en) | 2004-06-04 | 2014-09-26 | Genentech Inc | Method for treating multiple sclerosis |
CA2569645C (en) | 2004-06-07 | 2014-10-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
WO2005121348A1 (en) * | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
WO2006025920A2 (en) * | 2004-06-19 | 2006-03-09 | Human Biomolecular Research Institute | Modulators of central nervous system neurotransmitters |
EP1766077B1 (en) | 2004-06-21 | 2012-03-28 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
WO2006002538A1 (en) | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
US20060019893A1 (en) * | 2004-07-02 | 2006-01-26 | Genentech, Inc. | Factor VIIa variants |
MX2007000216A (en) * | 2004-07-08 | 2007-03-15 | Amgen Inc | Therapeutic peptides. |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
EP2471813B1 (en) | 2004-07-15 | 2014-12-31 | Xencor, Inc. | Optimized Fc variants |
US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
RU2393168C2 (en) * | 2004-07-19 | 2010-06-27 | Биокон Лимитед | Insulin-oligomer conjugates, preparations and use thereof |
AU2005269716B2 (en) | 2004-07-20 | 2011-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
CA2570323C (en) | 2004-07-26 | 2014-08-26 | Genentech, Inc. | Methods and compositions for modulating hepatocyte growth factor activation |
US7927594B2 (en) * | 2004-07-30 | 2011-04-19 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide |
WO2006013552A2 (en) | 2004-08-02 | 2006-02-09 | Ramot At Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
US9132116B2 (en) * | 2004-08-02 | 2015-09-15 | Willowcroft Pharm Inc. | Mast cell stabilizers to prevent or treat laminitis |
JP4934036B2 (en) | 2004-08-17 | 2012-05-16 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Anti-adhesion barrier |
JP2006056807A (en) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | Preparation for use in photodynamic therapy |
US7732479B2 (en) | 2004-08-19 | 2010-06-08 | Tel Aviv University Future Technology Development L.P. | Compositions for treating amyloid associated diseases |
JP4715133B2 (en) * | 2004-08-26 | 2011-07-06 | コニカミノルタエムジー株式会社 | Anti-tumor liposome preparation and production method thereof |
JP2006069929A (en) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | Preparation for treating mycosis and method for producing the same |
WO2006027780A2 (en) * | 2004-09-08 | 2006-03-16 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1793805A1 (en) * | 2004-09-09 | 2007-06-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions |
JP2008512445A (en) * | 2004-09-09 | 2008-04-24 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム | Use of liposomal glucocorticoids for the treatment of inflammatory conditions |
US6998028B1 (en) * | 2004-09-24 | 2006-02-14 | Superpower, Inc. | Methods for forming superconducting conductors |
DK1797127T3 (en) * | 2004-09-24 | 2017-10-02 | Amgen Inc | Modified Fc molecules |
CA2581896C (en) | 2004-09-29 | 2015-11-10 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
EP1812060A2 (en) | 2004-10-05 | 2007-08-01 | Genentech, Inc. | Method for treating vasculitis |
WO2006042112A2 (en) | 2004-10-05 | 2006-04-20 | California Institute Of Technology | Aptamer regulated nucleic acids and uses thereof |
CA2943949C (en) * | 2004-10-06 | 2020-03-31 | Mayo Foundation For Medical Education And Research | B7-h1 and methods of diagnosis, prognosis, and treatment of cancer |
AU2005295072A1 (en) * | 2004-10-08 | 2006-04-20 | Alza Corporation | Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves |
TW200612993A (en) * | 2004-10-08 | 2006-05-01 | Alza Corp | Lipopolymer conjugates |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CN101119750B (en) * | 2004-10-26 | 2013-03-06 | 法马马私人股份有限公司 | Anti-cancer treatment |
US20060110441A1 (en) * | 2004-10-28 | 2006-05-25 | Harry Wong | Lyophilized liposome formulations and method |
DK1658848T3 (en) | 2004-10-29 | 2007-11-26 | Pharma Mar Sa | Formulations comprising ecteinascidin and a disaccharide |
JP4990786B2 (en) | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | Compositions and methods for stabilizing drug liposome formulations |
TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
EP1811963A4 (en) * | 2004-11-08 | 2010-01-06 | Transave Inc | Methods of treating cancer with lipid-based platinum compound formulations administered intraperitoneally |
CN101142234A (en) * | 2004-11-11 | 2008-03-12 | 阿费麦克斯公司 | Novel peptides that bind to the erythropoietin receptor |
EP1817004A2 (en) * | 2004-11-15 | 2007-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combination therapy associating preferably a ceramide with a cytotoxic drug |
WO2006053430A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
EP1813288B1 (en) * | 2004-11-18 | 2018-07-18 | Terumo Kabushiki Kaisha | Medicinal composition, medicinal preparation, and combination preparation |
US7361752B2 (en) * | 2004-12-14 | 2008-04-22 | Alnylam Pharmaceuticals, Inc. | RNAi modulation of MLL-AF4 and uses thereof |
JP2008526883A (en) | 2005-01-07 | 2008-07-24 | ディアデクサス インコーポレーテッド | Ovr110 antibody compositions and methods of use |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
CN101141981A (en) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Fixed dosing of her antibodies |
JP5221126B2 (en) * | 2005-01-28 | 2013-06-26 | 協和発酵キリン株式会社 | Method for producing fine particles surface-modified with water-soluble substances |
EP1853289A4 (en) | 2005-01-31 | 2008-04-09 | Vaxinnate Corp | Novel polypeptide ligands for toll-like receptor 2 (tlr2) |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
EP1855694B1 (en) | 2005-02-09 | 2020-12-02 | Sarepta Therapeutics, Inc. | Antisense composition for treating muscle atrophy |
JP5651285B2 (en) | 2005-02-15 | 2015-01-07 | デューク ユニバーシティ | Anti-CD19 antibodies and use in oncology |
EP1885356A2 (en) * | 2005-02-17 | 2008-02-13 | Icos Corporation | Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation |
US20090202619A1 (en) * | 2005-02-18 | 2009-08-13 | The University Of Tokushima | Polyoxyalkylene chain-containing lipid derivative and lipid film structure containing such derivative |
US8329178B2 (en) | 2005-02-18 | 2012-12-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against CXCR4 and methods of use thereof |
DK1850874T3 (en) | 2005-02-23 | 2013-11-11 | Genentech Inc | Extension of time to disease progression or survival for ovarian cancer using pertuzumab |
TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
WO2006096861A2 (en) * | 2005-03-08 | 2006-09-14 | Genentech, Inc. | METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs) |
JP2008535796A (en) | 2005-03-10 | 2008-09-04 | ジェネンテック・インコーポレーテッド | Methods and compositions for regulating vascular integrity |
JP2006248978A (en) * | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | New liposome preparation |
US20070065359A1 (en) * | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
JP2008538351A (en) | 2005-03-21 | 2008-10-23 | メタボレックス インコーポレーティッド | Method for avoiding edema in the treatment or prevention of PPARγ-responsive diseases including cancer |
CN1840193B (en) * | 2005-03-29 | 2010-05-12 | 中国科学院生物物理研究所 | Nanometer capsule of anthracene nucleus anticancer antibiotic with polyethylene glycol-phospholipid |
EP1866414B9 (en) | 2005-03-31 | 2012-10-03 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
UY29504A1 (en) * | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | DIRECTED ANTIBODIES AGAINST BETA AMYLOID PEPTIDE AND METHODS USING THE SAME. |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
ES2561628T3 (en) | 2005-05-06 | 2016-02-29 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
US8124084B2 (en) | 2005-05-17 | 2012-02-28 | University Of Connecticut | Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra |
US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7919461B2 (en) * | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
US7550433B2 (en) | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
JP2008541781A (en) | 2005-06-06 | 2008-11-27 | ジェネンテック・インコーポレーテッド | Transgenic animals for different genes and their use for characterizing genes |
WO2007005754A2 (en) * | 2005-07-01 | 2007-01-11 | Alza Corporation | Liposomal delivery vehicle for hydrophobic drugs |
WO2007008943A2 (en) | 2005-07-08 | 2007-01-18 | Xencor, Inc. | Optimized anti-ep-cam antibodies |
CN101282994B (en) | 2005-07-22 | 2013-09-18 | Y's治疗有限公司 | Anti-CD26 antibodies and methods of use thereof |
EP2277916A3 (en) * | 2005-07-28 | 2011-04-27 | Novartis AG | Use of antibody to M-CSF |
WO2007016285A2 (en) * | 2005-07-28 | 2007-02-08 | Novartis Ag | M-csf specific monoclonal antibody and uses thereof |
US8998881B2 (en) | 2005-08-10 | 2015-04-07 | Alza Corporation | Method for delivering drugs to tissue under microjet propulsion |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
JP2009504183A (en) | 2005-08-15 | 2009-02-05 | ジェネンテック・インコーポレーテッド | Gene disruption and related compositions and methods |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
US10004828B2 (en) * | 2005-10-11 | 2018-06-26 | Romat at Tel-Aviv University Ltd. | Self-assembled Fmoc-ff hydrogels |
US7875602B2 (en) * | 2005-10-21 | 2011-01-25 | Sutter West Bay Hospitals | Camptothecin derivatives as chemoradiosensitizing agents |
AR056142A1 (en) | 2005-10-21 | 2007-09-19 | Amgen Inc | METHODS TO GENERATE THE MONOVALENT IGG ANTIBODY |
SI2500360T1 (en) | 2005-10-31 | 2015-11-30 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
EP2395012B8 (en) * | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
DE102005053066A1 (en) * | 2005-11-04 | 2007-05-10 | Basf Ag | Use of copolymers as solubilizers for sparingly water-soluble compounds |
WO2007056236A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with lipid-based platinum compound formulations administered intravenously |
US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
WO2007056263A2 (en) * | 2005-11-08 | 2007-05-18 | Transave, Inc. | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
EP2564864B8 (en) | 2005-11-12 | 2015-05-13 | The Board of Trustees of The Leland Stanford Junior University | FGF2-related methods for diagnosing and treating depression |
PT2380592T (en) | 2005-11-14 | 2018-06-06 | Teva Pharmaceuticals Int Gmbh | Antagonist antibody directed against calcitonin gene-related peptide |
PE20070684A1 (en) | 2005-11-14 | 2007-08-06 | Amgen Inc | RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
CN101360826B (en) | 2005-11-18 | 2014-04-30 | 格兰马克药品股份有限公司 | Anti-alpha2 integrin antibodies and their uses |
CA2630432A1 (en) | 2005-11-21 | 2007-07-19 | Genentech, Inc. | Novel gene disruptions, compositions and methods relating thereto |
WO2007062380A2 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
US20070122350A1 (en) * | 2005-11-30 | 2007-05-31 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
KR101453570B1 (en) | 2005-12-02 | 2014-10-22 | 제넨테크, 인크. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
EP1979379B1 (en) | 2005-12-02 | 2013-09-18 | Dana-Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
WO2007066335A2 (en) * | 2005-12-08 | 2007-06-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods for affecting liposome composition by ultrasound irradiation |
WO2007065846A2 (en) * | 2005-12-09 | 2007-06-14 | Basf Se | Use of polyvinyl lactam-polyoxyalkylene block copolymers as solubilisers for poorly water-soluble compounds |
WO2007070705A2 (en) | 2005-12-15 | 2007-06-21 | The Trustees Of The University Of Pennsylvania | Cationic lipid-mediated vectors |
EP2705854A1 (en) | 2006-01-05 | 2014-03-12 | Novartis AG | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
US20090215084A1 (en) * | 2006-01-05 | 2009-08-27 | Mayo Foundation For Medical Education And Research | B7-h1 and b7-h4 in cancer |
WO2007082144A2 (en) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | B7-h1 and survivin in cancer |
EP1973941A2 (en) | 2006-01-26 | 2008-10-01 | Recopharma AB | Compositions and methods for inhibiting viral adhesion |
EP3210633B1 (en) | 2006-01-26 | 2019-06-19 | Ionis Pharmaceuticals, Inc. | Compositions and their uses directed to huntingtin |
US7829097B2 (en) * | 2006-02-06 | 2010-11-09 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of HMGB1 for protection against ischemia reperfusion injury |
WO2007114979A2 (en) | 2006-02-17 | 2007-10-11 | Genentech, Inc. | Gene disruptons, compositions and methods relating thereto |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20070218116A1 (en) * | 2006-03-14 | 2007-09-20 | Schwendener Reto A | Compositions and methods for the treatment of tumors and tumor metastases |
US9119782B2 (en) * | 2006-03-20 | 2015-09-01 | Mary P. McCourt | Drug delivery means |
PL1989231T3 (en) | 2006-03-21 | 2015-10-30 | Genentech Inc | Combinatorial therapy involving alpha5beta1 antagonists |
EP2004221A2 (en) | 2006-03-23 | 2008-12-24 | Novartis Pharma AG | Anti-tumor cell antigen antibody therapeutics |
AU2007243946B2 (en) | 2006-04-05 | 2012-11-29 | Curis, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
US8758723B2 (en) | 2006-04-19 | 2014-06-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for cellular imaging and therapy |
US20090288176A1 (en) | 2006-04-19 | 2009-11-19 | Genentech, Inc. | Novel Gene Disruptions, Compositions and Methods Relating Thereto |
WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
WO2007121522A1 (en) | 2006-04-21 | 2007-11-01 | Minister for Primary Industries For And On Behalf Of The State Of New South Wales | Pestivirus species |
CA2656990A1 (en) * | 2006-04-28 | 2007-11-08 | University Of South Florida | Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor |
US8298818B2 (en) * | 2006-04-28 | 2012-10-30 | University Of Florida Research Foundation, Inc. | Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter |
US8697120B2 (en) * | 2006-05-01 | 2014-04-15 | Johns Hopkins University | Method and use of nano-scale devices for reduction of tissue injury in ischemic and reperfusion injury |
WO2007125173A2 (en) * | 2006-05-03 | 2007-11-08 | Baltic Technology Development, Ltd. | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
US20070264322A1 (en) * | 2006-05-10 | 2007-11-15 | Huang Ken S | Method for making liposomes conjugated with temperature-sensitive ligands |
JP5282031B2 (en) * | 2006-05-15 | 2013-09-04 | ドミトリィ ビー カーポティン | Magnetic fine particles containing organic matter |
AU2007249160B2 (en) | 2006-05-15 | 2013-09-12 | I2 Pharmaceuticals, Inc. | Neutralizing antibodies to influenza viruses |
EP2029157A4 (en) * | 2006-05-19 | 2009-11-18 | Georgia Tech Res Inst | Abc transporter ligand |
EP2023938A4 (en) * | 2006-05-23 | 2010-11-10 | Isis Pharmaceuticals Inc | Modulation of chrebp expression |
US7862812B2 (en) | 2006-05-31 | 2011-01-04 | Lpath, Inc. | Methods for decreasing immune response and treating immune conditions |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
US7981425B2 (en) * | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2007149433A2 (en) * | 2006-06-19 | 2007-12-27 | The Johns Hopkins University | Tumor-specific delivery of therapeutic agents via liposomase |
EP2452683A3 (en) | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
ES2599319T3 (en) | 2006-06-26 | 2017-02-01 | Macrogenics, Inc. | Fc RIIB specific antibodies and their methods of use |
JP5072275B2 (en) * | 2006-07-03 | 2012-11-14 | テルモ株式会社 | Method for separating closed vesicles, method for producing preparation and evaluation method |
CN101511181B (en) | 2006-07-11 | 2013-08-21 | 新泽西医科和牙科大学 | Proteins, nucleic acids encoding the same and associated methods of use |
US8343539B2 (en) | 2006-07-14 | 2013-01-01 | Regents Of The University Of Minnesota | Compounds that bind α5β1 integrin and methods of use |
US8324158B2 (en) * | 2006-07-14 | 2012-12-04 | Georgia Tech Research Corporation | Methods for inhibiting CLC-2 channel with GATX2 |
ES2612383T3 (en) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1 / IL-27 as a target for anti-inflammatory responses |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
JP4936312B2 (en) * | 2006-07-20 | 2012-05-23 | 株式会社島津製作所 | Novel amphiphile, drug delivery system and molecular imaging system using the same |
WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
JP5406027B2 (en) | 2006-08-04 | 2014-02-05 | ノバルティス アーゲー | EphB3-specific antibodies and uses thereof |
CA2660286A1 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
ME01786B (en) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimized antibodies that target cd19 |
AR062435A1 (en) | 2006-08-18 | 2008-11-05 | Xoma Technology Ltd | PRLR SPECIFIC ANTIBODY (PROLACTIN RECEPTOR) AND ITS USES |
EP2061900A2 (en) | 2006-08-25 | 2009-05-27 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
EP2064243A2 (en) | 2006-08-28 | 2009-06-03 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic human light-specific human monoclonal antibodies |
BRPI0716143A2 (en) | 2006-08-29 | 2013-11-26 | Genentech Inc | USE OF TENECTEPLASE TO TREAT ACUTE ISCHEMICAL SPILL |
SI2594586T1 (en) | 2006-09-01 | 2014-11-28 | Zymogenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
CA2600220C (en) * | 2006-09-07 | 2014-12-09 | Canadian Blood Services | Surface cross-linked lipidic particles, methods of production and uses therefor |
PL2066694T3 (en) | 2006-09-29 | 2016-04-29 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
US9505821B2 (en) | 2006-10-03 | 2016-11-29 | Rutgers, The State University Of New Jersey | ATAP peptides, nucleic acids encoding the same and associated methods of use |
US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
AR063384A1 (en) * | 2006-10-25 | 2009-01-28 | Amgen Inc | THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS |
CN101687031B (en) | 2006-10-27 | 2014-05-14 | 勒帕斯公司 | Compositions and methods for treating ocular diseases and conditions |
JP5795833B2 (en) * | 2006-10-27 | 2015-10-14 | エルパス・インコーポレイテッドLpath, Inc. | Compositions and methods for binding sphingosine-1-phosphate |
WO2008058291A2 (en) * | 2006-11-09 | 2008-05-15 | California Institute Of Technology | Modular aptamer-regulated ribozymes |
AU2007317203B2 (en) | 2006-11-10 | 2010-12-16 | Dimerix Bioscience Pty Ltd | Detection system and uses therefor |
EP2097422A4 (en) * | 2006-11-13 | 2010-04-14 | Lilly Co Eli | Thienopyrimidinones for treatment of inflammatory disorders and cancers |
WO2008067283A2 (en) | 2006-11-27 | 2008-06-05 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
MX2009006034A (en) | 2006-12-07 | 2009-10-12 | Novartis Ag | Antagonist antibodies against ephb3. |
EP1932517A3 (en) * | 2006-12-11 | 2008-07-16 | Universiteit Utrecht Holding B.V. | Liposomes containing a polyphenol derivative such as caffeic acid and a method of post-loading thereof |
US20100203110A1 (en) * | 2006-12-18 | 2010-08-12 | The Johns Hopkins University | Therapeutics for Cancer Using 3-Bromopyruvate and Other Selective Inhibitors of ATP Production |
WO2008079973A2 (en) * | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Egfr binding peptides and uses thereof |
WO2008079982A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Liposome composition for targeting egfr receptor |
WO2008079976A2 (en) | 2006-12-21 | 2008-07-03 | Centocor, Inc. | Dimeric high affinity egfr constructs and uses thereof |
WO2008094370A2 (en) | 2006-12-22 | 2008-08-07 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
WO2008083169A2 (en) * | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for the treatment of immunologic disorders |
JP5481199B2 (en) | 2006-12-27 | 2014-04-23 | ザ ジョンズ ホプキンス ユニバーシティー | Compositions and methods for treating inflammation and autoimmune diseases |
US20090142342A1 (en) * | 2006-12-27 | 2009-06-04 | Johns Hopkins University | B7-h4 receptor agonist compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
US20100329664A1 (en) * | 2007-01-23 | 2010-12-30 | Lim Dae-Soon | Shutter device for camera |
US20100093836A1 (en) | 2007-01-29 | 2010-04-15 | Isis Pharmaceuticals, Inc | Compounds and methods for modulating protein expression |
WO2008094275A1 (en) | 2007-01-30 | 2008-08-07 | New York University | Peptides for treatment of conditions associated with nitric oxide |
CA2676790A1 (en) | 2007-02-22 | 2008-08-28 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
EP2132573B1 (en) | 2007-03-02 | 2014-04-23 | Genentech, Inc. | Predicting response to a her dimerisation inhbitor based on low her3 expression |
EP2146692A1 (en) * | 2007-03-19 | 2010-01-27 | Fresenius Kabi Oncology Limited | Proliposomal and liposomal compositions |
JP4510842B2 (en) * | 2007-03-26 | 2010-07-28 | キヤノン株式会社 | Polyhydroxyalkanoate-coated liposome |
ES2540807T3 (en) | 2007-05-04 | 2015-07-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Variable domains of rabbit antibodies modified by genetic engineering and uses thereof |
KR20100017514A (en) | 2007-05-07 | 2010-02-16 | 메디뮨 엘엘씨 | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20090175784A1 (en) | 2007-05-11 | 2009-07-09 | Joshua Goldstein | Anti-Alpha V Immunoliposome Composition, Methods, and Uses |
US20090196913A1 (en) * | 2007-05-11 | 2009-08-06 | Ken Shi Kun Huang | Anti-Alpha-V Immunoliposome Composition, Methods, and Uses |
US20090163698A1 (en) * | 2007-05-11 | 2009-06-25 | John Joseph Grigsby | Method for Preparing Antibody Conjugates |
WO2009101479A2 (en) | 2007-05-14 | 2009-08-20 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
EP2160200B1 (en) | 2007-05-14 | 2013-07-10 | The University of Chicago | Antibody-LIGHT fusion products as cancer therapeutics |
EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2008148023A2 (en) * | 2007-05-23 | 2008-12-04 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for treating neurological disorders |
AU2008256644B2 (en) | 2007-05-24 | 2014-07-03 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
WO2008150841A1 (en) | 2007-05-30 | 2008-12-11 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
TW200916094A (en) * | 2007-06-27 | 2009-04-16 | Poniard Pharmaceuticals Inc | Stabilized picoplatin dosage form |
EP2514762B1 (en) | 2007-07-13 | 2015-04-08 | The Johns Hopkins University | B7-DC variants |
US20090082217A1 (en) * | 2007-07-16 | 2009-03-26 | California Institute Of Technology | Selection of nucleic acid-based sensor domains within nucleic acid switch platform |
EP2641618A3 (en) | 2007-07-16 | 2013-10-23 | Genentech, Inc. | Humanized anti-CD79B antibodies and immunoconjugates and methods of use |
SG183023A1 (en) | 2007-07-16 | 2012-08-30 | Genentech Inc | Anti-cd79b antibodies and immunoconjugates and methods of use |
US8183381B2 (en) * | 2007-07-19 | 2012-05-22 | Metabolex Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
SI2489731T1 (en) | 2007-07-26 | 2014-12-31 | Amgen Inc. Patent Operations, M/S 28-2-C | Modified lecithin-cholesterol acyltransferase enzymes |
US20100204425A1 (en) * | 2007-07-26 | 2010-08-12 | Basf Se | Process for preparing copolymers obtained by graft polymerization in solution and based on polyethers in solid form |
US7666973B2 (en) | 2007-07-30 | 2010-02-23 | Tyco Healthcare Group Lp | Carbonate copolymers |
US8679485B2 (en) | 2007-08-02 | 2014-03-25 | Gilead Biologics, Inc. | Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis |
US20110269942A1 (en) * | 2007-08-09 | 2011-11-03 | Daiichi Sankyo Company, Limited | Antibodies modified with hydrophobic molecule |
US8268958B2 (en) | 2007-08-15 | 2012-09-18 | Tyco Healthcare Group Ip | Phospholipid copolymers |
US20090048423A1 (en) * | 2007-08-15 | 2009-02-19 | Tyco Healthcare Group Lp | Phospholipid Copolymers |
US8367815B2 (en) * | 2007-08-28 | 2013-02-05 | California Institute Of Technology | Modular polynucleotides for ligand-controlled regulatory systems |
US20120165387A1 (en) | 2007-08-28 | 2012-06-28 | Smolke Christina D | General composition framework for ligand-controlled RNA regulatory systems |
EP2197890A1 (en) * | 2007-09-07 | 2010-06-23 | Gencia Corporation | Mitochondrial compositions and uses thereof |
US8865667B2 (en) * | 2007-09-12 | 2014-10-21 | California Institute Of Technology | Higher-order cellular information processing devices |
US20110014118A1 (en) * | 2007-09-21 | 2011-01-20 | Lawrence Tamarkin | Nanotherapeutic colloidal metal compositions and methods |
EP2200932A4 (en) * | 2007-09-21 | 2014-09-10 | Cytimmune Sciences Inc | Nanotherapeutic colloidal metal compositions and methods |
CN106310293A (en) | 2007-09-27 | 2017-01-11 | 免疫疫苗技术有限公司 | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
WO2009040426A1 (en) | 2007-09-28 | 2009-04-02 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
CA2700953A1 (en) | 2007-10-02 | 2009-04-09 | Amgen Inc. | Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
MX2010003979A (en) * | 2007-10-16 | 2010-06-02 | Biocon Ltd | An orally administerable solid pharmaceutical composition and a process thereof. |
US8361465B2 (en) * | 2007-10-26 | 2013-01-29 | Lpath, Inc. | Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
WO2009060124A2 (en) * | 2007-11-05 | 2009-05-14 | Baltic Technology Development, Ltd. | Use of oligonucleotides with modified bases in hybridization of nucleic acids |
ES2557352T3 (en) | 2007-11-05 | 2016-01-25 | Medimmune, Llc | Methods of treatment of scleroderma |
PT2514436T (en) | 2007-11-07 | 2018-03-21 | Genentech Inc | Il-22 for use in treating microbial disorders |
WO2010135521A2 (en) | 2009-05-20 | 2010-11-25 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
US20110033476A1 (en) * | 2007-11-12 | 2011-02-10 | Theraclone Sciences Inc. | Compositions and methods for the therapy and diagnosis of influenza |
DK2220116T3 (en) | 2007-11-12 | 2012-11-26 | Theraclone Sciences Inc | COMPOSITIONS AND PROCEDURES FOR THE THERAPY AND DIAGNOSTICATION OF INFLUENZA |
US8598165B2 (en) * | 2007-11-26 | 2013-12-03 | University Of Kansas | Morpholines as selective inhibitors of cytochrome P450 2A13 |
EP3524619A1 (en) | 2007-12-06 | 2019-08-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
KR101603109B1 (en) | 2007-12-07 | 2016-03-25 | 지모제넥틱스, 인코포레이티드 | Humanized antibody molecules specific for il-31 |
US9029524B2 (en) * | 2007-12-10 | 2015-05-12 | California Institute Of Technology | Signal activated RNA interference |
US8591898B2 (en) | 2007-12-17 | 2013-11-26 | Pfizer Limited | Treatment of interstitial cystitis |
US8962806B2 (en) | 2007-12-28 | 2015-02-24 | Dana-Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
US20090181094A1 (en) * | 2008-01-15 | 2009-07-16 | Eric Yueh-Lang Sheu | Molecular Cage for Sustained Release Control of Pharmaceutical and Cosmetic Agents |
AR070141A1 (en) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | SPECIFIC HUMANIZED ANTIBODIES FOR VON WILLEBRAND FACTOR |
TWI472339B (en) | 2008-01-30 | 2015-02-11 | Genentech Inc | Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof |
IL295449A (en) | 2008-01-31 | 2022-10-01 | Genentech Inc | Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates |
WO2009111315A2 (en) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Methods for reducing granulomatous inflammation |
AU2009223688B2 (en) * | 2008-03-10 | 2014-12-11 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of cytomegalovirus infections |
AU2009228058A1 (en) | 2008-03-28 | 2009-10-01 | Sea Lane Biotechnologies, Llc | Neutralizing molecules to viral antigens |
MX2010010562A (en) * | 2008-03-31 | 2010-12-07 | Metabolex Inc | Oxymethylene aryl compounds and uses thereof. |
BRPI0911332A2 (en) | 2008-04-04 | 2019-09-24 | Calando Pharmaceuticals Inc | compositions and use of epas1 inhibitors |
HUE036780T2 (en) | 2008-04-09 | 2018-07-30 | Genentech Inc | Novel compositions and methods for the treatment of immune related diseases |
AU2009234389B2 (en) | 2008-04-10 | 2014-08-21 | Cell Signaling Technology, Inc. | Compositions and methods for detecting EGFR mutations in cancer |
PL2279254T3 (en) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
EP2280995A2 (en) * | 2008-04-29 | 2011-02-09 | Wyeth LLC | Methods for treating inflammation |
US20090280134A1 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting toxin a from clostridium difficile |
CA2722127A1 (en) * | 2008-05-09 | 2009-11-12 | Recopharma Ab | Compositions and methods for inhibiting shiga toxin and shiga-like toxin |
EP2279004B1 (en) | 2008-05-16 | 2015-01-14 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
US8093018B2 (en) | 2008-05-20 | 2012-01-10 | Otsuka Pharmaceutical Co., Ltd. | Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same |
CN102036658A (en) * | 2008-05-23 | 2011-04-27 | 香港大学 | Combination therapy for the treatment of influenza |
JP5531332B2 (en) | 2008-06-05 | 2014-06-25 | 株式会社島津製作所 | Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, molecular imaging system and drug delivery system |
AU2009253780B2 (en) * | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
WO2009150623A1 (en) | 2008-06-13 | 2009-12-17 | Pfizer Inc | Treatment of chronic prostatitis |
WO2009155431A1 (en) * | 2008-06-18 | 2009-12-23 | University Of Louisville Research Foundation, Inc. | Methods for targeted cancer treatment and detection |
WO2010005567A2 (en) | 2008-07-08 | 2010-01-14 | Oncomed Pharmaceuticals, Inc. | Notch1 receptor binding agents and methods of use thereof |
KR101647334B1 (en) * | 2008-07-10 | 2016-08-10 | 세리나 쎄라퓨틱스, 인코포레이티드 | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
US20100008900A1 (en) * | 2008-07-14 | 2010-01-14 | The University Of Hong Kong | Annexin ii compositions for treating or monitoring inflammation or immune-mediated disorders |
US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
EP2323667A4 (en) * | 2008-08-07 | 2012-07-25 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression for the treatment of cns related disorders |
WO2010019702A2 (en) | 2008-08-12 | 2010-02-18 | Oncomed Pharmaceuticals, Inc. | Ddr1-binding agents and methods of use thereof |
EP2484666A1 (en) | 2008-08-15 | 2012-08-08 | Georgetown University | Fluorescent regulators of RASSF1A expression and human cancer cell proliferation |
DK2331092T3 (en) * | 2008-08-21 | 2014-05-19 | Univ Johns Hopkins | Methods and compositions for administering 3-halopyruvate and associated compounds for the treatment of cancer |
DK2367812T3 (en) | 2008-08-22 | 2015-12-21 | Sanofi Sa | [4- (5-aminomethyl-2-fluoro-phenyl) -piperidin-1-yl] - [7-fluoro-1- (2-methoxyethyl) -4-trifluoromethoxy-1H-indol-3-yl] methanone as an inhibitor of mast cell tryptase |
AU2009288289B2 (en) * | 2008-08-25 | 2012-11-08 | Amplimmune, Inc. | PD-1 antagonists and methods of use thereof |
CA2736799A1 (en) | 2008-08-25 | 2010-03-11 | Burnham Institute For Medical Research | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
PE20110435A1 (en) | 2008-08-25 | 2011-07-20 | Amplimmune Inc | ANTAGONIST COMPOSITIONS OF PD-1 |
WO2010030813A2 (en) | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Methods for inhibiting ocular angiogenesis |
TWI445716B (en) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9 antagonists |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
US8796443B2 (en) | 2008-09-22 | 2014-08-05 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
US9173840B2 (en) | 2008-10-09 | 2015-11-03 | Northeastern University | Multifunctional self-assembling polymeric nanosystems |
US8147847B2 (en) * | 2008-10-21 | 2012-04-03 | International Vaccine Institute | Shigella protein antigens and methods |
MX2011004125A (en) | 2008-10-21 | 2011-05-19 | Metabolex Inc | Aryl gpr120 receptor agonists and uses thereof. |
US8871202B2 (en) | 2008-10-24 | 2014-10-28 | Lpath, Inc. | Prevention and treatment of pain using antibodies to sphingosine-1-phosphate |
AU2009312532B2 (en) * | 2008-11-06 | 2013-05-16 | Ichnos Sciences SA | Treatment with anti-alpha2 integrin antibodies |
EP4241767A3 (en) | 2008-11-10 | 2023-11-01 | Arbutus Biopharma Corporation | Novel lipids and compositions for the delivery of therapeutics |
NZ592880A (en) | 2008-11-13 | 2013-06-28 | Gilead Calistoga Llc | Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
KR101807319B1 (en) | 2008-11-22 | 2017-12-11 | 제넨테크, 인크. | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer |
WO2010068414A2 (en) * | 2008-11-25 | 2010-06-17 | Bowen Richard L | Methods for treating obesity related disease |
US20110160222A1 (en) * | 2008-11-26 | 2011-06-30 | Metabolex, Inc. | Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders |
EP2370580B1 (en) | 2008-12-04 | 2019-09-11 | CuRNA, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
RU2746478C2 (en) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
CN102317458B (en) | 2008-12-04 | 2018-01-02 | 库尔纳公司 | Pass through treatment of the suppression of erythropoietin(EPO) (EPO) natural antisense transcript to EPO relevant diseases |
WO2010068680A1 (en) | 2008-12-10 | 2010-06-17 | Mount Sinai School Of Medicine Of New York University | Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
TW201034675A (en) | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
AR074760A1 (en) * | 2008-12-18 | 2011-02-09 | Metabolex Inc | GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME. |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2748034A1 (en) * | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections |
PA8855601A1 (en) | 2008-12-23 | 2010-07-27 | NUCLEOSID FORFORMIDATES | |
CN102325783A (en) | 2008-12-23 | 2012-01-18 | 法莫赛特股份有限公司 | Synthesis of purine nucleosides |
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
WO2010086828A2 (en) | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
PT2396038E (en) | 2009-02-12 | 2016-02-19 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
CN102439149B (en) | 2009-02-12 | 2018-01-02 | 库尔纳公司 | By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF) |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
EP2403863B1 (en) | 2009-03-02 | 2013-08-28 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
CA2754749C (en) | 2009-03-04 | 2019-04-30 | Opko Curna, Llc | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1 |
EP2228059A1 (en) | 2009-03-12 | 2010-09-15 | Universitätsspital Basel | Chemotherapeutic composition for the treatment of cancer |
ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
SI3260136T1 (en) | 2009-03-17 | 2021-05-31 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv) -neutralizing antibodies |
CA2756347A1 (en) | 2009-03-24 | 2010-09-30 | Gilead Calistoga Llc | Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
SG10201609416XA (en) | 2009-03-25 | 2016-12-29 | Genentech Inc | NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF |
PE20120878A1 (en) | 2009-04-01 | 2012-08-06 | Genentech Inc | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES |
KR101766927B1 (en) | 2009-04-01 | 2017-08-09 | 제넨테크, 인크. | Treatment of insulin-resistant disorders |
US9145555B2 (en) | 2009-04-02 | 2015-09-29 | California Institute Of Technology | Integrated—ligand-responsive microRNAs |
WO2010123931A1 (en) * | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals Inc. | Methods of treatment for solid tumors |
EP3248618A1 (en) | 2009-04-22 | 2017-11-29 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
SG175305A1 (en) | 2009-04-23 | 2011-11-28 | Theraclone Sciences Inc | Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies |
CN102459346B (en) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | The method manufacturing heteromultimers molecule |
EP2248903A1 (en) | 2009-04-29 | 2010-11-10 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages |
US8524783B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
US8524784B2 (en) | 2009-04-30 | 2013-09-03 | Intezyne Technologies, Incorporated | Polymer micelles containing anthracylines for the treatment of cancer |
CA2760589C (en) | 2009-05-01 | 2019-08-20 | Joseph Collard | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
NZ621981A (en) | 2009-05-05 | 2015-09-25 | Tekmira Pharmaceuticals Corp | Lipid compositions |
EP2427203B1 (en) | 2009-05-05 | 2018-10-17 | Novimmune S.A. | Anti-il-17f antibodies and use thereof |
CA3045126A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
KR101722541B1 (en) | 2009-05-06 | 2017-04-04 | 큐알엔에이, 인크. | Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN103223177B (en) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
CA2762369C (en) | 2009-05-18 | 2021-12-28 | Joseph Collard | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
TWI576352B (en) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
WO2011019423A2 (en) | 2009-05-20 | 2011-02-17 | Schering Corporation | Modulation of pilr receptors to treat microbial infections |
EP2432882B1 (en) | 2009-05-22 | 2019-12-25 | CuRNA, Inc. | TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3 |
CA2764683A1 (en) | 2009-05-28 | 2010-12-02 | Joseph Collard | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
HUE056773T2 (en) | 2009-06-10 | 2022-03-28 | Arbutus Biopharma Corp | Improved lipid formulation |
US20120100206A1 (en) | 2009-06-11 | 2012-04-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Targeted liposomes comprising n-containing bisphosphonates and uses thereof |
EP2443237B1 (en) | 2009-06-16 | 2017-02-22 | CuRNA, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
WO2010146511A1 (en) | 2009-06-17 | 2010-12-23 | Pfizer Limited | Treatment of overactive bladder |
CN102597238B (en) | 2009-06-24 | 2016-06-29 | 库尔纳公司 | The relevant disease of TNFR2 is treated by suppressing for the natural antisense transcript of tumor necrosis factor receptor 2 (TNFR2) |
CN102482672B (en) | 2009-06-26 | 2016-11-09 | 库尔纳公司 | By suppressing the natural antisense transcript treatment Down syndrome gene-associated diseases of Down syndrome gene |
AU2010265949B2 (en) | 2009-06-26 | 2016-05-05 | I2 Pharmaceuticals, Inc. | Expression of surrogate light chains |
WO2011000384A1 (en) | 2009-06-30 | 2011-01-06 | Общество С Ограниченной Ответсвенностью "Онкомакс" | Method for suppressing tumor growth by blocking fibroblast growth factor receptor, and method for diagnosing malignant neoplasms |
EP2449114B9 (en) | 2009-07-01 | 2017-04-19 | Protiva Biotherapeutics Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
CN102471381A (en) | 2009-07-07 | 2012-05-23 | 霍夫曼-拉罗奇有限公司 | Diagnosis and treatment of autoimmune demyelinating diseases |
US8920775B2 (en) | 2009-07-17 | 2014-12-30 | Technical University Of Denmark | Loading technique for preparing radionuclide containing nanoparticles |
JP2013500257A (en) | 2009-07-21 | 2013-01-07 | ギリアード カリストガ エルエルシー | Treatment of liver damage with PI3K inhibitors |
WO2011017297A2 (en) | 2009-08-03 | 2011-02-10 | The University Of North Carolina At Chapel Hill | Biodegradable delivery system complexes for the delivery of bioactive compounds |
CN102762731B (en) | 2009-08-05 | 2018-06-22 | 库尔纳公司 | By inhibiting to treat insulin gene (INS) relevant disease for the natural antisense transcript of insulin gene (INS) |
JP6088246B2 (en) | 2009-08-15 | 2017-03-01 | ジェネンテック, インコーポレイテッド | Anti-angiogenic therapy for the treatment of previously treated breast cancer |
FR2955324A1 (en) | 2010-01-15 | 2011-07-22 | Sanofi Aventis | DISUBSTITUTED 4- (5-AMINOMETHYL-PHENYL) -PIPERIDIN-1-YL] -1H-INDOL-3-YL] -METHANONES |
JP5964232B2 (en) | 2009-08-25 | 2016-08-03 | カッパーアールエヌエー,インコーポレイテッド | Treatment of IQGAP-related diseases by inhibition of natural antisense transcripts against 'IQ motif-containing GTPase-activating protein' (IQGAP) |
IN2012DN02753A (en) | 2009-08-31 | 2015-09-18 | Amplimmune Inc | |
US20110059111A1 (en) | 2009-09-01 | 2011-03-10 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Mammalian receptors as targets for antibody and active vaccination therapy against mold infections |
JP5887270B2 (en) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | Mutant SMOOTHENED AND METHOD OF USING THE SAME |
ES2497566T3 (en) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
MX368790B (en) * | 2009-10-15 | 2019-10-16 | Genentech Inc | Chimeric fibroblast growth factors with altered receptor specificity. |
ES2895226T3 (en) | 2009-10-16 | 2022-02-18 | Mereo Biopharma 5 Inc | Therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
RU2539772C2 (en) | 2009-10-22 | 2015-01-27 | Дженентек, Инк. | Methods and compositions for hepsin modulation of macrophage-stimulating protein |
LT2496567T (en) | 2009-11-05 | 2017-11-27 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
WO2011062997A2 (en) | 2009-11-17 | 2011-05-26 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
CN103755809B (en) | 2009-11-30 | 2016-06-01 | 霍夫曼-拉罗奇有限公司 | The antibody of the tumour of SLC34A2 (TAT211=SEQID2) is expressed in treatment and diagnosis |
CA2783372C (en) | 2009-12-07 | 2019-07-16 | Muthiah Manoharan | Compositions for nucleic acid delivery |
US20120269830A1 (en) | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
AU2010329847A1 (en) | 2009-12-11 | 2012-07-26 | Genecode As | Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators |
WO2011081904A1 (en) | 2009-12-14 | 2011-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Delivery of transthyretin across the blood-brain barrier as a treatment for alzheimer's disease |
KR101823702B1 (en) | 2009-12-16 | 2018-01-30 | 큐알엔에이, 인크. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US8691227B2 (en) | 2009-12-17 | 2014-04-08 | Merck Sharp & Dohme Corp. | Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α |
ES2749426T3 (en) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Nucleic Acid Administration Methods and Compositions |
CA2785439A1 (en) | 2009-12-23 | 2011-06-30 | Sanofi | [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
HUE028629T2 (en) | 2009-12-23 | 2016-12-28 | Synimmune Gmbh | Anti-flt3 antibodies and methods of using the same |
JP6031356B2 (en) | 2009-12-23 | 2016-11-24 | カッパーアールエヌエー,インコーポレイテッド | Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2. |
CN102791702A (en) | 2009-12-23 | 2012-11-21 | 赛诺菲 | Prodrugs of [4[4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1H-pyrrolo-pyridin-yl)-methanones and synthesis thereof |
US8940708B2 (en) | 2009-12-23 | 2015-01-27 | Curna, Inc. | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF |
EP3450459B1 (en) | 2009-12-28 | 2021-05-26 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
CA2785177C (en) | 2009-12-29 | 2019-09-24 | Curna, Inc. | Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63 |
CN102782134B (en) | 2009-12-29 | 2017-11-24 | 库尔纳公司 | NRF1 relevant diseases are treated by suppressing the natural antisense transcript of the core breathing factor 1 (NRF1) |
WO2011082187A1 (en) | 2009-12-30 | 2011-07-07 | Genentech, Inc. | Methods for modulating a pdgf-aa mediated biological response |
WO2011082409A2 (en) | 2010-01-04 | 2011-07-07 | Curna, Inc. | Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8 |
WO2011085066A2 (en) | 2010-01-06 | 2011-07-14 | Curna, Inc. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene |
EP2522366B1 (en) * | 2010-01-08 | 2018-10-31 | FUJIFILM Corporation | Targeting agent for tumor site |
EP2524039B1 (en) | 2010-01-11 | 2017-11-29 | CuRNA, Inc. | Treatment of sex hormone binding globulin (shbg) related diseases by inhibition of natural antisense transcript to shbg |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088215A2 (en) | 2010-01-13 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Notch1 binding agents and methods of use thereof |
WO2011090971A2 (en) | 2010-01-19 | 2011-07-28 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
WO2011089211A1 (en) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anti-cd133 antibodies and methods of using the same |
RU2611192C2 (en) | 2010-01-25 | 2017-02-21 | Курна, Инк. | TREATMENT OF RNase H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNase H1 |
US8198337B2 (en) * | 2010-01-27 | 2012-06-12 | Momentive Performance Materials Inc. | Demulsifier compositions and methods for separating emulsions using the same |
EP2531175A2 (en) | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
US8962586B2 (en) | 2010-02-22 | 2015-02-24 | Curna, Inc. | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1 |
EP2539367A2 (en) | 2010-02-23 | 2013-01-02 | F. Hoffmann-La Roche AG | Anti-angiogenesis therapy for the treatment of ovarian cancer |
RU2545401C2 (en) | 2010-02-23 | 2015-03-27 | Санофи | Anti-integrin alpha-2 antibodies and using them |
AR080243A1 (en) | 2010-02-23 | 2012-03-21 | Genentech Inc | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT |
AR080291A1 (en) | 2010-02-24 | 2012-03-28 | Rinat Neuroscience Corp | ANTI-BODIES ANTAGONISTS ANTI RECEIVER OF IL-7 AND PROCEDURES |
US8889193B2 (en) | 2010-02-25 | 2014-11-18 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
KR20120138241A (en) | 2010-03-11 | 2012-12-24 | 화이자 인코포레이티드 | Antibodies with ph dependent antigen binding |
MX354867B (en) | 2010-03-22 | 2018-03-23 | Genentech Inc Star | Compositions and methods useful for stabilizing protein-containing formulations. |
US9080171B2 (en) | 2010-03-24 | 2015-07-14 | RXi Parmaceuticals Corporation | Reduced size self-delivering RNAi compounds |
CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
CA2794708C (en) | 2010-03-29 | 2021-11-16 | Zymeworks Inc. | Antibodies with enhanced or suppressed effector function |
PT3178851T (en) | 2010-03-31 | 2020-07-17 | Boehringer Ingelheim Int | Anti-cd40 antibodies |
TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
SG184323A1 (en) | 2010-03-31 | 2012-11-29 | Gilead Pharmasett Llc | Stereoselective synthesis of phosphorus containing actives |
WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
WO2011125015A2 (en) | 2010-04-05 | 2011-10-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
TWI644675B (en) | 2010-04-09 | 2018-12-21 | 可娜公司 | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2011133868A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
EP3085387A1 (en) | 2010-04-26 | 2016-10-26 | Abraxis BioScience, LLC | Sparc binding antibodies and uses thereof |
WO2011135905A1 (en) * | 2010-04-28 | 2011-11-03 | 国立大学法人北海道大学 | Lipid membrane structure |
BR112012027547B1 (en) | 2010-04-29 | 2022-06-14 | Ionis Pharmaceuticals, Inc | SINGLE STRIP MODIFIED OLIGONUCLEOTIDE, COMPOSITION, AND ITS USES TO TREAT TRANSTHIRRETIN AYLOIDOSIS, REDUCE ITS SYMPTOMS, AND TO REDUCE TRANSTHIRRETIN MRNA OR PROTEIN EXPRESSION |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
ES2552954T3 (en) | 2010-04-30 | 2015-12-03 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for the use of antibodies |
KR101915115B1 (en) | 2010-05-03 | 2018-11-05 | 큐알엔에이, 인크. | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
WO2011139718A1 (en) | 2010-05-03 | 2011-11-10 | Genentech, Inc. | Compositions and methods useful for reducing the viscosity of protein-containing formulations |
SG185027A1 (en) | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
TWI531370B (en) | 2010-05-14 | 2016-05-01 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
CN103068824B (en) | 2010-05-17 | 2017-09-08 | 印蔻真治疗公司 | It is used as new 3,5 2 substitution 3H imidazos [4,5 B] pyridine and 3,5 2 substitution 3H [1,2,3] triazol [4,5 B] pyridine compounds of protein kinase modulators |
JP6267510B2 (en) | 2010-05-18 | 2018-01-24 | ニューメディシンズ,インコーポレーテッド | IL-12 formulation for enhancing hematopoiesis |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
US8895528B2 (en) | 2010-05-26 | 2014-11-25 | Curna, Inc. | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 |
WO2011153243A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Anti-angiogenesis therapy for treating gastric cancer |
EP3957653A1 (en) | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
IL300109A (en) | 2010-06-03 | 2023-03-01 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
WO2011159297A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
US9566238B2 (en) | 2010-06-19 | 2017-02-14 | Western University Of Health Sciences | Formulation of PEGylated-liposome encapsulated glycopeptide antibiotics |
EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
AU2011270828B2 (en) | 2010-06-24 | 2015-09-24 | Genentech, Inc. | Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations |
CN102309448B (en) * | 2010-06-29 | 2014-07-09 | 中国人民解放军军事医学科学院毒物药物研究所 | Pulmonary delivery ciprofloxacin pharmaceutical composition and preparation method thereof |
WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
LT3243526T (en) | 2010-07-06 | 2020-02-10 | Glaxosmithkline Biologicals S.A. | Delivery of rna to trigger multiple immune pathways |
BR112013000244A2 (en) | 2010-07-06 | 2016-05-17 | Novartis Ag | lipid liposomes having advantageous pka for administration of rna |
PL2590676T3 (en) | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Virion-like delivery particles for self-replicating rna molecules |
JP5940064B2 (en) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | Immunization of large mammals with low doses of RNA |
US20120208855A1 (en) | 2010-07-12 | 2012-08-16 | Sanofi | Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders |
MX2013000491A (en) | 2010-07-12 | 2013-02-26 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates. |
US8980860B2 (en) | 2010-07-14 | 2015-03-17 | Curna, Inc. | Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG |
JP2013538191A (en) | 2010-07-23 | 2013-10-10 | トラスティーズ オブ ボストン ユニバーシティ | Anti-DEsupR inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery |
US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
US20130323269A1 (en) | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
WO2012019093A1 (en) | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
AU2011289275A1 (en) | 2010-08-12 | 2013-02-21 | Theraclone Sciences, Inc. | Anti-hemagglutinin antibody compositions and methods of use thereof |
EP4066819B1 (en) | 2010-08-31 | 2023-03-01 | GlaxoSmithKline Biologicals SA | Small liposomes for delivery of immunogen-encoding rna |
WO2012030904A2 (en) | 2010-08-31 | 2012-03-08 | Theraclone Sciences, Inc. | Human immunodeficiency virus (hiv)-neutralizing antibodies |
SI2611461T1 (en) | 2010-08-31 | 2022-08-31 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding rna |
US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
CN103210086B (en) | 2010-10-06 | 2017-06-09 | 库尔纳公司 | NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4) |
AU2011316707A1 (en) | 2010-10-11 | 2013-05-09 | Novartis Ag | Antigen delivery platforms |
EP2630241B1 (en) | 2010-10-22 | 2018-10-17 | CuRNA, Inc. | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
EP2633317A1 (en) | 2010-10-25 | 2013-09-04 | Genentech, Inc. | Treatment of gastrointestinal inflammation and psoriasis a |
JP6073795B2 (en) | 2010-10-27 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1) |
EP3456740A1 (en) | 2010-11-04 | 2019-03-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
WO2012061811A2 (en) | 2010-11-05 | 2012-05-10 | Fibrogen, Inc. | Treatment method for lung remodeling diseases |
WO2012065044A2 (en) | 2010-11-12 | 2012-05-18 | Purdue Research Foundation | Treating bladder tumor cells using fibronectin attachment protein as a target |
EP2640831A1 (en) | 2010-11-17 | 2013-09-25 | Sea Lane Biotechnologies,llc. | Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody |
RU2018102375A (en) | 2010-11-18 | 2019-02-21 | Зе Дженерал Хоспитал Корпорейшен | NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY |
KR102010598B1 (en) | 2010-11-23 | 2019-08-13 | 큐알엔에이, 인크. | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
CA2818853A1 (en) | 2010-11-30 | 2012-06-07 | Gilead Pharmasset Llc | 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus |
JP5947807B2 (en) | 2010-12-14 | 2016-07-06 | テクニカル ユニバーシティ オブ デンマークTechnical University Of Denmark | Encapsulation of radionuclides in nanoparticle compositions |
EP2468259A1 (en) * | 2010-12-23 | 2012-06-27 | Traslational Cancer Drugs Pharma, S.L. | Pharmaceutical compositions of pyridinium and quinolinium derivatives |
CA2834968C (en) | 2011-01-05 | 2018-01-09 | Livon Laboratories | Methods of making liposomes, liposome compositions made by the methods, and methods of using the same |
WO2012099755A1 (en) | 2011-01-11 | 2012-07-26 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
AU2012206945B2 (en) | 2011-01-11 | 2015-02-19 | Dimerix Bioscience Pty Ltd | Combination therapy |
RU2440142C1 (en) | 2011-02-07 | 2012-01-20 | Общество С Ограниченной Ответственностью "Онкомакс" | Antibody, stopping or retarding tumour growth (versions), method of suppressing tumour growth, method of diagnosing malignant lesions |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
AU2012217867A1 (en) | 2011-02-14 | 2013-09-05 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
PL226015B1 (en) * | 2011-03-03 | 2017-06-30 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną | Liposome preparation containing anticancer active substance, process for the preparation thereof and pharmaceutical compositions containing thereof |
KR101938343B1 (en) | 2011-03-09 | 2019-01-14 | 셀 시그널링 테크놀러지, 인크. | Methods and reagents for creating monoclonal antibodies |
MX2013010367A (en) | 2011-03-15 | 2014-04-14 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza. |
EP2686340A2 (en) | 2011-03-16 | 2014-01-22 | Amgen Inc. | Potent and selective inhibitors of nav1.3 and nav1.7 |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
WO2012134975A1 (en) | 2011-03-28 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions employing immunogenic fusion proteins |
EP3412309A1 (en) | 2011-03-31 | 2018-12-12 | F. Hoffmann-La Roche AG | Methods of administering beta7 integrin antagonists |
EP2508176A1 (en) | 2011-04-08 | 2012-10-10 | Lipotarg Gmbh | Novel combination treatment of cancer |
CA2832972C (en) | 2011-04-13 | 2019-04-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of ptp1b expression |
RU2625034C2 (en) | 2011-04-20 | 2017-07-11 | МЕДИММЬЮН, ЭлЭлСи | Antibodies and other molecules binding b7-h1 and pd-1 |
KR101589135B1 (en) | 2011-04-20 | 2016-01-29 | 주식회사 셀앤바이오 | Humanized anti-EMAPII antibodies and uses thereof |
RS58326B1 (en) | 2011-05-04 | 2019-03-29 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
CN103842383B (en) | 2011-05-16 | 2017-11-03 | 健能隆医药技术(上海)有限公司 | Polyspecific FAB fusion proteins and its application method |
CA2838588C (en) | 2011-06-09 | 2021-09-14 | Curna, Inc. | Treatment of frataxin (fxn) related diseases by inhibition of natural antisense transcript to fxn |
AU2012267786B2 (en) | 2011-06-10 | 2017-08-03 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
CN103597074A (en) | 2011-06-16 | 2014-02-19 | Isis制药公司 | Antisense modulation of fibroblast growth factor receptor 4 expression |
EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
WO2013003652A1 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
ES2656050T3 (en) | 2011-07-06 | 2018-02-22 | Glaxosmithkline Biologicals Sa | Immunogenic combination compositions and uses thereof |
DK2731591T3 (en) | 2011-07-13 | 2020-09-21 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | LIPOSOMES WHICH ENCAPLATE A BISPHOSPHONATE AND AN AMFIFILATE |
EP2731623A1 (en) | 2011-07-14 | 2014-05-21 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
US9120858B2 (en) | 2011-07-22 | 2015-09-01 | The Research Foundation Of State University Of New York | Antibodies to the B12-transcobalamin receptor |
US20130022551A1 (en) | 2011-07-22 | 2013-01-24 | Trustees Of Boston University | DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS |
WO2013015821A1 (en) | 2011-07-22 | 2013-01-31 | The Research Foundation Of State University Of New York | Antibodies to the b12-transcobalamin receptor |
AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
FR2979239A1 (en) * | 2011-08-25 | 2013-03-01 | Trophos | LIPOSOME COMPRISING AT LEAST ONE CHOLESTEROL DERIVATIVE |
US8822651B2 (en) | 2011-08-30 | 2014-09-02 | Theraclone Sciences, Inc. | Human rhinovirus (HRV) antibodies |
CA2847057C (en) | 2011-08-31 | 2019-06-11 | St. Jude Children's Research Hospital | Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use |
MY170725A (en) | 2011-09-09 | 2019-08-27 | Univ Osaka | Dengue-virus serotype neutralizing antibodies |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
AU2012312654B2 (en) | 2011-09-19 | 2017-04-13 | Gencia Corporation | Modified creatine compounds |
EP2758533B1 (en) | 2011-09-20 | 2018-04-11 | Ionis Pharmaceuticals, Inc. | Antisense modulation of gcgr expression |
PE20141537A1 (en) | 2011-09-23 | 2014-11-17 | Oncomed Pharm Inc | AGENTS OF LINKING THE VASCULAR ENDOTHELIAL GROWTH FACTOR / LIGANDO 4 SIMILAR TO DELTA (VEGF / DLL4) AND USES OF THE SAME |
JP2014533929A (en) | 2011-09-23 | 2014-12-18 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | Bispecific binding molecules for 5T4 and CD3 |
EP2758434A2 (en) | 2011-09-23 | 2014-07-30 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA | Anti-tumor necrosis factor-alpha agents and uses thereof |
WO2013049328A1 (en) | 2011-09-27 | 2013-04-04 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
JP6368645B2 (en) | 2011-09-29 | 2018-08-01 | ピーエルエックス オプコ インコーポレーテッド | PH-dependent carriers for targeted release of drugs along the gastrointestinal tract, compositions thereby, and their manufacture and use |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
SG11201401177WA (en) | 2011-10-06 | 2014-04-28 | Immunovaccine Technologies Inc | Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof |
KR102102862B1 (en) | 2011-10-14 | 2020-04-22 | 제넨테크, 인크. | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE |
US8883989B2 (en) | 2011-10-18 | 2014-11-11 | Regents Of The University Of Minnesota | Fractalkine binding polynucleotides and methods of use |
CA2853373A1 (en) | 2011-10-25 | 2013-05-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of gccr expression |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
KR20140097205A (en) | 2011-10-28 | 2014-08-06 | 제넨테크, 인크. | Therapeutic combinations and methods of treating melanoma |
EP3091029B1 (en) | 2011-10-31 | 2022-12-28 | F. Hoffmann-La Roche AG | Anti-il13 antibody formulations |
JP6205095B2 (en) * | 2011-11-03 | 2017-09-27 | タイワン リポサム カンパニー、エルティーディー. | Pharmaceutical composition of hydrophobic camptothecin derivative |
US10980798B2 (en) | 2011-11-03 | 2021-04-20 | Taiwan Liposome Company, Ltd. | Pharmaceutical compositions of hydrophobic camptothecin derivatives |
BR112014011331A2 (en) | 2011-11-11 | 2017-04-25 | Rinat Neuroscience Corp | trop-2 specific antibodies and their uses |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
EP3536710A1 (en) | 2011-11-16 | 2019-09-11 | Boehringer Ingelheim International GmbH | Anti il-36r antibodies |
US9493532B2 (en) | 2011-12-15 | 2016-11-15 | The University Of Chicago | Compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
WO2013093693A1 (en) | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
EP2794659A1 (en) | 2011-12-22 | 2014-10-29 | Rinat Neuroscience Corp. | Human growth hormone receptor antagonist antibodies and methods of use thereof |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
CA2863216C (en) | 2012-01-09 | 2020-06-02 | Covx Technologies Ireland Limited | Mutant antibodies and conjugation thereof |
EP2804620A4 (en) | 2012-01-18 | 2016-04-13 | Neumedicines Inc | Il-12 for radiation protection and radiation-induced toxicity mitigation |
EP2804631B1 (en) | 2012-01-20 | 2021-03-17 | i2 Pharmaceuticals, Inc. | Surrobody conjugates |
US20150004219A1 (en) | 2012-02-02 | 2015-01-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Stable liposomes for drug delivery |
EA034778B1 (en) | 2012-02-06 | 2020-03-19 | Инхибркс, Инк. | Cd47 antibodies and methods of use thereof |
CA2864469C (en) * | 2012-02-17 | 2020-07-07 | Celsion Corporation | Thermosensitive nanoparticle formulations and method of making the same |
WO2013128027A1 (en) | 2012-03-01 | 2013-09-06 | Amgen Research (Munich) Gmbh | Long life polypeptide binding molecules |
AP2014007875A0 (en) | 2012-03-05 | 2014-08-31 | Gilead Calistoga Llc | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
KR20140136488A (en) | 2012-03-15 | 2014-11-28 | 큐알엔에이, 인크. | Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
US9453076B2 (en) | 2012-03-29 | 2016-09-27 | Novimmune S.A. | Anti-TLR4 antibodies and uses thereof |
MX359888B (en) | 2012-03-30 | 2018-10-15 | Rhizen Pharmaceuticals Sa | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases. |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
AU2013252909B2 (en) | 2012-04-24 | 2017-09-28 | University Of Miami | Perforin 2 defense against invasive and multidrug resistant pathogens |
US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
US9441045B2 (en) | 2012-05-04 | 2016-09-13 | Dana-Farber Cancer Institute, Inc. | Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use |
AU2013256008B2 (en) | 2012-05-04 | 2016-02-25 | The Johns Hopkins University | Lipid-based drug carriers for rapid penetration through mucus linings |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9789193B2 (en) | 2012-06-15 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compositions for treating cancer and methods for making the same |
WO2013192546A1 (en) | 2012-06-22 | 2013-12-27 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and mehtods of using the same |
EP2679596B1 (en) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 env glycoprotein variant |
AU2013292647B2 (en) | 2012-07-18 | 2018-03-15 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
CN103565745A (en) | 2012-08-10 | 2014-02-12 | 德克萨斯州大学系统董事会 | Neuroprotective liposome compositions and methods for treatment of stroke |
WO2014027959A1 (en) | 2012-08-14 | 2014-02-20 | Nanyang Technological University | Angiopoietin-like 4 antibody and a method of its use in cancer treatment |
DK2892524T3 (en) | 2012-09-04 | 2021-01-25 | Eleison Pharmaceuticals LLC | PREVENTION OF PULMONAL CANCER RECYCLING WITH LIPID-COMPLEXED CISPLATIN |
US20160136159A1 (en) | 2012-09-17 | 2016-05-19 | Chemedest Ltd. | Method for Treating Peripheral Neuropathy |
CN107892719B (en) | 2012-10-04 | 2022-01-14 | 达纳-法伯癌症研究所公司 | Human monoclonal anti-PD-L1 antibodies and methods of use |
WO2014055824A1 (en) | 2012-10-05 | 2014-04-10 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
CA2887711A1 (en) | 2012-10-23 | 2014-05-01 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
EP2914961A4 (en) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | Methods and monitoring of treatment with a dll4 antagonist |
RU2019118257A (en) | 2012-12-03 | 2019-06-24 | Новиммун С.А. | ANTI-CD47 ANTIBODIES AND METHODS OF THEIR APPLICATION |
WO2014092858A1 (en) | 2012-12-12 | 2014-06-19 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of cancer |
WO2014100439A2 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | B7-h4 specific antibodies, and compositions and methods of use thereof |
ES2764090T3 (en) | 2012-12-19 | 2020-06-02 | Univ New York State Res Found | Compositions and Procedure for Light Activated Release of Nanovesicle Materials |
GB201223053D0 (en) | 2012-12-20 | 2013-02-06 | Medical Res Council | Receptor |
EP2935311B1 (en) | 2012-12-20 | 2021-03-31 | Amgen Inc. | Apj receptor agonists and uses thereof |
BR112015014621A2 (en) | 2012-12-21 | 2017-10-03 | Amplimmune Inc | ANTI-H7CR ANTIBODIES |
US9920121B2 (en) | 2013-01-25 | 2018-03-20 | Amgen Inc. | Antibodies targeting CDH19 for melanoma |
JO3519B1 (en) | 2013-01-25 | 2020-07-05 | Amgen Inc | Antibody constructs for CDH19 and CD3 |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
ES2944477T3 (en) | 2013-02-06 | 2023-06-21 | Inhibrx Inc | Non-Platelet Reducing and Non-Red Cell Reducing CD47 Antibodies and Methods of Using Them |
EP2956169B1 (en) | 2013-02-12 | 2018-04-11 | THE UNITED STATES OF AMERICA, represented by the S | Monoclonal antibodies that neutralize norovirus |
US10344060B2 (en) | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
AU2014236559B2 (en) | 2013-03-14 | 2020-03-12 | Julie HUGHES | Cholestosome vesicles for incorporation of molecules into chylomicrons |
US9707244B2 (en) | 2013-03-15 | 2017-07-18 | Gencia Corporation | Compositions and methods for treating conditions that affect epidermis |
MX367668B (en) | 2013-03-15 | 2019-08-30 | Dana Farber Cancer Inst Inc | Flavivirus neutralizing antibodies and methods of use thereof. |
AU2014240045A1 (en) | 2013-03-15 | 2015-09-10 | Dyax Corp. | Anti-plasma kallikrein antibodies |
US20140283157A1 (en) | 2013-03-15 | 2014-09-18 | Diadexus, Inc. | Lipoprotein-associated phospholipase a2 antibody compositions and methods of use |
EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
US11156608B2 (en) | 2013-03-15 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Method for the site-specific covalent cross-linking of antibodies to surfaces |
CA2907175C (en) * | 2013-03-15 | 2022-11-08 | M. Alphabet 3, L.L.C. | Methods and compositions for enhancing oxygen levels in tissues |
WO2014140358A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Research (Munich) Gmbh | Single chain binding molecules comprising n-terminal abp |
US10052364B2 (en) | 2013-03-15 | 2018-08-21 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
EP3495814A3 (en) | 2013-03-27 | 2019-07-17 | F. Hoffmann-La Roche AG | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
KR20220044380A (en) | 2013-04-12 | 2022-04-07 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Method for treating post-traumatic stress disorder |
JP2016518140A (en) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Method for inducing cyclic dinucleotide of type I interferon |
PL2981822T3 (en) | 2013-05-06 | 2021-07-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
SG11201508264UA (en) | 2013-05-07 | 2015-11-27 | Rinat Neuroscience Corp | Anti-glucagon receptor antibodies and methods of use thereof |
EP2994163B1 (en) | 2013-05-09 | 2019-08-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
WO2014190356A2 (en) | 2013-05-24 | 2014-11-27 | Amplimmune, Inc. | Anti-b7-h5 antibodies and their uses |
SG11201509839TA (en) | 2013-05-31 | 2016-01-28 | Genentech Inc | Anti-wall teichoic antibodies and conjugates |
CA2913011A1 (en) | 2013-05-31 | 2014-12-04 | Genentech, Inc. | Anti-wall teichoic antibodies and conjugates |
AU2014274660B2 (en) | 2013-06-06 | 2019-05-16 | Pierre Fabre Médicament | Anti-C10orf54 antibodies and uses thereof |
WO2014197938A1 (en) | 2013-06-13 | 2014-12-18 | Antisense Therapeutics Ltd | Combination therapy |
US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
ES2683268T3 (en) | 2013-07-25 | 2018-09-25 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods for using them |
US20160193148A1 (en) * | 2013-08-01 | 2016-07-07 | University Of Georgia Research Foundation, Inc. | Liposomal formulations for the treatment of bacterial infections |
MX371455B (en) | 2013-08-02 | 2020-01-28 | Pfizer | Anti-cxcr4 antibodies and antibody-drug conjugates. |
JP6463359B2 (en) | 2013-08-12 | 2019-01-30 | ジェネンテック, インコーポレイテッド | Compositions and methods for treating complement related conditions |
CA2921398C (en) | 2013-08-14 | 2021-12-14 | The Governing Council Of The University Of Toronto | Antibodies for inhibiting frizzled receptors and pharmaceutical compositions containing antibodies for inhibiting frizzled receptors |
EP3038600B1 (en) * | 2013-08-27 | 2020-06-03 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
CA2930859C (en) | 2013-09-04 | 2022-05-03 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
EP2848937A1 (en) | 2013-09-05 | 2015-03-18 | International Aids Vaccine Initiative | Methods of identifying novel HIV-1 immunogens |
WO2015035231A1 (en) | 2013-09-05 | 2015-03-12 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
TWI688401B (en) | 2013-09-13 | 2020-03-21 | 美商安進公司 | Combination of epigenetic factors and bispecific compounds targeting cd33 and cd3 in the treatment of myeloid leukemia |
US20160228364A1 (en) * | 2013-09-16 | 2016-08-11 | Glycomine, Inc. | Pharmaceutical preparation of carbohydrates for therapeutic use |
DE102013015334A1 (en) * | 2013-09-17 | 2015-03-19 | Fresenius Medical Care Deutschland Gmbh | Magnesium-liposome complexes |
US10036020B2 (en) | 2013-09-19 | 2018-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Compositions and methods for inhibiting JC virus (JCV) |
NZ756892A (en) | 2013-09-25 | 2022-05-27 | Cytomx Therapeutics Inc | Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof |
WO2015050663A1 (en) | 2013-10-01 | 2015-04-09 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of bim |
US10058604B2 (en) | 2013-10-07 | 2018-08-28 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3070167A4 (en) | 2013-11-06 | 2017-06-07 | Osaka University | Antibody having broad neutralizing activity in group 1 influenza a virus |
WO2015087187A1 (en) | 2013-12-10 | 2015-06-18 | Rinat Neuroscience Corp. | Anti-sclerostin antibodies |
EP3080611B1 (en) | 2013-12-13 | 2018-11-14 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
US9708327B2 (en) | 2013-12-20 | 2017-07-18 | Gilead Calistoga Llc | Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
MX2016008259A (en) | 2013-12-20 | 2016-10-13 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors. |
EP3094317B1 (en) | 2014-01-14 | 2019-10-02 | The Johns Hopkins University | Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof |
EP3099715B1 (en) | 2014-01-31 | 2020-11-18 | Boehringer Ingelheim International GmbH | Novel anti-baff antibodies |
CN106459153B (en) | 2014-01-31 | 2021-12-21 | 西托姆克斯治疗公司 | Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
CA2937539A1 (en) | 2014-02-04 | 2015-08-13 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EP3450571B1 (en) | 2014-02-24 | 2023-04-05 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
EP4043489A1 (en) | 2014-03-19 | 2022-08-17 | Dana-Farber Cancer Institute, Inc. | Immunogenetic restriction on elicitation of antibodies |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
AR099856A1 (en) | 2014-03-27 | 2016-08-24 | Genentech Inc | METHODS TO DIAGNOSE AND TREAT INFLAMMED INTESTINE DISEASE |
CA2944401A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
KR20160145813A (en) | 2014-04-25 | 2016-12-20 | 다나-파버 캔서 인스티튜트 인크. | Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof |
RS61516B1 (en) | 2014-04-30 | 2021-03-31 | Pfizer | Anti-ptk7 antibody-drug conjugates |
WO2015168474A1 (en) | 2014-04-30 | 2015-11-05 | President And Fellows Of Harvard College | Fusion proteins for treating cancer and related methods |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
ES2936810T3 (en) | 2014-05-16 | 2023-03-22 | Pfizer | Bispecific antibodies with engineered CH1-CL interfaces |
WO2015179654A1 (en) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti b7-h1 antibodies |
EA028614B1 (en) | 2014-05-22 | 2017-12-29 | Общество С Ограниченной Ответственностью "Русские Фармацевтические Технологии" | Selective inhibitors interfering with fibroblast growth factor receptor and frs2 interaction for the prevention and treatment of cancer |
PT3148581T (en) | 2014-05-30 | 2020-01-06 | Henlix Biotech Co Ltd | Anti-epidermal growth factor receptor (egfr) antibodies |
WO2015191781A2 (en) | 2014-06-10 | 2015-12-17 | Amgen Inc. | Apelin polypeptides |
EA201692202A1 (en) | 2014-06-11 | 2017-06-30 | Джилид Сайэнс, Инк. | METHODS OF TREATING CARDIOVASCULAR DISEASES |
MX2016016530A (en) | 2014-06-13 | 2017-03-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors. |
TWI695011B (en) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | Monoclonal antibodies against her2 epitope and methods of use thereof |
US10562946B2 (en) | 2014-06-20 | 2020-02-18 | Genentech, Inc. | Chagasin-based scaffold compositions, methods, and uses |
US10487314B2 (en) | 2014-06-26 | 2019-11-26 | The Trustees Of Columbia University In The City Of New York | Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
US10669337B2 (en) | 2014-07-25 | 2020-06-02 | Cytomx Therapeutics, Inc. | Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same |
CA2956471A1 (en) | 2014-07-31 | 2016-02-04 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody constructs |
UY36245A (en) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 |
US20170224816A1 (en) | 2014-08-06 | 2017-08-10 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016034968A1 (en) | 2014-09-02 | 2016-03-10 | Pfizer Inc. | Therapeutic antibody |
WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
WO2016054638A1 (en) | 2014-10-03 | 2016-04-07 | Dana-Farber Cancer Institute, Inc. | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
AU2015328273B2 (en) | 2014-10-06 | 2020-09-17 | Dana-Farber Cancer Institute, Inc. | Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof |
ES2808153T3 (en) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Combination therapy for disease treatment |
US20170306046A1 (en) | 2014-11-12 | 2017-10-26 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
WO2016077566A1 (en) | 2014-11-12 | 2016-05-19 | Research Institute At Nationwide Children's Hospital | Modulation of alternative mdm2 splicing |
JP7175608B2 (en) | 2014-11-19 | 2022-11-21 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Osteocalcin as a treatment for age-related frailty |
WO2016090038A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof |
MX2017007231A (en) | 2014-12-03 | 2017-11-08 | Genentech Inc | Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof. |
US10072070B2 (en) | 2014-12-05 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Potent anti-influenza A neuraminidase subtype N1 antibody |
TWI595006B (en) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | Anti-pd-1 antibodies and methods of use thereof |
KR20170087500A (en) | 2014-12-11 | 2017-07-28 | 피에르 파브르 메디카먼트 | Anti-C10ORF54 antibodies and uses thereof |
SG10201903210WA (en) | 2014-12-15 | 2019-05-30 | Univ Johns Hopkins | Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders |
MA41374A (en) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF |
US10485757B2 (en) | 2015-01-27 | 2019-11-26 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
WO2016123329A2 (en) | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
EP3250588A1 (en) | 2015-01-29 | 2017-12-06 | Board of Trustees of Michigan State University | Cryptic polypeptides and uses thereof |
WO2016134066A1 (en) * | 2015-02-17 | 2016-08-25 | Mallinckrodt Llc | Modified docetaxel liposome formulations and uses thereof |
US10550173B2 (en) | 2015-02-19 | 2020-02-04 | Compugen, Ltd. | PVRIG polypeptides and methods of treatment |
HUE049791T2 (en) | 2015-02-19 | 2020-10-28 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
MX2017010336A (en) | 2015-02-26 | 2017-12-20 | Genentech Inc | Integrin beta7 antagonists and methods of treating crohn's disease. |
EP3265059A4 (en) | 2015-03-03 | 2018-08-29 | Cureport Inc. | Combination liposomal pharmaceutical formulations |
FI3265123T3 (en) | 2015-03-03 | 2023-01-31 | Antibodies, uses & methods | |
EP3265063A4 (en) * | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
MX2017011644A (en) | 2015-03-13 | 2017-12-04 | Cytomx Therapeutics Inc | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof. |
EP3270898B1 (en) | 2015-03-17 | 2021-05-05 | Lipomedix Pharmaceuticals Ltd. | Methods for the treatment of bladder cancer |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
US10174292B2 (en) | 2015-03-20 | 2019-01-08 | International Aids Vaccine Initiative | Soluble HIV-1 envelope glycoprotein trimers |
EP3072901A1 (en) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Soluble hiv-1 envelope glycoprotein trimers |
US9758575B2 (en) | 2015-04-06 | 2017-09-12 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof |
CA2981969C (en) | 2015-04-08 | 2023-12-05 | Dana-Farber Cancer Institute, Inc. | Humanized influenza monoclonal antibodies and methods of use thereof |
BR112017019785B1 (en) | 2015-04-13 | 2022-11-16 | Pfizer Inc | BISPECIFIC ANTIBODY, ITS USE AND PHARMACEUTICAL COMPOSITION |
SG10201909308XA (en) | 2015-04-17 | 2019-11-28 | Amgen Res Munich Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
EP3288977B1 (en) | 2015-05-01 | 2021-11-17 | Dana-Farber Cancer Institute, Inc. | Methods of mediating cytokine expression with anti ccr4 antibodies |
CA2984945A1 (en) | 2015-05-04 | 2016-11-10 | Cytomx Therapeutics, Inc. | Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof |
BR112017023868A2 (en) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereof |
DK3292150T3 (en) | 2015-05-04 | 2020-04-27 | Cytomx Therapeutics Inc | ACTIVABLE ANTI-CD166 ANTIBODIES AND PROCEDURES FOR USE THEREOF |
EP3736287A1 (en) | 2015-05-11 | 2020-11-11 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
US20180117076A1 (en) | 2015-05-14 | 2018-05-03 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (Cnic) | MiRNA compositions for the treatment of mature B-cell neoplasms |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
EP3763827A1 (en) | 2015-05-29 | 2021-01-13 | F. Hoffmann-La Roche AG | Pd-l1 promoter methylation in cancer |
EP3851531A1 (en) | 2015-06-01 | 2021-07-21 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
CA2989115C (en) | 2015-06-10 | 2024-01-02 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders |
AU2016291846B2 (en) | 2015-07-13 | 2022-05-26 | Compugen Ltd. | HIDE1 Compositions and Methods |
WO2017011580A2 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
BR112018001202A2 (en) | 2015-07-21 | 2018-09-25 | Dyax Corp | monoclonal antibody, nucleic acid, vector, host cell, pharmaceutical composition and method |
CN107849126B (en) | 2015-07-29 | 2022-04-08 | 阿勒根公司 | Heavy chain-only anti-ANG-2 antibodies |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI717375B (en) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for cd70 and cd3 |
TWI744242B (en) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for egfrviii and cd3 |
TW202346349A (en) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for dll3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
JP2018523673A (en) | 2015-08-14 | 2018-08-23 | アラーガン、インコーポレイテッドAllergan,Incorporated | Heavy chain only antibody against PDGF |
MX2018001659A (en) | 2015-08-20 | 2018-05-28 | Ipsen Biopharm Ltd | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment. |
CN108495629A (en) | 2015-08-21 | 2018-09-04 | 益普生生物制药有限公司 | Use the method comprising liposome Irinotecan and the combination therapy to treat metastatic cancer of pancreas of oxaliplatin |
HUE063528T2 (en) | 2015-09-01 | 2024-01-28 | Boehringer Ingelheim Int | Use of anti-cd40 antibodies for treatment of lupus nephritis |
TWI799366B (en) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | Cystine knot scaffold platform |
PT3350220T (en) | 2015-09-15 | 2021-08-06 | Scholar Rock Inc | Anti-pro/latent-myostatin antibodies and uses thereof |
EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
WO2017058881A1 (en) | 2015-09-28 | 2017-04-06 | The Trustees Of Columbia University In The City Of New York | Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
IL293708A (en) | 2015-10-06 | 2022-08-01 | Genentech Inc | Method for treating multiple sclerosis |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
GB201518172D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for use in medicine |
GB201518171D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for topical administration with therapeutic agent |
GB201518170D0 (en) | 2015-10-14 | 2015-11-25 | Cantab Biopharmaceuticals Patents Ltd | Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent |
US10456360B2 (en) | 2015-10-16 | 2019-10-29 | Ipsen Biopharm Ltd. | Stabilizing camptothecin pharmaceutical compositions |
WO2017066714A1 (en) | 2015-10-16 | 2017-04-20 | Compugen Ltd. | Anti-vsig1 antibodies and drug conjugates |
WO2017075037A1 (en) | 2015-10-27 | 2017-05-04 | Scholar Rock, Inc. | Primed growth factors and uses thereof |
IL295097A (en) | 2015-10-30 | 2022-09-01 | Genentech Inc | Anti-htra1 antibodies and methods of use thereof |
WO2017075045A2 (en) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Antibodies to b7-h1 |
AU2016349954B2 (en) | 2015-11-05 | 2022-08-25 | Antisense Therapeutics Ltd | Mobilizing leukemia cells |
EP3370712A4 (en) | 2015-11-06 | 2019-10-09 | The Johns Hopkins University | Methods of treating liver fibrosis by administering 3-bromopyruvate |
PL3373910T3 (en) | 2015-11-10 | 2023-10-09 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
JP2018533596A (en) | 2015-11-12 | 2018-11-15 | グレイバグ ビジョン インコーポレイテッド | Aggregated microparticles for medical therapy |
CN116217729A (en) | 2015-11-12 | 2023-06-06 | 思进公司 | Glycan interaction compounds and methods of use |
CA2949033A1 (en) | 2015-11-30 | 2017-05-30 | Pfizer Inc. | Antibodies and antibody fragments for site-specific conjugation |
TWI726942B (en) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | Site specific her2 antibody drug conjugates |
KR20180100122A (en) | 2015-12-02 | 2018-09-07 | 주식회사 에스티사이언스 | Antibodies specific for glycated BTLA (B- and T-lymphocyte weakening factor) |
ES2861449T3 (en) | 2015-12-02 | 2021-10-06 | Stcube & Co Inc | Antibodies and Molecules that Immunospecifically Bind to BTN1A1 and Their Therapeutic Uses |
WO2017100562A1 (en) | 2015-12-09 | 2017-06-15 | Alexion Pharmaceuticals, Inc, | Modified mrna encoding a uridine diphopsphate glucuronosyl transferase and uses thereof |
US10548844B2 (en) | 2015-12-14 | 2020-02-04 | Massachusetts Institute Of Technology | pH-responsive mucoadhesive polymeric encapsulated microorganisms |
WO2017106630A1 (en) | 2015-12-18 | 2017-06-22 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
EP3395370B1 (en) | 2015-12-21 | 2021-01-20 | FUJIFILM Corporation | Liposome and liposome composition |
WO2017117218A1 (en) | 2015-12-30 | 2017-07-06 | Momenta Pharmaceuticals, Inc. | Methods related to biologics |
SG11201805709RA (en) | 2016-01-08 | 2018-07-30 | Scholar Rock Inc | Anti-pro/latent myostatin antibodies and methods of use thereof |
WO2017127750A1 (en) | 2016-01-22 | 2017-07-27 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
TWI797073B (en) | 2016-01-25 | 2023-04-01 | 德商安美基研究(慕尼黑)公司 | Pharmaceutical composition comprising bispecific antibody constructs |
BR112018015715A2 (en) | 2016-02-03 | 2019-02-05 | Amgen Inc | bispecific bcma and cd3 t cell coupling antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
EP3411404B1 (en) | 2016-02-03 | 2022-11-09 | Amgen Research (Munich) GmbH | Psma and cd3 bispecific t cell engaging antibody constructs |
JP2019509721A (en) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | Mutant smoothened and method of using the same |
CN109071669A (en) | 2016-03-07 | 2018-12-21 | 查尔斯顿制药有限责任公司 | Anti- paranuclein antibody |
EP3426306A1 (en) * | 2016-03-07 | 2019-01-16 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
ES2951648T3 (en) | 2016-03-11 | 2023-10-24 | Scholar Rock Inc | Tgfbeta1-binding immunoglobulins and their use |
CN109476756B (en) | 2016-03-15 | 2022-05-31 | 埃泰美德(香港)有限公司 | Multi-specificity Fab fusion protein and application thereof |
AU2017254106A1 (en) | 2016-04-18 | 2018-11-01 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
WO2017181379A1 (en) | 2016-04-21 | 2017-10-26 | Versitech Limited | Compositions and methods for lightening skin and reducing hyperpigmentation |
ES2963807T3 (en) | 2016-06-08 | 2024-04-02 | Xencor Inc | Treatment of IgG4-related diseases with anti-CD19 antibodies cross-linking to CD32B |
ITUA20164630A1 (en) | 2016-06-23 | 2017-12-23 | Paolo Blasi | PHARMACOLOGICAL ADIUVANTS FOR TUMOR THERMAL WELDING |
ES2887573T3 (en) | 2016-06-27 | 2021-12-23 | Alexion Pharma Inc | Methods for treating hypophosphatasia in children and adolescents |
WO2018005657A1 (en) | 2016-06-28 | 2018-01-04 | Verily Life Sciences Llc | Serial filtration to generate small cholesterol-containing liposomes |
IL296127A (en) | 2016-07-22 | 2022-11-01 | Dana Farber Cancer Inst Inc | Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof |
KR20190035752A (en) | 2016-08-03 | 2019-04-03 | 사이머베이 쎄라퓨틱스, 인코퍼레이티드 | An oxymethylene aryl compound for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
TWI754659B (en) | 2016-08-08 | 2022-02-11 | 台灣微脂體股份有限公司 | Delivery vehicle, method and kit for preparing a liposomal composition containing mild acidic agent |
AU2017321973A1 (en) | 2016-09-02 | 2019-03-07 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating B cell disorders |
EP3509633A1 (en) | 2016-09-06 | 2019-07-17 | Dana-Farber Cancer Institute, Inc. | Methods of treating or preventing zika virus infection |
EP3509616A1 (en) | 2016-09-09 | 2019-07-17 | H. Hoffnabb-La Roche Ag | Selective peptide inhibitors of frizzled |
TW201825674A (en) | 2016-09-09 | 2018-07-16 | 美商艾斯合顧問有限公司 | Oncolytic virus expressing bispecific engager molecules |
EP3512564B1 (en) | 2016-09-14 | 2024-01-17 | The Trustees of The University of Pennsylvania | Proximity-based sortase-mediated protein purification and ligation |
RU2752832C2 (en) | 2016-09-16 | 2021-08-09 | Шанхай Хенлиус Байотек, Инк. | Anti-pd-1 antibodies |
JP6937368B2 (en) | 2016-09-23 | 2021-09-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲー・エム・ベー・ハー | How to treat intractable migraine |
AU2017331592A1 (en) | 2016-09-23 | 2019-04-11 | Teva Pharmaceuticals International Gmbh | Treating cluster headache |
EP3532070A1 (en) | 2016-10-26 | 2019-09-04 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
CA3040395A1 (en) | 2016-11-02 | 2018-05-11 | Ipsen Biopharm Ltd. | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
AU2017353936A1 (en) | 2016-11-04 | 2019-05-02 | Novimmune Sa | Anti-CD19 antibodies and methods of use thereof |
JP2020500020A (en) | 2016-11-14 | 2020-01-09 | ノバルティス アーゲー | Compositions, methods, and therapeutic uses related to the fusogenic protein MINION |
EP3541847A4 (en) | 2016-11-17 | 2020-07-08 | Seattle Genetics, Inc. | Glycan-interacting compounds and methods of use |
WO2018106738A1 (en) | 2016-12-05 | 2018-06-14 | Massachusetts Institute Of Technology | Brush-arm star polymers, conjugates and particles, and uses thereof |
DK3555064T5 (en) | 2016-12-16 | 2023-05-01 | Pfizer | GLP-1 receptor agonists and uses thereof |
US10772926B2 (en) | 2016-12-16 | 2020-09-15 | Nutragen Health Innovations, Inc. | Natural drugs for the treatment of inflammation and melanoma |
WO2018129395A1 (en) | 2017-01-06 | 2018-07-12 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
US20180207267A1 (en) | 2017-01-06 | 2018-07-26 | Scholar Rock, Inc. | Isoform-specific, context-permissive tgfb1 inhibitors and use thereof |
US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
CN117224710A (en) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | Immunomodulatory therapeutic MRNA compositions encoding mutant peptides that activate oncogenes |
JOP20190189A1 (en) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | Low ph pharmaceutical composition comprising t cell engaging antibody constructs |
WO2018152496A1 (en) | 2017-02-17 | 2018-08-23 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Compositions and methods for the diagnosis and treatment of zika virus infection |
EP3589319A4 (en) | 2017-03-03 | 2021-07-14 | Seagen Inc. | Glycan-interacting compounds and methods of use |
EP3589657A1 (en) | 2017-03-03 | 2020-01-08 | Rinat Neuroscience Corp. | Anti-gitr antibodies and methods of use thereof |
US20180303952A1 (en) | 2017-03-09 | 2018-10-25 | Cytomx Therapeutics, Inc. | Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof |
US20180273627A1 (en) | 2017-03-27 | 2018-09-27 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
US11359200B2 (en) | 2017-04-09 | 2022-06-14 | The Cleveland Clinic Foundation | Cancer treatment by MALAT1 inhibition |
CA3059542A1 (en) | 2017-04-12 | 2018-10-18 | Pfizer Inc. | Antibodies having conditional affinity and methods of use thereof |
EP3610010A4 (en) | 2017-04-14 | 2021-02-24 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
AU2018255244A1 (en) | 2017-04-21 | 2019-10-31 | Mellitus, Llc | Methods and antibodies for diabetes-related applications |
EP3615569A1 (en) | 2017-04-25 | 2020-03-04 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of epstein barr virus infection |
US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
AU2018261951A1 (en) | 2017-05-05 | 2019-10-31 | Amgen Inc. | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
JP2020519585A (en) | 2017-05-10 | 2020-07-02 | グレイバグ ビジョン インコーポレイテッド | Extended release microparticles and suspensions thereof for medical therapy |
WO2018209288A1 (en) | 2017-05-12 | 2018-11-15 | Massachusetts Institute Of Technology | Argonaute protein-double stranded rna complexes and uses related thereto |
CN110662760A (en) | 2017-05-12 | 2020-01-07 | 奥古斯塔大学研究所公司 | Human alpha-fetoprotein specific T cell receptor and uses thereof |
AU2018272311A1 (en) | 2017-05-26 | 2019-12-19 | Novimmune Sa | Anti-CD47 x anti-mesothelin antibodies and methods of use thereof |
WO2018222685A1 (en) | 2017-05-31 | 2018-12-06 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
US20200148768A1 (en) | 2017-05-31 | 2020-05-14 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
KR20200026209A (en) | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | How to treat cancer using antibodies and molecules that bind BTN1A1 or BTN1A1-ligand |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
CN110997002A (en) | 2017-07-13 | 2020-04-10 | 麻省理工学院 | Targeting HDAC2-SP3 complexes to enhance synaptic function |
US11220544B2 (en) | 2017-07-14 | 2022-01-11 | Cytomx Therapeutics, Inc. | Anti-CD166 antibodies and uses thereof |
WO2019018629A1 (en) | 2017-07-19 | 2019-01-24 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection |
EP3655779A1 (en) | 2017-07-20 | 2020-05-27 | CytomX Therapeutics, Inc. | Methods of qualitatively and/or quantitatively analyzing properties of activatable antibodies and uses thereof |
WO2019016784A1 (en) | 2017-07-21 | 2019-01-24 | Universidade De Coimbra | Anti-nucleolin antibody |
WO2019018765A1 (en) | 2017-07-21 | 2019-01-24 | Modernatx, Inc. | Modified mrna encoding a propionyl-coa carboxylase and uses thereof |
EP3658672A1 (en) | 2017-07-24 | 2020-06-03 | Modernatx, Inc. | Modified mrna encoding a glucose-6-phosphatase and uses thereof |
CN116271012A (en) | 2017-07-27 | 2023-06-23 | 瑞颂医药公司 | High concentration anti-C5 antibody formulations |
MA49690A (en) | 2017-07-28 | 2021-05-19 | Scholar Rock Inc | SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES |
US11135187B2 (en) | 2017-08-22 | 2021-10-05 | National Institutes Of Health (Nih) | Compositions and methods for treating diabetic retinopathy |
KR20200058406A (en) | 2017-08-30 | 2020-05-27 | 싸이톰스 테라퓨틱스, 인크. | Activatable anti-CD166 antibodies and methods of use |
CN111133005A (en) | 2017-09-07 | 2020-05-08 | 奥古斯塔大学研究所公司 | Programmed cell death protein 1 antibodies |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
AU2018347521A1 (en) | 2017-10-12 | 2020-05-07 | Immunowake Inc. | VEGFR-antibody light chain fusion protein |
AU2018347607A1 (en) | 2017-10-14 | 2020-03-26 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
BR112020007586A2 (en) | 2017-10-17 | 2020-09-24 | Rhizen Pharmaceuticals Sa | crac channel modulators to treat esophageal cancer |
JP7394753B2 (en) | 2017-10-18 | 2023-12-08 | サレプタ セラピューティクス, インコーポレイテッド | antisense oligomer compounds |
WO2019082124A1 (en) | 2017-10-26 | 2019-05-02 | Rhizen Pharmaceuticals Sa | Composition and method for treating diffuse large b-cell lymphoma |
CA3205442A1 (en) | 2017-10-27 | 2019-05-02 | Pfizer, Inc. | Antibodies and antibody-drug conjugates specific for cd123 and uses thereof |
SG11202003437PA (en) | 2017-10-30 | 2020-05-28 | Rhizen Pharmaceuticals Sa | Calcium release-activated calcium channel modulators for treating hematological and solid cancers |
WO2019086626A1 (en) | 2017-11-03 | 2019-05-09 | Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) | MIRNAs AND COMBINATIONS THEREOF FOR USE IN THE TREATMENT OF HUMAN B CELL NEOPLASIAS |
US20200289520A1 (en) | 2017-12-06 | 2020-09-17 | Rhizen Pharmaceuticals Sa | Composition and method for treating peripheral t-cell lymphoma and cutaneous t-cell lymphoma |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
US20210163592A1 (en) | 2017-12-11 | 2021-06-03 | Amgen Inc | Continuous manufacturing process for bispecific antibody products |
UY38041A (en) | 2017-12-29 | 2019-06-28 | Amgen Inc | CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3 |
WO2019165101A1 (en) | 2018-02-22 | 2019-08-29 | Verily Life Sciences Llc | Combining orthogonal chemistries for preparation of multiplexed nanoparticles |
WO2019166946A1 (en) | 2018-02-28 | 2019-09-06 | Pfizer Inc. | Il-15 variants and uses thereof |
WO2019173771A1 (en) | 2018-03-09 | 2019-09-12 | Cytomx Therapeutics, Inc. | Activatable cd147 antibodies and methods of making and use thereof |
CN112166123B (en) | 2018-03-14 | 2022-09-30 | 北京轩义医药科技有限公司 | Anti-claudin 18.2 antibodies |
AU2019235523A1 (en) | 2018-03-14 | 2020-10-29 | Novimmune Sa | Anti-CD3 epsilon antibodies and methods of use thereof |
EP3768306A1 (en) | 2018-03-21 | 2021-01-27 | Colorado State University Research Foundation | Cancer vaccine compositions and methods of use thereof |
US10722528B2 (en) | 2018-03-28 | 2020-07-28 | Augusta University Research Institute, Inc. | Compositions and methods for inhibiting metastasis |
CN112334485A (en) | 2018-04-06 | 2021-02-05 | 百进生物科技公司 | Anti-tetraspanin 33agents and compositions thereof and methods of making and using |
EP3772928A4 (en) | 2018-04-06 | 2021-12-29 | Children's Medical Center Corporation | Compositions and methods for somatic cell reprogramming and modulating imprinting |
EP3774925A1 (en) | 2018-04-13 | 2021-02-17 | Institut national de la santé et de la recherche médicale (INSERM) | Fc-engineered anti-human ige antibodies and methods of use |
EP3788071A1 (en) | 2018-05-02 | 2021-03-10 | The United States Of America, As Represented By The Secretary, Department of Health and Human Services | Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
MX2020012539A (en) | 2018-05-23 | 2021-02-16 | Pfizer | Antibodies specific for cd3 and uses thereof. |
WO2019234680A1 (en) | 2018-06-08 | 2019-12-12 | Pfizer Inc. | Methods of treating iron metabolic disease with a neutralizing antibody binding erhythroferrone |
US10934279B2 (en) | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
WO2019239371A1 (en) | 2018-06-15 | 2019-12-19 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
WO2019245817A1 (en) | 2018-06-19 | 2019-12-26 | Armo Biosciences, Inc. | Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy |
BR112020025824A2 (en) | 2018-06-28 | 2021-03-23 | Crispr Therapeutics Ag | compositions and methods for genome editing by inserting donor polynucleotides |
WO2020006347A1 (en) | 2018-06-29 | 2020-01-02 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
CA3105161C (en) | 2018-07-06 | 2022-11-15 | Pfizer Inc. | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof |
US20210122814A1 (en) | 2018-07-11 | 2021-04-29 | Scholar Rock, Inc. | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF |
TW202019957A (en) | 2018-07-11 | 2020-06-01 | 美商供石公司 | Tgfβ1 inhibitors and use thereof |
SI3677278T1 (en) | 2018-07-11 | 2022-01-31 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
EP3849515A1 (en) * | 2018-09-11 | 2021-07-21 | Memorial Sloan Kettering Cancer Center | Bone marrow-, reticuloendothelial system-, and/or lymph node-targeted radiolabeled liposomes and methods of their diagnostic and therapeutic use |
EP3856343A1 (en) | 2018-09-25 | 2021-08-04 | Biolegend, Inc. | Anti-tlr9 agents and compositions and methods for making and using the same |
SG11202103025PA (en) | 2018-09-27 | 2021-04-29 | Phosphogam Inc | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
AU2019349874A1 (en) | 2018-09-28 | 2021-04-29 | Lyvgen Biopharma Holdings Limited | Anti-CD40 binding molecules having engineered Fc domains and therapeutic uses thereof |
EP3864127A1 (en) | 2018-10-10 | 2021-08-18 | Boehringer Ingelheim International GmbH | Method for membrane gas transfer in high density bioreactor culture |
AU2019356564A1 (en) | 2018-10-11 | 2021-04-29 | Amgen Inc. | Downstream processing of bispecific antibody constructs |
WO2020079652A1 (en) | 2018-10-17 | 2020-04-23 | Insilico Medicine Hong Kong Limited | Kinase inhibitors |
EP3870286A1 (en) | 2018-10-23 | 2021-09-01 | Scholar Rock, Inc. | Rgmc-selective inhibitors and use thereof |
US20210379545A1 (en) * | 2018-10-26 | 2021-12-09 | University Of Connecticut | A Continuous Processing System And Methods For Internal And External Modifications To Nanoparticles |
CA3118445A1 (en) | 2018-11-02 | 2020-05-07 | Cytomx Therapeutics, Inc. | Activatable anti-cd166 antibodies and methods of use thereof |
WO2020103815A1 (en) | 2018-11-22 | 2020-05-28 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
CN113271956A (en) | 2018-12-06 | 2021-08-17 | 西托姆克斯治疗公司 | Matrix metalloprotease cleavable and serine or cysteine protease cleavable substrates and methods of use thereof |
BR112021012172A2 (en) | 2018-12-12 | 2021-08-31 | Kite Pharma, Inc. | CHIMERIC AND T-CELL ANTIGEN RECEPTORS AND METHODS OF USE |
MX2021008800A (en) | 2019-01-22 | 2021-11-12 | Massachusetts Inst Technology | In vitro human blood brain barrier. |
JP2020117502A (en) | 2019-01-28 | 2020-08-06 | ファイザー・インク | Method of treating signs and symptoms of osteoarthritis |
EA202192130A1 (en) | 2019-01-30 | 2021-12-28 | Сколар Рок, Инк. | LTBP-SPECIFIC TGF INHIBITORS AND THEIR APPLICATIONS |
US20220144846A1 (en) | 2019-02-15 | 2022-05-12 | Pfizer Inc. | Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof |
JP2020143045A (en) | 2019-02-18 | 2020-09-10 | ファイザー・インク | Method of treatment of chronic low back pain |
CN113874394B (en) | 2019-02-20 | 2024-01-19 | 和铂抗体有限公司 | Antibodies to |
US11739078B2 (en) | 2019-02-22 | 2023-08-29 | Insilico Medicine Ip Limited | Methods of inhibiting kinases |
WO2020176672A1 (en) | 2019-02-26 | 2020-09-03 | Cytomx Therapeutics, Inc. | Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies |
US20200283796A1 (en) | 2019-03-05 | 2020-09-10 | Massachusetts Institute Of Technology | Dna launched rna replicon system (drep) and uses thereof |
WO2020185293A1 (en) | 2019-03-08 | 2020-09-17 | Massachusetts Institute Of Technology | Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy |
AU2020248645A1 (en) | 2019-03-27 | 2021-10-28 | Tigatx, Inc. | Engineered IgA antibodies and methods of use |
TW202102266A (en) | 2019-04-01 | 2021-01-16 | 美商建南德克公司 | Compositions and methods for stabilizing protein-containing formulations |
JP7284830B2 (en) | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | protein tyrosine phosphatase inhibitor |
TW202115086A (en) | 2019-06-28 | 2021-04-16 | 美商輝瑞大藥廠 | Bckdk inhibitors |
CA3144848C (en) | 2019-06-28 | 2023-11-21 | Pfizer Inc. | 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases |
LT6699B (en) | 2019-07-15 | 2020-02-10 | UAB "Valentis" | Method for production of proliposomes by using up to 5% ethanol and the use thereof for encapsulation of lipophilic substances |
CN112300279A (en) | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | Methods and compositions directed to anti-CD 73 antibodies and variants |
US10758329B1 (en) | 2019-08-20 | 2020-09-01 | Raymond L. Wright, III | Hydrating mouth guard |
CN114650844A (en) | 2019-09-23 | 2022-06-21 | 西托姆克斯治疗公司 | anti-CD 47 antibodies, activatable anti-CD 47 antibodies, and methods of use thereof |
WO2021062096A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Microrna-based logic gates and uses thereof |
EP4041767A1 (en) | 2019-09-26 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
WO2021062092A1 (en) | 2019-09-26 | 2021-04-01 | Massachusetts Institute Of Technology | Trans-activated functional rna by strand displacement and uses thereof |
WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
TWI771766B (en) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | Diacylglycerol acyltransferase 2 inhibitor |
US20240050529A1 (en) | 2019-10-07 | 2024-02-15 | University Of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022552282A (en) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | Antibodies specific for glycosylated LAG3 and methods of use thereof |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
WO2021072244A1 (en) | 2019-10-11 | 2021-04-15 | Beth Israel Deaconess Medical Center, Inc. | Anti-tn antibodies and uses thereof |
CA3155215A1 (en) | 2019-10-21 | 2021-04-29 | Srikant Viswanadha | Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia |
CN115175893A (en) | 2019-12-10 | 2022-10-11 | 辉瑞公司 | Solid forms of 2- ((4- ((S) -2- (5-chloropyridin-2-yl) -2-methylbenzo [ d ] [1,3] dioxol-4-yl) piperidin-1-yl) methyl) -1- (((S) -oxetan-2-yl) methyl) -1H-benzo [ d ] imidazole-6-carboxylic acid, 1, 3-dihydroxy-2- (hydroxymethyl) propan-2-amine salt |
US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
BR112022013733A2 (en) | 2020-01-11 | 2022-11-01 | Scholar Rock Inc | TGFBETA INHIBITORS AND THEIR USE |
JP2023511274A (en) | 2020-01-14 | 2023-03-17 | シンセカイン インコーポレイテッド | IL2 orthologs and usage |
CN115427447A (en) | 2020-01-17 | 2022-12-02 | 百进生物科技公司 | anti-TLR 7 agents and compositions and methods of making and using the same |
EP4093426A1 (en) | 2020-01-24 | 2022-11-30 | University of Virginia Patent Foundation | Modulating lymphatic vessels in neurological disease |
JP2022058085A (en) | 2020-02-24 | 2022-04-11 | ファイザー・インク | Combination of inhibitors of diacylglycerol acyltransferase 2 and inhibitors of acetyl-coa carboxylase |
WO2021178877A1 (en) | 2020-03-06 | 2021-09-10 | The Colorado State University Research Foundation | Production of vaccines comprising inactivated sars-cov-2 viral particles |
WO2021181233A2 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
GB202003632D0 (en) | 2020-03-12 | 2020-04-29 | Harbour Antibodies Bv | SARS-Cov-2 (SARS2, COVID-19) antibodies |
WO2021188096A1 (en) | 2020-03-17 | 2021-09-23 | Dst Pharma, Inc. | Methods and compositions for treating viral infections |
AU2021244695A1 (en) | 2020-03-26 | 2022-11-10 | Plx Opco Inc. | Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same |
JP2021155415A (en) | 2020-03-27 | 2021-10-07 | ファイザー・インク | Treatment of type 2 diabetes or obesity or overweight using 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or pharmaceutical salt thereof |
AU2021252213A1 (en) | 2020-04-08 | 2022-11-03 | Pfizer Inc. | Crystalline forms of 3-cyano-1-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo(1,5-a)pyrazin-4-yl)-1H-pyrazol-1-yl)cyclobutaneacetonitrile, and use thereof |
KR20230005268A (en) | 2020-04-24 | 2023-01-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Anti-CD19 Antibodies and Uses Thereof |
WO2021224850A1 (en) | 2020-05-06 | 2021-11-11 | Crispr Therapeutics Ag | Mask peptides and masked anti-ptk7 antibodies comprising such |
WO2021229502A1 (en) | 2020-05-15 | 2021-11-18 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
CA3179890A1 (en) | 2020-05-27 | 2021-12-02 | Qilu Regor Therapeutics Inc. | Salt and crystal forms of glp-1r agonists and uses thereof |
EP4161927A1 (en) | 2020-06-09 | 2023-04-12 | Pfizer Inc. | Spiro compounds as melanocortin 4 receptor antagonists and uses thereof |
MX2022016590A (en) | 2020-06-26 | 2023-02-01 | Pfizer | Methods of treating inflammatory bowel disease with tl1a antibodies. |
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
CA3189590A1 (en) | 2020-07-17 | 2022-01-20 | Pfizer Inc. | Therapeutic antibodies and their uses |
EP4185274A1 (en) | 2020-07-24 | 2023-05-31 | Strand Therapeutics Inc. | Lipidnanoparticle comprising modified nucleotides |
CA3187393A1 (en) | 2020-07-28 | 2022-02-03 | Andrew BELFIELD | Chiral synthesis of fused bicyclic raf inhibitors |
US11858930B2 (en) | 2020-07-28 | 2024-01-02 | Jazz Pharmaceuticals Ireland Limited | Fused bicyclic RAF inhibitors and methods for use thereof |
MX2023001491A (en) | 2020-08-05 | 2023-03-08 | Synthekine Inc | Gp130 binding molecules and methods of use. |
CA3190415A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
JP2023536654A (en) | 2020-08-05 | 2023-08-28 | シンセカイン インコーポレイテッド | IL10Ra binding molecules and methods of use |
EP4192489A2 (en) | 2020-08-05 | 2023-06-14 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
AR123156A1 (en) | 2020-08-06 | 2022-11-02 | Qilu Regor Therapeutics Inc | GLP-1R AGONISTS AND THEIR USES |
CN116113689A (en) | 2020-08-14 | 2023-05-12 | 凯德药业股份有限公司 | Improving immune cell function |
JP2023541455A (en) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Single domain antibody against CD33 |
EP4213939A1 (en) | 2020-09-21 | 2023-07-26 | Boehringer Ingelheim International GmbH | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
CA3194386A1 (en) | 2020-10-06 | 2022-04-14 | Ying Ding | Biomarkers, methods, and compositions for treating autoimmune disease including systemic lupus erythematous (sle) |
US20230382899A1 (en) | 2020-10-14 | 2023-11-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
WO2022093641A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2a agents and compositions and methods for making and using the same |
WO2022093640A1 (en) | 2020-10-30 | 2022-05-05 | BioLegend, Inc. | Anti-nkg2c agents and compositions and methods for making and using the same |
US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
AU2021400221A1 (en) | 2020-12-18 | 2023-07-13 | Momenta Pharmaceuticals, Inc. | Antibodies against integrin alpha 11 beta 1 |
TW202241931A (en) | 2021-01-08 | 2022-11-01 | 美商斯特蘭德治療股份有限公司 | Expression constructs and uses thereof |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
EP4288457A2 (en) | 2021-02-05 | 2023-12-13 | Boehringer Ingelheim International GmbH | Anti-il1rap antibodies |
US11530197B2 (en) | 2021-02-24 | 2022-12-20 | Insilico Medicine Ip Limited | Analogs for the treatment of disease |
KR20230155521A (en) | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | Improved immune cell function |
WO2022195504A1 (en) | 2021-03-19 | 2022-09-22 | Pfizer Inc. | Method of treating osteoarthritis pain with an anti ngf antibody |
WO2022200389A1 (en) | 2021-03-22 | 2022-09-29 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
AU2022241935A1 (en) | 2021-03-22 | 2023-09-28 | Novimmune S.A. | Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof |
US11952461B2 (en) | 2021-03-22 | 2024-04-09 | Sunbio, Inc. | Siloxy polyethylene glycol and derivatives thereof |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
WO2022215054A1 (en) | 2021-04-09 | 2022-10-13 | Takeda Pharmaceutical Company Limited | Antibodies targeting complement factor d and uses therof |
EP4326873A1 (en) | 2021-04-22 | 2024-02-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
WO2022232035A1 (en) | 2021-04-26 | 2022-11-03 | Millennium Pharmaceuticals, Inc. | Anti-adgre2 antibodies and uses thereof |
EP4330284A2 (en) | 2021-04-26 | 2024-03-06 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
WO2022245859A1 (en) | 2021-05-17 | 2022-11-24 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
US20230115257A1 (en) | 2021-05-17 | 2023-04-13 | Curia Ip Holdings, Llc | Sars-cov-2 spike protein antibodies |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
IL309078A (en) | 2021-06-23 | 2024-02-01 | Scholar Rock Inc | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
US20230048743A1 (en) | 2021-07-12 | 2023-02-16 | Genentech Inc. | Structures for Reducing Antibody-Lipase Binding |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
WO2023007374A1 (en) | 2021-07-27 | 2023-02-02 | Pfizer Inc. | Method of treatment of cancer pain with tanezumab |
GB202111757D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
GB202111759D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
GB202111758D0 (en) | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
AU2022336407A1 (en) | 2021-08-31 | 2024-02-22 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
WO2023034901A1 (en) | 2021-09-01 | 2023-03-09 | The Broad Institute, Inc. | Tumor avatar vaccine compositions and uses thereof |
WO2023036982A1 (en) | 2021-09-10 | 2023-03-16 | Harbour Antibodies Bv | Anti-sars2-s antibodies |
GB202112935D0 (en) | 2021-09-10 | 2021-10-27 | Harbour Antibodies Bv | Sars-cov-2 (sars2, covid-19) heavy chain only antibodies |
TW202330612A (en) | 2021-10-20 | 2023-08-01 | 日商武田藥品工業股份有限公司 | Compositions targeting bcma and methods of use thereof |
WO2023077148A1 (en) | 2021-11-01 | 2023-05-04 | Tome Biosciences, Inc. | Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo |
WO2023081471A1 (en) | 2021-11-05 | 2023-05-11 | Dana-Farber Cancer Institute, Inc. | Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023100061A1 (en) | 2021-12-01 | 2023-06-08 | Pfizer Inc. | 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure |
WO2023105387A1 (en) | 2021-12-06 | 2023-06-15 | Pfizer Inc. | Melanocortin 4 receptor antagonists and uses thereof |
WO2023105371A1 (en) | 2021-12-08 | 2023-06-15 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023111817A1 (en) | 2021-12-17 | 2023-06-22 | Pfizer Inc. | Crystalline forms of [(1r,5s,6r)-3-{2-[(2s)-2-methylazetidin-1-yl]-6-(trifluoromethyl) pyrimidin-4-yl}-3-azabicyclo[3.1.0]hex-6-yl]acetic acid |
WO2023122764A1 (en) | 2021-12-22 | 2023-06-29 | Tome Biosciences, Inc. | Co-delivery of a gene editor construct and a donor template |
WO2023178357A1 (en) | 2022-03-18 | 2023-09-21 | Evolveimmune Therapeutics, Inc. | Bispecific antibody fusion molecules and methods of use thereof |
WO2023201238A1 (en) | 2022-04-11 | 2023-10-19 | Vor Biopharma Inc. | Binding agents and methods of use thereof |
WO2023205744A1 (en) | 2022-04-20 | 2023-10-26 | Tome Biosciences, Inc. | Programmable gene insertion compositions |
WO2023212618A1 (en) | 2022-04-26 | 2023-11-02 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
WO2023215831A1 (en) | 2022-05-04 | 2023-11-09 | Tome Biosciences, Inc. | Guide rna compositions for programmable gene insertion |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023225670A2 (en) | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
WO2023235852A1 (en) | 2022-06-03 | 2023-12-07 | Zenas Biopharma, Inc. | Methods and compositions for treating igg4- related diseases |
WO2024020051A1 (en) | 2022-07-19 | 2024-01-25 | BioLegend, Inc. | Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030829A1 (en) | 2022-08-01 | 2024-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that bind to the underside of influenza viral neuraminidase |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
WO2024040114A2 (en) | 2022-08-18 | 2024-02-22 | BioLegend, Inc. | Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same |
WO2024075051A1 (en) | 2022-10-07 | 2024-04-11 | Pfizer Inc. | Hsd17b13 inhibitors and/or degraders |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0072111A1 (en) * | 1981-07-20 | 1983-02-16 | Lipid Specialties, Inc. | Synthetic phospholipid compounds and their preparation |
EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
WO1988004924A1 (en) * | 1986-12-24 | 1988-07-14 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0354855A2 (en) * | 1988-08-11 | 1990-02-14 | Terumo Kabushiki Kaisha | Liposomes on which adsorption of proteins is inhibited |
WO1990004384A1 (en) * | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
US4501728A (en) * | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
JPS60100516A (en) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | Preparation of sustained release microcapsule |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
IE58981B1 (en) * | 1985-10-15 | 1993-12-15 | Vestar Inc | Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles |
US4797285A (en) * | 1985-12-06 | 1989-01-10 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Lipsome/anthraquinone drug composition and method |
US4837028A (en) * | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4863739A (en) * | 1987-05-19 | 1989-09-05 | Board Of Regents, The University Of Texas System | Liposome compositions of anthracycline derivatives |
JPH0696636B2 (en) * | 1988-03-30 | 1994-11-30 | 富士写真フイルム株式会社 | 2,4-bis (o-methoxypolyethylene glycol) -6-cholesteryl-S-triazine compound |
AU616040B2 (en) * | 1988-08-11 | 1991-10-17 | Terumo Kabushiki Kaisha | Agents for inhibiting adsorption of proteins on the liposome surface |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
-
1989
- 1989-10-20 US US07/425,224 patent/US5013556A/en not_active Expired - Lifetime
-
1990
- 1990-10-19 ES ES91900513T patent/ES2071976T3/en not_active Expired - Lifetime
- 1990-10-19 JP JP51523890A patent/JP3571335B2/en not_active Expired - Fee Related
- 1990-10-19 AT AT90916409T patent/ATE115401T1/en not_active IP Right Cessation
- 1990-10-19 EP EP90916409A patent/EP0496813B1/en not_active Revoked
- 1990-10-19 DK DK91900513.2T patent/DK0496835T3/en active
- 1990-10-19 DE DE19675048C patent/DE19675048I2/en active Active
- 1990-10-19 DE DE69015207T patent/DE69015207T2/en not_active Revoked
- 1990-10-19 AU AU66374/90A patent/AU642679B2/en not_active Expired
- 1990-10-19 EP EP91900513A patent/EP0496835B1/en not_active Expired - Lifetime
- 1990-10-19 CA CA002067178A patent/CA2067178C/en not_active Expired - Lifetime
- 1990-10-19 CA CA002067133A patent/CA2067133C/en not_active Expired - Lifetime
- 1990-10-19 DE DE69019366T patent/DE69019366T2/en not_active Expired - Lifetime
- 1990-10-19 JP JP3501034A patent/JP2667051B2/en not_active Expired - Lifetime
- 1990-10-19 WO PCT/US1990/006034 patent/WO1991005545A1/en not_active Application Discontinuation
- 1990-10-19 KR KR1019920700919A patent/KR920703013A/en not_active Application Discontinuation
- 1990-10-19 AT AT91900513T patent/ATE122229T1/en active
- 1990-10-19 WO PCT/US1990/006211 patent/WO1991005546A1/en active IP Right Grant
- 1990-10-19 KR KR1019920700918A patent/KR0134982B1/en not_active IP Right Cessation
- 1990-10-19 AU AU68982/91A patent/AU654120B2/en not_active Expired
- 1990-10-21 IL IL9606990A patent/IL96069A/en not_active IP Right Cessation
- 1990-10-21 IL IL9607090A patent/IL96070A/en not_active IP Right Cessation
-
1991
- 1991-01-15 US US07/642,321 patent/US5213804A/en not_active Expired - Lifetime
-
1992
- 1992-03-27 NO NO920996A patent/NO304637B1/en not_active IP Right Cessation
- 1992-03-27 NO NO92921213A patent/NO921213L/en unknown
- 1992-04-21 FI FI921764A patent/FI105151B/en active Protection Beyond IP Right Term
- 1992-04-21 FI FI921763A patent/FI921763A0/en not_active Application Discontinuation
-
1995
- 1995-08-09 GR GR950402186T patent/GR3017060T3/en unknown
-
1996
- 1996-12-13 LU LU88854C patent/LU88854I2/en unknown
- 1996-12-18 NL NL960031C patent/NL960031I2/en unknown
-
1997
- 1997-02-05 HK HK14097A patent/HK14097A/en not_active IP Right Cessation
- 1997-03-17 JP JP9063661A patent/JP2889549B2/en not_active Expired - Lifetime
-
1999
- 1999-02-23 NO NO1999003C patent/NO1999003I1/en unknown
-
2001
- 2001-01-11 JP JP2001004291A patent/JP3921050B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0072111A1 (en) * | 1981-07-20 | 1983-02-16 | Lipid Specialties, Inc. | Synthetic phospholipid compounds and their preparation |
EP0118316A2 (en) * | 1983-03-07 | 1984-09-12 | Lipid Specialties, Inc. | Synthetic phospholipid compounds, their preparation and use |
GB2185397A (en) * | 1986-01-17 | 1987-07-22 | Cosmas Damian Ltd | Drug delivery system |
WO1988004924A1 (en) * | 1986-12-24 | 1988-07-14 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
EP0354855A2 (en) * | 1988-08-11 | 1990-02-14 | Terumo Kabushiki Kaisha | Liposomes on which adsorption of proteins is inhibited |
WO1990004384A1 (en) * | 1988-10-20 | 1990-05-03 | Royal Free Hospital School Of Medicine | Liposomes |
Non-Patent Citations (2)
Title |
---|
Derwent File Supplier WPIL, 1989, AN 89-335922 (46), Derwent Publications, Ltd. (London, GB), & JP-A-1249798 (FUJI PHOTO FILM CO., LTD), 5 October 1989 * |
Patent Abstracts of Japan, volume 13, no. 592 (C-671)(3940), 26 December 1989; & JP-A-1249717 (FUJI PHOTO FILM CO., LTD.) 5 October 1989 * |
Cited By (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
WO1994007537A1 (en) * | 1992-10-05 | 1994-04-14 | Stichting Voor De Technische Wetenschappen | Pharmaceutical composition for site-specific release of a clot-dissolving protein |
WO1994007466A1 (en) * | 1992-10-07 | 1994-04-14 | Liposome Technology, Inc. | Compositions for treatmewnt of inflamed tissues |
WO1994020073A1 (en) * | 1993-03-03 | 1994-09-15 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
WO1994026251A1 (en) * | 1993-05-07 | 1994-11-24 | Sequus Pharmaceuticals, Inc. | Subcutaneous liposome delivery method |
US5514670A (en) * | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
US5993846A (en) * | 1993-08-13 | 1999-11-30 | Pharmos Corporation | Bioadhesive emulsion preparations for enhanced drug delivery |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
WO1996010391A1 (en) * | 1994-09-30 | 1996-04-11 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6673364B1 (en) | 1995-06-07 | 2004-01-06 | The University Of British Columbia | Liposome having an exchangeable component |
US6096720A (en) * | 1995-08-01 | 2000-08-01 | Novartis Ag | Liposomal oligonucleotide compositions |
US6165501A (en) * | 1995-12-11 | 2000-12-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
WO1997021429A1 (en) * | 1995-12-11 | 1997-06-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid |
US5817856A (en) * | 1995-12-11 | 1998-10-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiation-protective phospholipid and method |
WO1998008489A1 (en) * | 1996-08-26 | 1998-03-05 | Transgene S.A. | Cationic lipid-nucleic acid complexes |
US6271208B1 (en) | 1996-08-26 | 2001-08-07 | Transgene S.A. | Process of making cationic lipid-nucleic acid complexes |
US6316024B1 (en) | 1996-10-11 | 2001-11-13 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
WO1998016202A3 (en) * | 1996-10-11 | 1998-07-16 | Sequus Pharm Inc | Fusogenic liposome composition and method |
AU715063B2 (en) * | 1996-10-11 | 2000-01-13 | Alza Corporation | Fusogenic liposome composition and method |
WO1998016202A2 (en) * | 1996-10-11 | 1998-04-23 | Sequus Pharmaceuticals, Inc. | Fusogenic liposome composition and method |
US6224903B1 (en) | 1996-10-11 | 2001-05-01 | Sequus Pharmaceuticals, Inc. | Polymer-lipid conjugate for fusion of target membranes |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
US6083923A (en) * | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
WO1999027908A1 (en) * | 1997-12-04 | 1999-06-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
WO2000066126A2 (en) * | 1999-04-29 | 2000-11-09 | Alza Corporation | Liposome compositions for improved drug retention |
WO2000066126A3 (en) * | 1999-04-29 | 2001-04-05 | Alza Corp | Liposome compositions for improved drug retention |
WO2001011069A1 (en) | 1999-08-06 | 2001-02-15 | Celltech R&D Limited | Freeze/thawed lipid complexes and their preparation |
EP2213291A1 (en) | 2000-01-18 | 2010-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2329830A2 (en) | 2000-01-18 | 2011-06-08 | ISIS Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2003207A2 (en) | 2000-01-18 | 2008-12-17 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PTP1B expression |
EP2246443A1 (en) | 2001-05-14 | 2010-11-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2365094A1 (en) | 2001-05-14 | 2011-09-14 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
EP2270024A1 (en) | 2001-06-21 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP2221376A2 (en) | 2001-06-21 | 2010-08-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP2280019A1 (en) | 2001-07-25 | 2011-02-02 | ISIS Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
EP2332955A2 (en) | 2001-07-30 | 2011-06-15 | ISIS Pharmaceuticals, Inc. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
EP2336145A1 (en) | 2001-08-01 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2174945A1 (en) | 2001-08-01 | 2010-04-14 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2316968A1 (en) | 2001-08-07 | 2011-05-04 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2272985A1 (en) | 2001-08-07 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (A) expression |
EP2270231A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2270230A2 (en) | 2001-10-09 | 2011-01-05 | ISIS Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
EP2388318A1 (en) | 2001-12-10 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
US8008269B2 (en) | 2002-09-13 | 2011-08-30 | Replicor Inc. | Antiviral oligonucleotides |
US8067385B2 (en) | 2002-09-13 | 2011-11-29 | Replicor, Inc. | Antiviral oligonucleotides targeting HBV |
US8008270B2 (en) | 2002-09-13 | 2011-08-30 | Replicor Inc. | Antiviral oligonucleotides targeting viral families |
EP2330194A2 (en) | 2002-09-13 | 2011-06-08 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US7358068B2 (en) | 2002-09-13 | 2008-04-15 | Replicor, Inc. | Antiviral oligonucleotides |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
EP2336318A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP2336319A1 (en) | 2002-11-13 | 2011-06-22 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
EP1651187A4 (en) * | 2003-07-31 | 2009-03-11 | Univ Texas | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
EP1651187A2 (en) * | 2003-07-31 | 2006-05-03 | The Board Of Regents, The University Of Texas System | Sterile preparations of phospholipids and anti-inflammatory pharmaceuticals and methods for making and using same |
EP2284267A2 (en) | 2003-08-18 | 2011-02-16 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US8338381B2 (en) | 2003-10-24 | 2012-12-25 | ADER Enterprise, Inc. | Composition and method for the treatment of eye disease |
US7960350B2 (en) | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
EP2527444A2 (en) | 2004-02-06 | 2012-11-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
EP2468865A1 (en) | 2004-02-06 | 2012-06-27 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of stat3 expression |
US8293719B2 (en) | 2004-03-12 | 2012-10-23 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
EP2944646A1 (en) | 2005-09-29 | 2015-11-18 | Astex Pharmaceuticals, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
EP2202239A1 (en) | 2005-11-01 | 2010-06-30 | Alnylam Pharmaceuticals Inc. | RNAI inhibition of influenza virus replication |
US7718629B2 (en) | 2006-03-31 | 2010-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
WO2007115168A2 (en) | 2006-03-31 | 2007-10-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of eg5 gene |
US7691824B2 (en) | 2006-04-28 | 2010-04-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a gene from the JC virus |
EP2392583A1 (en) | 2006-05-19 | 2011-12-07 | Alnylam Europe AG. | RNAi modulation of Aha and therapeutic uses thereof |
EP2584051A1 (en) | 2006-05-22 | 2013-04-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expressions of IKK-B gene |
US7888498B2 (en) | 2006-05-22 | 2011-02-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US8048998B2 (en) | 2007-01-19 | 2011-11-01 | Exiqon A/S | Mediated cellular delivery of LNA oligonucleotides |
EP2905336A1 (en) | 2007-03-29 | 2015-08-12 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of a gene from the ebola |
US7718632B2 (en) | 2007-06-15 | 2010-05-18 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US8119612B2 (en) | 2007-06-15 | 2012-02-21 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US9074212B2 (en) | 2007-06-15 | 2015-07-07 | Arrowhead Research Corporation | RNAi inhibition of alpha-ENaC expression |
US8168606B2 (en) | 2007-06-15 | 2012-05-01 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US7943592B2 (en) | 2007-06-15 | 2011-05-17 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US10544418B2 (en) | 2007-06-15 | 2020-01-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US9476052B2 (en) | 2007-06-15 | 2016-10-25 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US9914927B2 (en) | 2007-06-15 | 2018-03-13 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
US7939508B2 (en) | 2007-06-15 | 2011-05-10 | Novartis Ag | RNAi inhibition of alpha-ENaC expression |
US11208662B2 (en) | 2007-06-15 | 2021-12-28 | Arrowhead Pharmaceuticals, Inc. | RNAi inhibition of alpha-ENaC expression |
EP2848688A1 (en) | 2007-12-10 | 2015-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
EP2617828A1 (en) | 2007-12-10 | 2013-07-24 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of factor VII gene |
EP2712926A2 (en) | 2008-03-05 | 2014-04-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
US8148344B2 (en) | 2008-03-27 | 2012-04-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for mediating RNAi in vivo |
US8324366B2 (en) | 2008-04-29 | 2012-12-04 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for delivering RNAI using lipoproteins |
EP2140872A2 (en) | 2008-07-02 | 2010-01-06 | Kenneth Wileford | Composition for the treatment of skin conditions comprising sea water with additional magnesium |
EP3081648A1 (en) | 2008-08-25 | 2016-10-19 | Excaliard Pharmaceuticals, Inc. | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
WO2010042281A2 (en) | 2008-08-25 | 2010-04-15 | Excaliard Pharmaceuticals | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
EP3208337A1 (en) | 2008-09-02 | 2017-08-23 | Alnylam Pharmaceuticals, Inc. | Compositions for combined inhibition of mutant egfr and il-6 expression |
EP2690175A2 (en) | 2008-09-02 | 2014-01-29 | Alnylam Pharmaceuticals | Compositions and methods for combined inhibition of mutant EGFR gene and IL-6 expression |
EP3109321A1 (en) | 2008-09-25 | 2016-12-28 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
EP3584320A1 (en) | 2008-09-25 | 2019-12-25 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
EP3848461A1 (en) | 2008-10-20 | 2021-07-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP3354733A1 (en) | 2008-10-20 | 2018-08-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP2937418A1 (en) | 2008-10-20 | 2015-10-28 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
EP3225281A1 (en) | 2008-12-10 | 2017-10-04 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
WO2010068816A1 (en) | 2008-12-10 | 2010-06-17 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
US8926955B2 (en) | 2008-12-22 | 2015-01-06 | Creabilis S.A. | Synthesis of polymer conjugates of indolocarbazole compounds |
WO2010099341A1 (en) | 2009-02-26 | 2010-09-02 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of mig-12 gene |
WO2010105209A1 (en) | 2009-03-12 | 2010-09-16 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
EP2810643A2 (en) | 2009-08-14 | 2014-12-10 | Alnylam Pharmaceuticals Inc. | Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus |
EP4089169A1 (en) | 2009-10-12 | 2022-11-16 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
EP3252068A2 (en) | 2009-10-12 | 2017-12-06 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
EP3329924A1 (en) | 2010-03-29 | 2018-06-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
EP3456827A2 (en) | 2010-06-02 | 2019-03-20 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
WO2012064824A1 (en) | 2010-11-09 | 2012-05-18 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
WO2012078967A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for increasing erythropoietin (epo) production |
WO2012106508A1 (en) | 2011-02-02 | 2012-08-09 | Pfizer Inc. | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
EP3674409A1 (en) | 2011-03-29 | 2020-07-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of tmprss6 gene |
EP3354343A1 (en) | 2011-06-02 | 2018-08-01 | President and Fellows of Harvard College | Methods and uses for ex vivo tissue culture systems |
WO2012166903A1 (en) | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
EP3693464A2 (en) | 2011-06-21 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP3564393A1 (en) | 2011-06-21 | 2019-11-06 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
WO2012177947A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
EP3388068A1 (en) | 2011-06-21 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | Composition and methods for inhibition of expression of protein c (proc) genes |
WO2012177906A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Assays and methods for determining activity of a therapeutic agent in a subject |
WO2012177949A2 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein c (proc) genes |
EP3597750A1 (en) | 2011-06-23 | 2020-01-22 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP4134433A1 (en) | 2011-06-23 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP3366312A1 (en) | 2011-06-23 | 2018-08-29 | Alnylam Pharmaceuticals, Inc. | Serpina 1 sirnas: compositions of matter and methods of treatment |
WO2013003112A1 (en) | 2011-06-27 | 2013-01-03 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
US9138492B2 (en) * | 2012-02-23 | 2015-09-22 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
US20130224121A1 (en) * | 2012-02-23 | 2013-08-29 | Canon Kabushiki Kaisha | Particle containing hydrophobic dye having cyanine structure, and contrast agent containing the particle |
EP3868883A1 (en) | 2012-04-10 | 2021-08-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
EP3284824A1 (en) | 2012-04-10 | 2018-02-21 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2013155204A2 (en) | 2012-04-10 | 2013-10-17 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2014107731A1 (en) | 2013-01-07 | 2014-07-10 | Biomedical Research Models, Inc. | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
EP3708184A1 (en) | 2013-03-27 | 2020-09-16 | The General Hospital Corporation | Methods and agents for treating alzheimer s disease |
WO2014160871A2 (en) | 2013-03-27 | 2014-10-02 | The General Hospital Corporation | Methods and agents for treating alzheimer's disease |
WO2014182661A2 (en) | 2013-05-06 | 2014-11-13 | Alnylam Pharmaceuticals, Inc | Dosages and methods for delivering lipid formulated nucleic acid molecules |
WO2015050990A1 (en) | 2013-10-02 | 2015-04-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
EP3693463A1 (en) | 2013-10-04 | 2020-08-12 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
WO2016094897A1 (en) | 2014-12-12 | 2016-06-16 | The Jackson Laboratory | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease |
WO2016100716A1 (en) | 2014-12-18 | 2016-06-23 | Vasant Jadhav | Reversirtm compounds |
EP3797789A1 (en) | 2015-01-20 | 2021-03-31 | The Children's Medical Center Corporation | Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing |
US10485764B2 (en) | 2015-07-02 | 2019-11-26 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
WO2017015109A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
EP3919619A1 (en) | 2015-07-17 | 2021-12-08 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017048843A1 (en) | 2015-09-14 | 2017-03-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the alas1 gene |
US10590416B2 (en) | 2017-07-06 | 2020-03-17 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US11214802B2 (en) | 2017-07-06 | 2022-01-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for inhibiting expression of alpha-ENaC and methods of use |
US10519190B2 (en) | 2017-08-03 | 2019-12-31 | Otsuka Pharmaceutical Co., Ltd. | Drug compound and purification methods thereof |
WO2020037125A1 (en) | 2018-08-16 | 2020-02-20 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2020113135A1 (en) | 2018-11-29 | 2020-06-04 | Flagship Pioneering Innovations V, Inc. | Methods of modulating rna |
WO2021046122A1 (en) | 2019-09-03 | 2021-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2021067747A1 (en) | 2019-10-04 | 2021-04-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021087325A1 (en) | 2019-11-01 | 2021-05-06 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
WO2021207167A1 (en) | 2020-04-06 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing myoc expression |
WO2021207189A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing scn9a expression |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU642679B2 (en) | Liposome microreservoir composition and method | |
US5225212A (en) | Microreservoir liposome composition and method | |
EP0632719B1 (en) | Method of treatment of infected tissues | |
EP0662820B1 (en) | Compositions for treatmewnt of inflamed tissues | |
EP0225130A2 (en) | Liposome composition | |
JP2001510451A (en) | Ion carrier carrying weakly basic drug-liposome in the middle | |
US20030113369A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
AU2004218489A1 (en) | Liposome composition for reduction of liposome-induced complement activation | |
US20010051183A1 (en) | Liposomes with enhanced circulation time and method of treatment | |
WO2001041738A2 (en) | Lipid carrier compositions with protected surface reactive functions | |
WO2000009071A2 (en) | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases | |
WO2005021012A1 (en) | Drug carrier having gemcitabine enclosed therein | |
MXPA05007102A (en) | Non-pegylated long-circulating liposomes. | |
JPH04244017A (en) | Liposome preparation | |
WO2003022250A2 (en) | Unilamellar vesicles stabilized with short chain hydrophilic polymers | |
ZA200507816B (en) | Liposome composition for reduction of liposome-induced complement activation | |
KR100768265B1 (en) | Heparin coated liposomes to prolong circulation time in bloodstream and preparation method thereof | |
Scherphof et al. | In Vivo Uptake and Processing of Liposomes by Parenchymal and Non-Parenchymal Liver Cells; Application to Immunotherapeutic Treatment of Hepatic Metastases | |
WO1999065481A1 (en) | Liposomal formulations of busulphan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2067133 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 921763 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990916409 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1990916409 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1990916409 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990916409 Country of ref document: EP |